<SEC-DOCUMENT>0001193125-23-204493.txt : 20230807
<SEC-HEADER>0001193125-23-204493.hdr.sgml : 20230807
<ACCEPTANCE-DATETIME>20230807080259
ACCESSION NUMBER:		0001193125-23-204493
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230804
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230807
DATE AS OF CHANGE:		20230807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40287
		FILM NUMBER:		231145714

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d469204d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ikna="http://www.ikenaoncology.com/20230804" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-08-04_to_2023-08-04">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-08-04_to_2023-08-04">0001835579</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-08-04_to_2023-08-04" name="dei:CurrentFiscalYearEndDate" contextRef="duration_2023-08-04_to_2023-08-04">--12-31</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ikna-20230804.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-08-04_to_2023-08-04"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-04</xbrli:startDate> <xbrli:endDate>2023-08-04</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-08-04_to_2023-08-04">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): August&#160;7, 2023 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt:datemonthdayyearen">August 4, 2023</ix:nonNumeric>)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-08-04_to_2023-08-04">IKENA ONCOLOGY, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-08-04_to_2023-08-04">001-40287</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-08-04_to_2023-08-04">81-1697316</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-08-04_to_2023-08-04">Ikena Oncology, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-08-04_to_2023-08-04">645 Summer Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-08-04_to_2023-08-04">Suite 101</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-08-04_to_2023-08-04">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-08-04_to_2023-08-04">02210</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-08-04_to_2023-08-04">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-08-04_to_2023-08-04">273-8343</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trade</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-08-04_to_2023-08-04">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-08-04_to_2023-08-04">IKNA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-08-04_to_2023-08-04" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Agreement and Plan of Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;4, 2023, Ikena Oncology, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Ikena</span>&#8221;) acquired Pionyr Immunotherapeutics, Inc., a Delaware corporation (&#8220;<span style="text-decoration:underline">Pionyr</span>&#8221;), in accordance with the terms of the Agreement and Plan of Merger, dated August&#160;4, 2023 (the &#8220;<span style="text-decoration:underline">Merger Agreement</span>&#8221;), by and among Ikena, Portsmouth Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Ikena (&#8220;<span style="text-decoration:underline">First Merger Sub</span>&#8221;), Portsmouth Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Ikena (&#8220;<span style="text-decoration:underline">Second Merger Sub</span>&#8221;), Pionyr, and Fortis Advisors LLC, as securityholder agent. Pursuant to the Merger Agreement, First Merger Sub merged with and into Pionyr, pursuant to which Pionyr was the surviving corporation and became a wholly owned subsidiary of Ikena (the &#8220;<span style="text-decoration:underline">First Merger</span>&#8221;). Immediately following the First Merger, Pionyr merged with and into Second Merger Sub, pursuant to which Second Merger Sub was the surviving entity (together with the First Merger, the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;). The Merger is intended to qualify as a <span style="white-space:nowrap">tax-free</span> reorganization for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, at the closing of the Merger, Ikena issued the holders (the &#8220;<span style="text-decoration:underline">Pionyr Stockholders</span>&#8221;) of Pionyr common stock, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">Company Common Stock</span>&#8221;), a total of 1,800,652 shares of the common stock of Ikena, par value $0.001 per share (the &#8220;<span style="text-decoration:underline">Parent Common Stock</span>&#8221;) and 4,153,439 shares of Series A Preferred Stock (as defined below), each share of which is convertible into one (1)&#160;share of Parent Common Stock, subject to certain conditions described below. Under the terms of the Merger Agreement, 297,788 shares of Series A Preferred Stock will be withheld for a period of six months and be subject to indemnity claims by Ikena. Each Pionyr Stockholder shall be entitled to one contractual contingent value right (&#8220;<span style="text-decoration:underline">CVR</span>&#8221;) issued by Ikena, subject to and in accordance with the terms and conditions of the CVR Agreement (as defined below), for each share of Company Common Stock. Holders of Company Common Stock who were unaccredited investors received cash in lieu of shares of Parent Common Stock and Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the discussion of the Series A Preferred Stock in Item 5.03 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> which is incorporated into this Item 1.01 by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Merger Agreement, outstanding options to acquire Pionyr Common Stock (each, a &#8220;<span style="text-decoration:underline">Company Option</span>&#8221;) that had an exercise price greater than the Per Share Cash Consideration (as defined in the Merger Agreement) were cancelled and, in exchange therefore, holders of such Company Options received an amount in cash equal to the difference between such Company Options&#8217; exercise price and the Per Share Cash Consideration for each Company Option so cancelled. All Company Options not so exchanged for cash were immediately cancelled for no consideration. In addition, outstanding Pionyr restricted stock units (&#8220;<span style="text-decoration:underline">Company RSUs</span>&#8221;) were cancelled and, in exchange therefore, holders of such Company RSUs received an amount in cash equal to the Per Share Cash Consideration for each Company RSU so cancelled. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Ikena has agreed to hold a stockholders&#8217; meeting to submit the following matters to its stockholders for their consideration: (i)&#160;the approval of the conversion of the Series A Preferred Stock into shares of Parent Common Stock in accordance with Nasdaq Listing Rule 5635(a) (the &#8220;<span style="text-decoration:underline">Conversion Proposal</span>&#8221;), and, if deemed necessary by Ikena, (ii)&#160;the approval of an amendment to the certificate of incorporation of Ikena to authorize sufficient shares of Parent Common Stock for the conversion of the Series A Preferred Stock issued pursuant to the Merger Agreement (the &#8220;<span style="text-decoration:underline">Charter Amendment Proposal</span>&#8221; and together with the Conversion Proposal, the &#8220;<span style="text-decoration:underline">Meeting Proposals</span>&#8221;). In connection with these matters, Ikena intends to file with the Securities and Exchange Commission (&#8220;<span style="text-decoration:underline">SEC</span>&#8221;) a proxy statement and other relevant materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Ikena has agreed to exercise commercially reasonable efforts to prepare and file a resale registration statement with the SEC within 15 calendar days following the Closing Date, subject to extension under certain circumstances. Ikena will use commercially reasonable efforts to cause this registration statement to be declared effective by the SEC as soon as practicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors of Ikena (the &#8220;<span style="text-decoration:underline">Board</span>&#8221;) unanimously approved the Merger Agreement and the related transactions, and the consummation of the Merger was not subject to approval of the Ikena stockholders. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Merger and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Merger Agreement has been included to provide investors and security holders with information regarding its terms. It is not intended to provide any other factual information about Ikena or Pionyr. The Merger Agreement contains representations, warranties, and covenants that Ikena and Pionyr made to each other as of specific dates. The assertions embodied in those representations, warranties and covenants were made solely for purposes of the Merger Agreement between Ikena and Pionyr and may be subject to important qualifications and limitations agreed to by Ikena and Pionyr in connection with negotiating its terms, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Merger Agreement. Moreover, the representations and warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to investors or security holders, or may have been used for the purpose of allocating risk between Ikena and Pionyr, rather than establishing matters as facts. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in Ikena&#8217;s public disclosures. For the foregoing reasons, no person should rely on the representations and warranties as statements of factual information at the time they were made or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Support Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Merger Agreement, Ikena and Pionyr entered into stockholder support agreements (the &#8220;<span style="text-decoration:underline">Support Agreements</span>&#8221;) with certain stockholders of Ikena. The Support Agreements provide that, among other things, each of the stockholders has agreed to vote, or cause to be voted, all of the shares of Parent Common Stock owned by such stockholder in favor of the Meeting Proposals at the Ikena stockholders&#8217; meeting to be held in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Support Agreements does not purport to be complete and is qualified in its entirety by reference to the form of the Support Agreement, which is provided as Exhibit A to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Lock-up</span> Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Merger Agreement, certain Pionyr securityholders as of immediately prior to the Merger entered into <span style="white-space:nowrap">lock-up</span> agreements with Ikena and Pionyr, pursuant to which each such stockholder will be subject to a one hundred and twenty (120) day lockup on the sale or transfer of shares of Parent Common Stock and Series A Preferred Stock issued to such stockholder pursuant to the Merger Agreement (the &#8220;<span style="text-decoration:underline"><span style="white-space:nowrap">Lock-up</span> Agreements</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the <span style="white-space:nowrap">Lock-up</span> Agreements does not purport to be complete and is qualified in its entirety by reference to the form of the <span style="white-space:nowrap">Lock-up</span> Agreement, which is provided as Exhibit B to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contingent Value Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Merger, Ikena and the Rights Agent (as defined therein) entered into a contingent value rights agreement (the &#8220;<span style="text-decoration:underline">CVR Agreement</span>&#8221;), pursuant to which stockholders of Pionyr as of immediately prior to the First Effective Time (as defined in the Merger Agreement) shall be entitled to one contractual CVR issued by Ikena, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of Company Common Stock. Each contingent value right shall entitle the holder thereof to receive certain cash and/or stock payments from 50% of the net proceeds, if any, related to the disposition of Pionyr&#8217;s legacy assets within two years following the Closing Date (as defined in the Merger Agreement). The contingent value rights are not transferable, except in certain limited circumstances as provided in the CVR Agreement, will not be certificated or evidenced by any instrument, and will not be registered with the SEC or listed for trading on any exchange. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the CVR Agreement does not purport to be complete and is qualified in its entirety by reference to the CVR Agreement, which is filed as Exhibit 10.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Completion of Acquisition or Disposition of Assets </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;4, 2023, Ikena completed its business combination with Pionyr. The information contained in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated by reference into this Item 2.01. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;3.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Unregistered Sales of Equity Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, Ikena issued shares of Parent Common Stock and Series A Preferred Stock (the &#8220;<span style="text-decoration:underline">Ikena Securities</span>&#8221;) to Pionyr Stockholders. Such issuances were exempt from registration under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;), in reliance on Section&#160;4(a)(2) thereof and Regulation D promulgated thereunder. The information contained in Item 1.02 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated by reference into this Item 3.02. Each of the Pionyr Stockholders represented that it was an &#8220;accredited investor,&#8221; as defined in Regulation D, and is acquiring the Ikena Securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The Ikena Securities have not been registered under the Securities Act and such Ikena Securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Neither this Current Report on Form <span style="white-space:nowrap">8-K</span> nor any of the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock, preferred stock, or any other securities of Ikena. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.03.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;4, 2023, Ikena filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock with the Secretary of State of the State of Delaware (the &#8220;<span style="text-decoration:underline">Certificate of Designation</span>&#8221;) in connection with the Merger referenced in Item 1.01 above. The Certificate of Designation provides for the issuance of shares of Ikena Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock, par value $0.001 per share (the &#8220;<span style="text-decoration:underline">Series A Preferred Stock</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal, on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-if-converted-to-Common-Stock</span></span></span></span> basis, and in the same form as, dividends (if any) actually paid on shares of the Parent Common Stock. Except as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares of Series A Preferred Stock are outstanding, Ikena will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series A Preferred Stock, or alter or amend the Certificate of Designation, (b)&#160;amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Preferred Stock, (c)&#160;issue additional shares of Series A Preferred Stock or increase the number of authorized shares of Series A Preferred Stock, (d)&#160;prior to the stockholder approval of the Conversion Proposal, consummate a Fundamental Transaction (as defined in the Certificate of Designation) or a merger or consolidation of Ikena or stock sale or business combination in which the stockholders of Ikena immediately prior to such transaction do not hold at least a majority of the capital stock immediately after such transaction, (e)&#160;authorize or issue any class or series of stock that is senior to the Series A Preferred Stock, or (f)&#160;enter into any agreement to effect any of the foregoing. The Series A Preferred Stock does not have a preference upon any liquidation, dissolution, or <span style="white-space:nowrap">winding-up</span> of Ikena. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following stockholder approval of the Conversion Proposal, each share of Series A Preferred Stock is automatically convertible into one (1)&#160;share of Parent Common Stock, subject to certain limitations, including that if a holder of Series A Preferred Stock was a holder of Ikena&#8217;s <span style="white-space:nowrap">non-voting</span> Common Stock prior to the conversion, such holder would receive <span style="white-space:nowrap">non-voting</span> Common Stock to the extent such conversion would result in such holder beneficially owning more than 9.99% of Ikena&#8217;s voting Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Series A Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;7, 2023, Ikena issued a press release announcing, among other things, the consummation of the Merger. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including the information in the press release attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K,</span> is furnished pursuant to Item 7.01 of Form <span style="white-space:nowrap">8-K</span> and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including the information in the press release attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K,</span> shall not be deemed to be incorporated by reference in the filings of Ikena under the Securities Act of 1933, as amended. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: uses of proceeds; projected cash runways; future product development plans; stockholder approval of the conversion rights of the Series A Preferred Stock; and any future payouts under the CVR. The use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption &#8220;Risk Factors&#8221; in Ikena&#8217;s most recent Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;9.01 - Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:89%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">&#160;&#160;2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d469204dex21.htm">Agreement and Plan of Merger, dated August&#160;4, 2023, by and among Ikena Oncology, Inc., Portsmouth Merger Sub I, Inc., Portsmouth Merger Sub II, LLC, Pionyr Immunotherapeutics, Inc. and Fortis Advisors LLC, as securityholder agent (1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d469204dex31.htm">Certificate of Designations of Series A <span style="white-space:nowrap">Non-Voting</span> Convertible Preferred Stock </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d469204dex101.htm">Contingent Value Rights Agreement, dated August&#160;4, 2023, by and between Ikena Oncology, Inc. and Computershare Trust Company N.A, as rights agent </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap" align="center">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d469204dex991.htm">Press Release of Ikena Oncology, Inc., dated August&#160;7, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">Exhibit&#160;104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain information in this document has been excluded pursuant to Regulation <span style="white-space:nowrap">S-K,</span> Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private or confidential. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Ikena Oncology, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: August&#160;7, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Manfredi</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Mark Manfredi, Ph.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>d469204dex21.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 2.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">among: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IKENA ONCOLOGY,
INC.</B>; <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PORTSMOUTH MERGER SUB I,</B> <B>INC</B>; <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PORTSMOUTH MERGER SUB II, LLC</B>; <B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PIONYR IMMUNOTHERAPEUTICS, INC. </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">And </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORTIS ADVISORS LLC</B>,
as the Securityholder Agent </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated as of August&nbsp;4, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions and Interpretative Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Definitional and Interpretative Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Description of Transaction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>The Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effects of the Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing; First Effective Time; Second Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Designation; Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Stock Consideration</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conversion of Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Restricted Stock Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing of the Company&#146;s Transfer Books</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Surrender of Book-Entry Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Closing Cash Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Further Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Consequences</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Withholding</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Contravention; Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Real Property; Leasehold</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Intellectual Property</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Agreements, Contracts and Commitments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance; Permits; Restrictions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee and Labor Matters; Benefit Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Environmental Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.19</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.20</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Financial Advisor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.21</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.22</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Privacy and Data Security</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.23</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Anti Bribery</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.24</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Representations and Warranties of Parent and Merger Subs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Due Organization; Subsidiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Organizational Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authority; Binding Nature of Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Vote Required</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Contravention; Consents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Capitalization</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SEC Filings; Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Changes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Absence of Undisclosed Liabilities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title to Assets</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance; Permits; Restrictions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legal Proceedings; Orders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Transactions with Affiliates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Financial Advisors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.16</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Valid Issuance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.17</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Ownership of Company Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.18</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Other Representations or Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Agreements of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Stockholder Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Employee Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification of Officers and Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Tax Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Legends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Termination of Certain Agreements and Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Section 16 Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Allocation Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resale Registration and Related Procedures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conditions Precedent to Obligations of Each Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Restraints</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Stockholder Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Listing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions Precedent to Obligations of Parent and Merger Sub</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Stockholder Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Valuation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Allocation Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Accredited Investor Questionnaire</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company Lock-Up Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Additional Conditions Precedent to Obligation of the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificate of Designation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Parent Stockholder Support Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CVR Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnity Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Survival of Company Fundamental Representations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Period for Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resolution of Objections to Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Securityholder Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Third-Party Claims</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Indemnification Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(continued) </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Miscellaneous Provisions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Non-Survival of Representations, Warranties and Pre-Closing Covenants; Survival of Post-Closing Covenants</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Amendment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Applicable Law; Jurisdiction</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Assignability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cooperation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Other Remedies; Specific Performance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-iv- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exhibits:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Parent Stockholder Support Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Company Lock-Up Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Certificate of Designation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of CVR Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Accredited Investor Questionnaire</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exhibit F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Separation and Release Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Schedules:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule&nbsp;A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Knowledge Persons</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Parent Knowledge Persons</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule C</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Parent Support Persons</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule D</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Company Lock-Up Persons</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule E</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Continuing Employees</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Non-Voting Common Stock Issuance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule G</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Transaction Expenses</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Disclosure Schedule </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Parent Disclosure Schedule </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT AND PLAN OF MERGER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> A<SMALL>GREEMENT</SMALL> <SMALL>AND</SMALL> P<SMALL>LAN</SMALL> <SMALL>OF</SMALL>
M<SMALL>ERGER</SMALL></B><SMALL></SMALL> (this &#147;<B>Agreement</B>&#148;) is made and entered into as of August&nbsp;4, 2023, by and among<B> I<SMALL>KENA</SMALL> O<SMALL>NCOLOGY</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation
(&#147;<B>Parent</B>&#148;), <B>P<SMALL>ORTSMOUTH</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> I, INC</B>, a Delaware corporation and wholly owned subsidiary of Parent (&#147;<B>Merger Sub 1</B>&#148;),<B> P<SMALL>ORTSMOUTH</SMALL>
M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> II, LLC</B>, a Delaware limited liability company and wholly owned subsidiary of Parent (&#147;<B>Merger Sub 2</B>&#148; and, together with Merger Sub 1, &#147;<B>Merger Subs</B>&#148;),
<B>P<SMALL>IONYR</SMALL> I<SMALL>MMUNOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>, a Delaware corporation (the &#147;<B>Company</B>&#148;), and Fortis Advisors LLC, a Delaware limited liability company, as the Securityholder Agent.
Certain capitalized terms used in this Agreement are defined in <U>Section&nbsp;1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Parent and the Company intend to effect a merger of Merger Sub 1 with and into the Company (the &#147;<B>First Merger</B>&#148;) in
accordance with this Agreement and the DGCL. Upon consummation of the First Merger, Merger Sub 1 will cease to exist and the Company will become a wholly owned subsidiary of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and
into Merger Sub 2 (the &#147;<B>Second Merger</B>&#148; and, together with the First Merger, the &#147;<B>Merger</B>&#148;), with Merger Sub 2 being the surviving entity of the Second Merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C. The Parties intend that the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev.
Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a) of the Code and the Treasury Regulations, and that this Agreement be, and hereby is, adopted as a &#147;plan of
reorganization&#148; for the purposes of Section&nbsp;368 of the Code and Treasury Regulations Section&nbsp;1.368-2(g). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D. The Board of
Directors of Parent (the &#147;<B>Parent Board</B>&#148;) has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii)&nbsp;approved and declared advisable this
Agreement, the CVR Agreement and the Contemplated Transactions, including the issuance of shares of Parent Common Stock and Parent Preferred Stock to the Company Holders pursuant to the terms of this Agreement and (iii)&nbsp;resolved to recommend,
upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote (a)&nbsp;to approve the conversion of the Parent Preferred Stock issued pursuant to this Agreement in accordance with Nasdaq Listing Rule
5635(a) (the &#147;<B>Conversion Proposal</B>&#148;) and (b)&nbsp;if deemed necessary by Parent, to authorize sufficient shares of Parent Common Stock in Parent&#146;s certificate of incorporation for the conversion of the Parent Preferred Stock
issued pursuant to this Agreement (the &#147;<B>Charter Amendment Proposal</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The First Merger Sub Board has
(i)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub 1 and its sole stockholder, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions, and
(iii)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of Merger Sub 1 votes to adopt this Agreement and approve the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. The sole member of Merger Sub 2 has (i)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best
interests of Merger Sub 2 and its sole member, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions, and (iii)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this
Agreement, that the member of Merger Sub 2 votes to adopt this Agreement and approve the Contemplated Transactions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. The Board of Directors of the Company (the &#147;<B>Company Board</B>&#148;) has
(i)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of the Company and its stockholders, (ii)&nbsp;approved and declared advisable this Agreement and the Contemplated Transactions and
(iii)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and approve the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">H. Concurrently with the execution and delivery of this Agreement, and as a condition and inducement to the Company&#146;s willingness to
enter into this Agreement, the officers, directors and stockholders of Parent set forth on<U> Schedule C</U> hereto (solely in their capacity as stockholders of Parent), whose shares of Parent represent approximately 29% of the outstanding shares of
voting common stock of Parent, are executing support agreements in favor of the Company in substantially the form attached hereto as<U> Exhibit A</U> (the &#147;<B>Parent Stockholder Support Agreement</B>&#148;), pursuant to which such Persons have,
subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the Conversion Proposal and Charter Amendment Proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I. Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#146;s willingness to enter into
this Agreement, the officers, directors and stockholders of the Company listed on<U> Schedule D</U> hereto are executing lock-agreements in substantially the form attached hereto as<U> Exhibit B</U> (the &#147;<B>Lock-Up Agreement</B>,&#148; and
collectively, the &#147;<B>Company Lock-Up Agreements</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">J. Concurrently with the execution and delivery of this Agreement, the
stockholders of the Company sufficient to adopt and approve this Agreement and the First Merger, as required under the DGCL and the Company&#146;s Organizational Documents, are executing and delivering an action by written consent, in form and
substance reasonably acceptable to Parent in order to obtain the Required Company Stockholder Vote (each, a &#147;<B>Company Stockholder Written Consent</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">K. Immediately following the execution and delivery of this Agreement, but prior to the filing of the First Certificate of Merger, Parent will
file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Parties, intending to be legally bound, agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Definitions and Interpretative Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1 <U>Definitions</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
For purposes of the Agreement (including this <U>Section&nbsp;1</U>): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Accredited Investor</B>&#148; means a Company Stockholder
that has executed and delivered an Accredited Investor Questionnaire substantially in the form attached hereto as <U>Exhibit E</U>, demonstrating that such Company Holder is an &#147;accredited investor&#148; (within the meaning of Rule 501 of
Regulation D under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; shall have the meaning given to such term in Rule 145 under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Aggregate Cash Payments</B>&#148; means an amount in cash equal to (i)&nbsp;the product of (A)(x) the aggregate
number of shares of Company Common Stock held by Company Stockholders who are Unaccredited Investors as of immediately prior to the First Effective Time<I> plus</I> (y)&nbsp;the aggregate number of shares of Company Common Stock underlying any
In-the-Money Company Options and Company Restricted Stock Units as of immediately prior to the First Effective Time<I> multiplied by</I> (B)&nbsp;Per Share Cash Consideration<I> less</I> (ii)&nbsp;the aggregate exercise prices of the In-the-Money
Company Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day other than a day on which banks in the State
of California or the State of New York are authorized or obligated to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Certificate of Designation</B>&#148; means a
certificate of designation for Parent Preferred Stock in the form attached hereto as <U>Exhibit C</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>COBRA</B>&#148; means the
Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&nbsp;4980B of the Code and Part 6 of Title I of ERISA, as amended. &#147;<B>Code</B>&#148; means the Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Associate</B>&#148; means any current or former employee, independent contractor, officer, or director of the Company or any
of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Contract</B>&#148; means any Contract: (a)&nbsp;to which the Company or any of its Subsidiaries is
a Party, (b)&nbsp;by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation, or (c)&nbsp;under which the Company or any of its
Subsidiaries has or may acquire any right or interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Equity Securities</B>&#148; means the Company Common Stock,
Company Options and Company RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Fundamental Representations</B>&#148; means the representations and warranties of the
Company set forth in <U>Sections 3.1</U>, <U>3.2</U>, <U>3.3</U>, <U>3.6</U>, <U>3.16(b)</U> and <U>3.16(c)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Holder
Selling Expenses</B>&#148; means all discounts, selling commissions, fees of selling brokers, dealer managers, underwriters and similar securities industry professionals and stock transfer taxes applicable to the sale of Registrable Securities and
fees and disbursements of counsel for any Company Holder (excluding, for the avoidance of doubt, any fees and disbursements of counsel for Parent included in Registration Expenses). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Holders</B>&#148; means the Company Stockholders, the Company Optionholders and Company RSU Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Indemnitors</B>&#148; means the Company Stockholders other than Unaccredited Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IP Rights</B>&#148; means all Intellectual Property owned, exclusively licensed or controlled, or purported to be owned or
controlled, by the Company or its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IP Rights Agreement</B>&#148; means any Contract governing, related to
or pertaining to any Company IP Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company IT Systems</B>&#148; means all systems used by the Company in the conduct of its
business including the information and communications technology infrastructure and systems (including all software, hardware, firmware, networks and Company web sites), and any security and disaster recovery arrangements relating thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Material Adverse Effect</B>&#148; means any Effect that, considered
together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition,
assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, that Effects arising or resulting from the following shall not be taken into account in determining whether there has
been a Company Material Adverse Effect: (a)&nbsp;the announcement of the Agreement or the pendency of the Contemplated Transactions, (b)&nbsp;the taking of any action, or the failure to take any action, by the Company that is required to comply with
the terms of the Agreement, (c)&nbsp;any natural disaster or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening
of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d)&nbsp;any change in GAAP or applicable Law or the interpretation thereof, (e)&nbsp;general economic or political conditions
or conditions generally affecting the industries in which the Company and its Subsidiaries operate, or (f)&nbsp;any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business;
except in each case with respect to clauses (c), (d), and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and
its Subsidiaries operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Merger Shares</B>&#148; means the total number of shares of Parent Common Stock determined by
(i)&nbsp;dividing (x)&nbsp;the Company Valuation less the Aggregate Cash Payments less the Expense Fund Amount by (y)&nbsp;the Parent Share Price and (ii)&nbsp;subtracting from the quotient in clause (i), the Indemnity Shares (assuming the Indemnity
Shares are issued in the form of Parent Common Stock for these purposes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Options</B>&#148; means each outstanding and
unexercised option to purchase Company Common Stock that was granted by the Company under the Company Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company
Optionholders</B>&#148; means the holders of Company Options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Product Candidates</B>&#148; means investigational drug
products for which the Company is, or was, researching and developing, including PY314, PY159, and PY265. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Registered
IP</B>&#148; means all Company IP Rights that are owned by or exclusively licensed to the Company that are registered, filed or issued under the authority of, with, or by any Governmental Authority, including all patents, registered copyrights, and
registered trademarks, and all applications for the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Restricted Stock Units</B>&#148; means each outstanding
restricted stock unit representing the right to receive one or more shares of Company Common Stock or the cash value thereof upon vesting and settlement under the Company Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company RSU Holders</B>&#148; means the holders of Company Restricted Stock Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Stockholders</B>&#148; means the holders of Company Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Unaudited Interim Balance Sheet</B>&#148; means the unaudited consolidated balance sheet of the Company as of June&nbsp;30,
2023, provided to Parent prior to the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company Valuation</B>&#148; means $43,507,084.61. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidentiality Agreement</B>&#148; means the Confidentiality Agreement dated
May&nbsp;15, 2023, between the Company and Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Consent</B>&#148; means any approval, consent, ratification, permission,
waiver, or authorization (including any Governmental Authorization). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contemplated Transactions</B>&#148; means the Merger and
the other transactions contemplated by the Agreement, including the CVR Agreement, the Conversion Proposal and Charter Amendment Proposal (to the extent applicable and deemed necessary by Parent). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Contract</B>&#148; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or
personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>COVID-19 Relief Law</B>&#148; means the CARES Act, the Families First Corona Virus Response Act, the Coronavirus Preparedness and
Response Supplemental Appropriations Act, or any similar Law enacted or promulgated by the government of the United States of America or any political subdivision thereof in response to or in connection with COVID-19 or any mutation, strain or
variant thereof, or any similar or related disease caused by COVID-19 (all as in effect from time to time, together with all amendments thereto and all regulations and guidance issued by any Governmental Authority with respect thereto, regardless of
the date enacted, adopted, issued or implemented). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR</B>&#148; means one contingent value right representing the right to
receive the consideration set forth in, and subject in all respects to the terms and conditions of, the CVR Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR
Agreement</B>&#148; means the Contingent Value Rights Agreement in substantially the form attached hereto as <U>Exhibit D</U> to be entered into between Parent and Computershare Trust Company N.A. (or such other nationally recognized rights agent
agreed to between Parent and the Company) (the &#147;<B>Rights Agent</B>&#148;), with such revisions thereto requested by the Rights Agent that are not, individually or in the aggregate, materially detrimental to the holders of CVRs and reasonably
acceptable to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>DGCL</B>&#148; means the General Corporation Law of the State of Delaware, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>DLLCA</B>&#148; means the Delaware Limited Liability Company Act, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effect</B>&#148; means any effect, change, event, circumstance, or development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Employee Plan</B>&#148; means (A)&nbsp;an &#147;employee benefit plan&#148; within the meaning of Section&nbsp;3(3) of ERISA whether
or not subject to ERISA; (B)&nbsp;stock option plans, stock purchase plans, bonus (including any annual bonus and retention bonus) or incentive plans, severance pay plans, programs or arrangements, deferred compensation arrangements or agreements,
employment agreements, compensation plans, programs, agreements or arrangements, change in control plans, programs or arrangements, supplemental income arrangements, vacation plans, and all other employee benefit plans, agreements, and arrangements,
not described in (A)&nbsp;above; and (C)&nbsp;plans or arrangements providing compensation to employee and non- employee directors, in each case in which the Company or any ERISA Affiliate sponsors, contributes to, or provides benefits under or
through such plan, or has any obligation to contribute to or provide benefits under or through such plan, or if such plan provides benefits to or otherwise covers any current or former employee, officer or director of the Company or any ERISA
Affiliate (or their spouses, dependents, or beneficiaries), or under which the Company or any of its ERISA Affiliates has or may have any liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Encumbrance</B>&#148; means any lien, pledge, hypothecation, charge, mortgage,
security interest, lease, license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest, or restriction or encumbrance of any nature
(including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any
restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Enforceability
Exceptions</B>&#148; means the (a)&nbsp;Laws of general application relating to bankruptcy, insolvency, and the relief of debtors and (b)&nbsp;rules of law governing specific performance, injunctive relief, and other equitable remedies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Entity</B>&#148; means any corporation (including any non-profit corporation), partnership (including any general partnership,
limited partnership, or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company, or joint stock company), firm, society or other enterprise, association, organization
or entity, and each of its successors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Environmental Law</B>&#148; means any federal, state, local or foreign Law relating to
pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of
Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA</B>&#148; means the Employee Retirement Income Security Act of 1974, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ERISA Affiliates</B>&#148; means, any entity, trade or business that is, or at any applicable time was, a member of a group described
in Section&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Code or Section&nbsp;4001(b)(1) of ERISA that includes the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Expense Fund Amount</B>&#148; means $15,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Federal Health Care Program</B>&#148; means any federal health program as defined in 42 U.S.C. &#167; 1320a-7b(f), including
Medicare, Medicaid, TRICARE, CHAMPVA, and state healthcare programs (as defined therein). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>First Merger Sub Board</B>&#148; means
the board of directors of Merger Sub 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Fraud</B>&#148; means actual and intentional common law fraud under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authority</B>&#148; means any: (a)&nbsp;nation, state, commonwealth, province, territory, county, municipality,
district, or other jurisdiction of any nature, (b)&nbsp;federal, state, local, municipal, foreign, supra-national, or other government, (c)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division,
department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity, and any court or other tribunal, and, for the avoidance of doubt, any taxing authority), or
(d)&nbsp;self-regulatory organization (including Nasdaq). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Governmental Authorization</B>&#148; means any: (a)&nbsp;permit,
license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification, or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or
pursuant to any Law, or (b)&nbsp;right under any Contract with any Governmental Authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Hazardous Materials</B>&#148; means any pollutant, chemical, substance and any
toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any
Environmental Law, including, without limitation, crude oil or any fraction thereof, and petroleum products or by-products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>&#147;Health Care Laws&#148;</B> means all applicable Laws and implementing regulations pertaining to U.S. health care regulatory matters
to the extent applicable, including as amended from time to time, any such Law pertaining to: (a)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and the Public Health Service Act (42 U.S.C. &#167; 262 et seq.),
(b)&nbsp;any Federal Health Care Program, including those pertaining to providers of goods or services that are paid for by any Federal Health Care Program, including, the False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the criminal False
Claims Law (42 U.S.C. &#167; 1320a-7b(a)), the Federal Anti-kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Anti-Kickback Act of 1986 (41 U.S.C. &#167;&#167; 51-58), the federal False Statements Statute (42 U.S.C. &#167; 1320a-7b(a)), the
Exclusion Law (42 U.S.C. &#167; 1320a-7), the Federal Program Fraud Civil Remedies Act (31 U.S.C. &#167;&#167;3801-3812), the Civil Monetary Penalties Law (42 U.S.C. &#167; 1320a-7a and 1320a-7b), the U.S. Physician Payments Sunshine Act (42 U.S.C.
&#167; 1320a-7h), (c)&nbsp;any and all other applicable comparable state and foreign Laws, and (d)&nbsp;all regulations promulgated pursuant to the foregoing, each of (a)&nbsp;through (d)&nbsp;as amended or modified from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>HIPAA</B>&#148; means the following, as the same may be amended, modified or supplemented from time to time, and any successor
statute thereto, and any and all rules or regulations promulgated from time to time thereunder: (i)&nbsp;the Health Insurance Portability and Accountability Act of 1996; (ii)&nbsp;the Health Information Technology for Economic and Clinical Health
Act (Title XIII of the American Recovery and Reinvestment Act of 2009); and (iii)&nbsp;applicable state Laws regarding patient privacy and the security, exchange, use or disclosure of health care records or protected health information (as defined
by the Health Insurance Portability and Accountability Act of 1996). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>In-the-Money Company Option</B>&#148; means each Company
Option having an exercise price that is less than the Per Share Cash Consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnity Shares</B>&#148; means the total
number of shares of Parent Preferred Stock (and Parent Common Stock, as applicable) determined by (i)&nbsp;multiplying five percent (5%)&nbsp;by (ii)&nbsp;the quotient of (a)&nbsp;the Company Valuation<I> less</I> the Aggregate Cash Payments<I>
divided</I> by (b)&nbsp;the Parent Share Price; <U>provided</U>, that the Indemnity Shares shall consist of shares of Parent Preferred Stock and if, and only if, the number of shares of Parent Preferred Stock issued pursuant to
<U>Section&nbsp;2.5</U> is fewer than the number of such shares corresponding to five percent (5%)&nbsp;of the quotient of (a)&nbsp;the Company Valuation<I> less</I> the Aggregate Cash Payments <I>divided</I> by (b)&nbsp;the Parent Share Price, the
remainder of the Indemnity Shares shall consist of shares of Parent Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Intellectual Property</B>&#148; means any and
all of the following, as they exist in any jurisdiction throughout the world and under any international treaties or conventions: (a)&nbsp;patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals,
continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention, and the equivalents of any of the foregoing, statutory invention registrations, invention
disclosures and inventions (collectively, &#147;<B>Patents</B>&#148;), (b)&nbsp;trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and
applications for registration thereof, (c)&nbsp;copyrights in published and unpublished works, including registrations and applications for registration thereof, (d)&nbsp;software, including all source code, object code and related documentation,
(e)&nbsp;trade secrets and other confidential or proprietary information, including formulae, customer lists, know-how, whether patentable or not, and (f)&nbsp;any and all other intellectual property rights and/or proprietary rights equivalent to
any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>IRS</B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Key Employee</B>&#148; means, with respect to the Company or Parent, an executive officer of such Party or any officer of such Party
that reports directly to the board of directors of such Party or to the chief executive officer of such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Knowledge</B>&#148; means, (a)&nbsp;where used herein with respect to the Company means the actual knowledge of the persons named in
<U>Schedule A</U> after due inquiry in the ordinary course of the performance of such individual&#146;s employment responsibilities and (b)&nbsp;where used herein with respect to Parent means the actual knowledge of the persons named in <U>Schedule
B</U> after due inquiry in the ordinary course of the performance of such individual&#146;s employment responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Law</B>&#148; means any federal, state, national, supra-national, foreign, local, or municipal or other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling, or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority
(including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Legal Proceeding</B>&#148; means any
action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative, or appellate proceeding), hearing, inquiry, audit, examination, or investigation commenced, brought, conducted or heard by or before, or
otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Multiemployer
Plan</B>&#148; means a &#147;multiemployer plan,&#148; as defined in Section&nbsp;3(37) or 4001(a)(3) of ERISA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Multiple
Employer Plan</B>&#148; means a &#147;multiple employer plan&#148; within the meaning of Section&nbsp;413(c) of the Code or Section&nbsp;3(40) of ERISA, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Multiple Employer Welfare Arrangement</B>&#148; means a &#147;multiple employer welfare arrangement&#148; within the meaning of
Section&nbsp;3(40) of ERISA. &#147;<B>Nasdaq</B>&#148; means The Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Order</B>&#148; means any judgment, order,
writ, injunction, ruling, decision, or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement, or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court
or Governmental Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ordinary Course of Business</B>&#148; means (i)&nbsp;with respect to Parent, such actions taken in
the ordinary course of its normal operations and consistent with its past practices and (ii)&nbsp;with respect to the Company and its Subsidiaries, such actions taken in the ordinary course of its normal operations and consistent with its practices
in the last four (4)&nbsp;months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Organizational Documents</B>&#148; means, with respect to any Person (other than an
individual), (a)&nbsp;the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other
similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b)&nbsp;all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each
case, as amended or supplemented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Associate</B>&#148; means any current or former employee, independent
contractor, officer, or director of Parent or any of its Subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Capital Stock</B>&#148; means the Parent Common
Stock (including, for this purpose, any non-voting Common Stock of Parent issuable to Company Holder set forth on <U>Schedule F</U> hereto that own Parent Common Stock as of the First Effective Time as expressly provided in the Allocation
Certificate, upon conversion of the Parent Preferred Stock in accordance with the Certificate of Designation or pursuant to the terms of the CVR Agreement) and Parent Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Common Stock</B>&#148; means the common stock, $0.001 par value per share, of Parent. For the avoidance of doubt, shares of
Parent Common Stock issuable pursuant to this Agreement shall consist of shares of voting common stock under the Organizational Documents of Parent, except for the issuance of non-voting common stock of Parent to Company Holder set forth on
<U>Schedule F</U> hereto that own Parent Common Stock as of the First Effective Time as expressly provided in the Allocation Certificate, the Certificate of Designation or CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Contract</B>&#148; means any Contract: (a)&nbsp;to which Parent is a party, (b)&nbsp;by which Parent is or may become bound or
under which Parent has, or may become subject to, any obligation, or (c)&nbsp;under which Parent has or may acquire any right or interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Employee Plan</B>&#148; means any Employee Plan that Parent or any of its ERISA Affiliates sponsors, contributes to, or
provides benefits under or through such plan, or has any obligation to contribute to or provide benefits under or through such plan, or if such plan provides benefits to or otherwise covers any current or former employee, officer, director, or other
service provider of Parent or any of its ERISA Affiliates (or their spouses, dependents, or beneficiaries). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent IP
Rights</B>&#148; means all Intellectual Property owned or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent as presently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Material Adverse Effect</B>&#148; means any Effect that, considered together with all other Effects that have occurred prior
to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent;
provided, however, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a)&nbsp;the announcement of the Agreement or the pendency of the
Contemplated Transactions, (b)&nbsp;any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock
may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c)&nbsp;the taking of any action, or the failure to take any action, by Parent that is
required to comply with the terms of the Agreement, (d)&nbsp;any natural disaster or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any
escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e)&nbsp;any change in GAAP or applicable Law or the interpretation thereof, or
(f)&nbsp;general economic or political conditions or conditions generally affecting the industries in which Parent operates; except, in each case with respect to clauses (d), (e)&nbsp;and (f), to the extent disproportionately affecting Parent
relative to other similarly situated companies in the industries in which Parent operates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Options</B>&#148; means options or other rights to purchase shares of Parent
Common Stock issued by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Preferred Stock</B>&#148; means the Series A Non-Voting Convertible Preferred Stock,
$0.001 par value per share, of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Share Price</B>&#148; means $7.15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Transfer Agent</B>&#148; means Computershare Trust Company N.A. or its valid successor or assignee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Party</B>&#148; or &#147;<B>Parties</B>&#148; means the Company, Merger Subs, Parent and the Securityholder Agent. &#147;<B>Per Share
Cash Consideration</B>&#148; means an amount in cash equal to (i)&nbsp;the Company Valuation plus the aggregate exercise prices of the In-the-Money Company Options divided by (ii)&nbsp;the sum of (a)&nbsp;the aggregate number of shares of Company
Common Stock outstanding as of immediately prior to the First Effective Time<I> plus</I> (b)&nbsp;the aggregate number of Company Restricted Stock Units outstanding as of immediately prior to the First Effective Time<I> plus</I> (c)&nbsp;the
aggregate number of shares of Company Common Stock issuable upon exercise of all In-the-Money Company Options as of immediately prior to the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Per Share Expense Fund Amount</B>&#148; shall mean (a)&nbsp;the quotient of (i)&nbsp;the Expense Fund Amount, <I>divided</I> by
(ii)&nbsp;the aggregate number of shares of Company Common Stock held by Company Indemnitors outstanding as of immediately prior to the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Per Share Indemnity Shares</B>&#148; means a number of Indemnity Shares equal to the quotient of (a)&nbsp;the aggregate number of
Indemnity Shares<I> divided by</I> (b)&nbsp;the aggregate number of shares of Company Common Stock held by Accredited Investors as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Per Share Merger Shares</B>&#148; means a number of Company Merger Shares equal to the quotient of (a)&nbsp;the aggregate number of
Company Merger Shares<I> divided by</I> (b)&nbsp;the aggregate number of shares of Company Common Stock held by Accredited Investors as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Encumbrances</B>&#148; means (a)&nbsp;any liens for Taxes not yet due and payable or for Taxes that are being contested in
good faith and for which adequate reserves have been made on the Company Unaudited Interim Balance Sheet or the Parent Unaudited Interim Balance Sheet, as applicable, in accordance with GAAP, (b)&nbsp;minor liens that have arisen in the Ordinary
Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&nbsp;statutory liens to secure
obligations to landlords, lessors or renters under leases or rental agreements, (d)&nbsp;deposits or pledges made in connection with, or to secure payment of, workers&#146; compensation, unemployment insurance, or similar programs mandated by Law,
and (e)&nbsp;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means any individual, Entity, or Governmental Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Personal Information</B>&#148; means (i)&nbsp;information about an identified or identifiable individual and (ii)&nbsp;any other
similar information, each to the extent defined as &#147;personal information,&#148; &#147;personal data,&#148; or &#147;personally identifiable information&#148; or similar terms by Privacy Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Laws</B>&#148; mean Laws relating to privacy, security and/or collection,
use, or other processing of Personal Information and/or the use of Personal Information for direct marketing purposes, including HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Privacy Policies</B>&#148; mean the Company&#146;s written policies relating to privacy, information security and the Company&#146;s
processing of Personal Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pro Rata Share</B>&#148; means, with respect to any Company Indemnitor, such Person&#146;s
percentage interest in the Company Merger Shares as set forth on the Allocation Certificate; <U>provided</U>; that, the sum of all Pro Rata Shares shall equal 100% at all times. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Securities</B>&#148; means the shares of Parent Common Stock issued or issuable to Company Holders pursuant to this
Agreement (including pursuant to the Conversion Proposal) or the CVR Agreement and any securities issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to such shares;
<U>provided</U>, <U>however</U>, that Registrable Securities shall cease to be Registrable Securities with respect to a particular Company Holder when: (a)&nbsp;such securities have been disposed of in accordance with the Registration Statement or
pursuant to Rule 144; (b)&nbsp;such securities may be sold pursuant to Rule 144 without any manner of sale or volume limitations; or (c)&nbsp;such securities cease to be outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Expenses</B>&#148; means all expenses incurred by Parent in effecting the registration contemplated by
<U>Section&nbsp;5.11</U> of this Agreement, including all registration and filing fees, printing expenses, fees and disbursements of counsel for Parent, &#147;blue sky&#148; fees and expenses, and expenses of Parent&#146;s independent registered
public accounting firm in connection with any regular or special reviews or audits incident to or required by any such registration; <U>provided</U>, <U>however</U>, that such expenses shall not include Company Holder Selling Expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Release from Indemnity</B>&#148; means, with respect to any number of shares of Parent Capital Stock that comprise (in whole or in
part) the Indemnity Fund, the taking of all requisite action on the part of Parent and the Securityholder Agent (including, for the avoidance of doubt, the delivery of joint written instructions, delivery or cancellation orders, powers of attorney,
medallion guarantees and opinions, as necessary, to the Parent Transfer Agent) to (a)&nbsp;in the event such shares of Parent Capital Stock are to be released to the Company Indemnitors, remove any of the restrictions on transfer imposed on such
shares of Parent Capital Stock pursuant to <U>Section&nbsp;9.1(b)</U> (and the legend contemplated by<U> Section&nbsp;5.6(b)</U>) of this Agreement, such removal to be effected for each Company Indemnitor with respect to such Company
Indemnitor&#146;s Pro Rata Share of the number of shares of Parent Capital Stock to be so released to the Company Indemnitors, or (b)&nbsp;in the event such shares of Parent Common Stock are to be released to Parent, cancel such shares of Parent
Capital Stock, such cancellation to be effected for each Company Indemnitor with respect to such Company Indemnitor&#146;s Pro Rata Share of the aggregate number of shares of Parent Capital Stock to be so released to Parent; <U>provided</U> that
Parent and the Securityholder Agent shall cooperate in good faith, and coordinate with the Parent Transfer Agent, to take such actions as promptly as practicable and in a manner that gives effect to the intended consequences of clause (a)&nbsp;and
(b)&nbsp;above; <U>provided</U>, further, that, any opinion to be delivered to Parent Transfer Agent in connection with a Release from Indemnity shall be provided by Parent or its counsel. The phrase &#147;<B>Released from Indemnity</B>&#148; shall
have a corelative meaning. At the time any shares of Parent Capital Stock are Released from Indemnity, such shares of Parent Capital Stock shall no longer be part of the Indemnity Fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Representatives</B>&#148; means directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors, and
representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sarbanes-Oxley Act</B>&#148; means the Sarbanes-Oxley Act of 2002. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Entity shall be deemed to be a &#147;<B>Subsidiary</B>&#148; of a Person if such Person directly or indirectly owns or purports to own,
beneficially or of record, (a)&nbsp;an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#146;s board of directors or other governing
body, or (b)&nbsp;at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax</B>&#148; means (i)&nbsp;any U.S. federal, state, or local, or non-U.S. tax, including any income tax, franchise tax, capital
gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll
tax, customs duty, escheat, unclaimed property, alternative or add-on minimum or other tax or similar charge (whether imposed directly or through withholding and whether or not disputed) including any fees, levies, duties, tariffs, customs,
assessments, imports, re-advances and other like charges in the nature of a tax, and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the
nonpayment thereof), (ii)&nbsp;any liability for payment of amounts described in clause (i)&nbsp;as a result of transferee or successor liability, of being a member of an affiliated, consolidated, combined or unitary group for any period, or
otherwise through operation of Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Tax Return</B>&#148; means any return (including any information return), report, statement,
declaration, claims for refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental
Authority in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation, or enforcement of or compliance with any Law relating to any Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Treasury Regulations</B>&#148; means the United States Treasury regulations promulgated under the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Unaccredited Investor</B>&#148; means a Company Holder that is not an Accredited Investor and that is identified as such in the
Allocation Certificate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each of the following terms set forth in this<U> Section&nbsp;1.1(b)</U> is defined in the Section set forth
opposite such term: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Advisory Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aggregate Cash-in-Lieu Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.6(c)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Allocation Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Bribery Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.22(b)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Basket</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.4(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Capitalization Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.6(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Certifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.7(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Charter Amendment Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claim Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.6(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Claims Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Closing Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.6(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Disclosure Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Employee Plans</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.17(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Financials</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.7(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Holder Indemnitee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(e)(i)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Lock-Up Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Material Contract</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.13(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.14(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Plan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.6(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Real Estate Leases</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.11</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Regulatory Permits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.14(e)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company Stockholder Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion Proposal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.4(a)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D&amp;O Indemnified Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.4(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">D&amp;O Tail</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.4(d)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Damages</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.3(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissenting Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drug Regulatory Agency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.14(d)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnity Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnity Release Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Effectiveness Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(a)(ii)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exchange Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.10(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expense Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(d)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Step Surviving Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GAAP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.7(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Grace Period</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(b)(vii)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnity Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indemnity Release Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Intended Tax Treatment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.5(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor Agreements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lock-Up Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Malicious Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.22(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Sub 1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Sub 2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Merger Subs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Non-Continuing Employees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.3(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Non-Voting Common Stock</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.6(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Preamble</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Board Recommendation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Common Stock Consideration Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Disclosure Schedule</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Section 4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Indemnified Person</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.3(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent SEC Documents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.7(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholder Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholder Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.2(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Parent Stockholder Support Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Privacy Requirements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.22(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pro Rata Share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.6(a)(ii)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Prospectus Supplement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(a)(i)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.1(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Registration Statement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(a)(i)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Company Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Required Parent Stockholder Vote</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Certificate of Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Effective Time</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Second Merger</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Recitals</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securityholder Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(a)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Section</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securityholder Agent Engagement Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securityholder Agent Expenses</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Securityholder Agent Group</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.8(b)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Surviving Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third-Party Claim</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Transfer Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.5(a)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Violation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.11(e)(i)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">VWAP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">9.1(c)3.17(q)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">WARN Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.17(q)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Withholding Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.15</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2 <U>Other Definitional and Interpretative Provisions</U>. The words &#147;hereof,&#148; &#147;herein,&#148;
and &#147;hereunder,&#148; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall
be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits, and Schedules of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit or Schedule, but
not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and
neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#147;include,&#148; &#147;includes,&#148; or &#147;including&#148; are used in
this Agreement, they shall be deemed to be followed by the words &#147;without limitation,&#148; whether or not they are in fact followed by those words or words of like import. The word &#147;or&#148; is not exclusive. &#147;Writing,&#148;
&#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified,
or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations
promulgated thereunder, in each case as amended, modified, re-enacted thereof, and substituted, from time to time. References to &#147;$&#148; and &#147;dollars&#148; are to the currency of the United States. All accounting terms used herein will be
interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP, unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and
including, respectively. All references to &#147;days&#148; shall be to calendar days, unless otherwise indicated as a &#147;Business Day.&#148; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time
periods in this Agreement (including for purposes of &#147;Business Day&#148; and for hours in a day or Business Day), the time at which a thing, occurrence, or event shall begin or end shall be deemed to occur in the Eastern time zone of the United
States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosure Schedule or Parent Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in
<U>Section&nbsp;3</U> or <U>Section&nbsp;4</U>, respectively. The disclosures in any section or subsection of the Company Disclosure Schedule or the Parent Disclosure Schedule shall qualify other sections and subsections in <U>Section&nbsp;3</U> or
<U>Section&nbsp;4</U>, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &#147;delivered&#148; or &#147;made available&#148; mean,
with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been posted to and made available by a Party to the other Party and its
Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.
<U>Description of Transaction</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1 <U>The Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement, at the
First Effective Time, Merger Sub 1 shall be merged with and into the Company, and the separate existence of Merger Sub 1 shall cease. As a result of the First Merger, the Company will continue as the surviving corporation of the First Merger (the
&#147;<B>First Step Surviving Corporation</B>&#148;). Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Merger Sub 2, and the
separate existence of the First Step Surviving Corporation shall cease. As a result of the Second Merger, Merger Sub 2 will continue as the surviving company in the Second Merger (the &#147;<B>Surviving Company</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2 <U>Effects of the Merger</U>. At and after the First Effective Time, the First Merger shall have the effects set forth in this Agreement
and in the applicable provisions of the DGCL. As a result of the First Merger, the First Step Surviving Corporation will become a wholly owned subsidiary of Parent. At and after the Second Effective Time, the Second Merger shall have the effects set
forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing; First Effective Time; Second
Effective Time</U>. Subject to the satisfaction or waiver of the conditions set forth in <U>Section&nbsp;7</U>, <U>Section&nbsp;8</U>, and <U>Section&nbsp;9</U>, the consummation of the Merger (the &#147;<B>Closing</B>&#148;) shall take place
remotely, immediately following the execution of this Agreement, or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#147;<B>Closing
Date</B>.&#148; At the Closing, (i)&nbsp;the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the First Merger, satisfying the
applicable requirements of the DGCL, and in form and substance to be agreed upon by the Parties (the &#147;<B>First Certificate of Merger</B>&#148;), and (ii)&nbsp;the Parties shall cause the Second Merger to be consummated by executing and filing
with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA, and in form and substance to be agreed upon by the Parties (the
&#147;<B>Second Certificate of Merger</B>&#148;). The First Merger shall become effective at the time of the filing of such First Certificate of Merger with the Secretary of State of the State of Delaware, or at such later time as may be specified
in such First Certificate of Merger with the consent of Parent and the Company (the time as of which the First Merger becomes effective being referred to as the &#147;<B>First Effective Time</B>&#148;). The Second Merger shall become effective at
the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware, or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as
of which the Second Merger becomes effective being referred to as the &#147;<B>Second Effective Time</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.4 <U>Certificate of Designation; Organizational Documents</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Prior to the First Effective Time, Parent will file the Certificate of Designation with the office of the Secretary of State of the State
of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;As of the First Effective Time: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the certificate of incorporation of the First Step Surviving Corporation shall be amended and restated to read the same as
the certificate of incorporation of Merger Sub 1 as in effect immediately prior to the First Effective Time, until thereafter further amended in accordance with the DGCL and as provided in such amended and restated certificate of incorporation,
except that ARTICLE I of the certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in its entirety to read as follows: &#147;The name of this corporation is &#147;Pionyr Immunotherapeutics, Inc. (the
&#147;<B>Corporation</B>&#148;)&#148;; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the bylaws of the First Step Surviving Corporation shall be amended and
restated to read the same as the bylaws of Merger Sub 1 as in effect immediately prior to the First Effective Time, until thereafter further amended in accordance with the DGCL and as provided in the certificate of incorporation of the First Step
Surviving Corporation and such bylaws, except that all references to Merger Sub 1 in the bylaws of the First Step Surviving Corporation shall be changed to references to Pionyr Immunotherapeutics, Inc.; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) unless otherwise determined by Parent prior to the First Effective Time, the directors and officers of Merger Sub 1
immediately prior to the First Effective Time shall be the initial directors of the First Step Surviving Corporation immediately after the First Effective Time, each to hold office in accordance with the provisions of the DGCL, the certificate of
incorporation and bylaws of the First Step Surviving Corporation until their respective successors are duly elected or appointed, as applicable, and qualified; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) the certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately
prior to the First Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) As of the
Second Effective Time: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The manager of the Surviving Company, in accordance with the certificate of formation and
limited liability agreement of the Surviving Company, shall be Parent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the limited liability company agreement of
the Surviving Company shall be identical to the limited liability company agreement of Merger Sub 2 as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company
agreement; <U>provided</U>, that the limited liability company agreement of the Surviving Company shall comply with <U>Section&nbsp;5.3</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the certificate of formation of Merger Sub 2 as in effect immediately prior to the Second Effective Time shall be the
certificate of formation of the Surviving Company, until thereafter further amended in accordance with DLLCA and as provided in such certificate of formation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The certificate of incorporation, as amended by the Certificate of Designation, of Parent shall be identical to the certificate of
incorporation of Parent immediately prior to the Second Effective Time until thereafter amended as provided by the DGCL and as provided in such certificate of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.5 <U>Parent Stock Consideration</U>. Notwithstanding anything in this Agreement to the
contrary, the maximum aggregate number of shares of Parent Common Stock to be paid by Parent as consideration for all the outstanding shares of Company Common Stock at the First Effective Time (in each case, including both Company Merger Shares and
Indemnity Shares) shall be 1,800,680 shares of Parent Common Stock, which shares shall represent a number of shares equal to no more than 4.99% of the outstanding shares of voting Parent Common Stock as of immediately before the First Effective Time
(the &#147;<B>Parent Common Stock Consideration Cap</B>&#148;). In the event the aggregate number of shares of Parent Common Stock issuable to the Company Holders at the First Effective Time pursuant to <U>Section&nbsp;2</U> would result in the
issuance of shares of Parent Common Stock in an amount in excess of the Parent Common Stock Consideration Cap, Parent shall issue to each such Company Holder shares of Parent Common Stock up to 4.99% of the Parent Common Stock that would have been
issued to such Company Holder prior to the application of this <U>Section&nbsp;2.5</U> and shall issue the remaining balance to such Company Holders in the form of shares of Parent Preferred Stock on the basis of one (1)&nbsp;share of Parent
Preferred Stock for each share of Company Common Stock that otherwise would have been issued. Each share of Parent Preferred Stock shall be convertible into one (1)&nbsp;share of Parent Common Stock, subject to and contingent upon the affirmative
vote of a majority of the votes cast at a meeting of the stockholders of Parent to approve the Conversion Proposal (other than votes cast with respect to shares of Parent Common Stock that were issued as Company Merger Shares or Indemnity Shares).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.6 <U>Conversion of Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) At the First Effective Time, by virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the
Company, or any stockholder of the Company or Parent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any shares of Company Common Stock held as treasury stock or
held or owned by the Company or any wholly owned Subsidiary of the Company immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to <U>Section&nbsp;2.5</U> and <U>Section&nbsp;2.6(c)</U>, each share of Company Common Stock outstanding
immediately prior to the First Effective Time (excluding shares to be canceled pursuant to <U>Section&nbsp;2.6(a)(i)</U> and excluding any Dissenting Shares) shall be automatically converted into: (A)&nbsp;if the holder of such share of Company
Common Stock is an Accredited Investor, the right to receive (1)&nbsp;the Per Share Merger Shares, (2)&nbsp;the Per Share Indemnity Shares, (3)&nbsp;the contingent right to receive the Per Share Expense Fund Amount if, and to the extent, such
amounts become distributable to former holders of such shares of Company Common Stock in accordance with, and subject to, the terms and conditions of <U>Section&nbsp;9.8(d)</U> of this Agreement, and (4)&nbsp;one CVR; or (B)&nbsp;if the holder of
such share of Company Common Stock is an Unaccredited Investor, (1)&nbsp;cash in the amount of the Per Share Cash Consideration and (2)&nbsp;one CVR. Each CVR issued will be issued in book-entry form pursuant to the CVR Agreement and will not be
evidenced by a certificate or other instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No later than immediately prior to the First Effective Time, the Company shall take
all actions reasonably necessary to cause the vesting of any share of Company Common Stock outstanding immediately prior to the First Effective Time that is subject to a substantial risk of forfeiture within the meaning of Section&nbsp;83 of the
Code to accelerate in full and such substantial risk of forfeiture to immediately lapse. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No fractional shares of Parent Common Stock or Parent Preferred Stock shall be issued
in connection with the First Merger, and no certificates or scrip for any such fractional shares shall be issued. Any fractional shares of Parent Common Stock or Parent Preferred Stock a holder of Company Common Stock would otherwise be entitled to
receive shall be aggregated together first, prior to any remaining fractional share being paid in cash the dollar amount (rounded to the nearest whole cent), without interest and subject to any required Tax withholding, determined by multiplying
such fraction by the Parent Share Price (together, the &#147;<B>Aggregate Cash-in-Lieu Payments</B>&#148;). The payment of cash in lieu of fractional share interests pursuant to this <U>Section&nbsp;2.6(c)</U> is not a separately bargained-for
consideration but merely represents a mechanical rounding-off of the fractions in the exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) At the First Effective Time, by
virtue of the First Merger and without any further action on the part of Parent, Merger Subs, the Company, or any stockholder of the Company or Parent, each share of common stock of Merger Sub 1 issued and outstanding immediately prior to the First
Effective Time shall be converted into and exchanged for one share of common stock of the First Step Surviving Corporation. If applicable, each stock certificate of Merger Sub 1 evidencing ownership of any such shares shall, as of the First
Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) If, between the date of
this Agreement and the First Effective Time, the outstanding shares of Company Common Stock or Parent Common Stock or Parent Preferred Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason
of any stock dividend, subdivision, reclassification, recapitalization, split, combination, or exchange of shares or other like change, the Company Merger Shares and the Indemnity Shares shall, to the extent necessary, be equitably adjusted to
reflect such change to the extent necessary to provide the holders of Company Common Stock and Parent Common Stock and Parent Preferred Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision,
reclassification, recapitalization, split, combination, or exchange of shares or other like change; provided, however, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Common Stock or
Parent Common Stock or Parent Preferred Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) As of the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving
Corporation, Merger Sub 2 or their respective stockholders or members, as applicable, each share of common stock of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and
extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.7 <U>Company
Options</U>. At the First Effective Time, each Company Option, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall be cancelled and each In-the-Money Company Option shall be automatically converted
into the right to receive for each share of Company Common Stock underlying such Company Option, without interest and subject to deduction for any required withholding under applicable Tax Law, an amount in cash from Parent or the Surviving Company
equal to the excess of the Per Share Cash Consideration over the per share exercise price of such In-the-Money Company Option. For the avoidance of doubt, each Company Option that does not constitute an In-the-Money Company Option shall be cancelled
at the First Effective Time without any consideration payable therefor (whether in the form of cash or otherwise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.8 <U>Company
Restricted Stock Units</U>. At the First Effective Time, each Company Restricted Stock Unit, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall be automatically cancelled and converted into the right
to receive, without interest and subject to deduction for any required withholding under applicable Tax Law, an amount in cash from Parent or the Surviving Company equal to the Per Share Cash Consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.9 <U>Closing of the Company&#146;s Transfer Books</U>. At the First Effective Time:
(a)&nbsp;all shares of Company Common Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with <U>Section&nbsp;2.6(a)</U>, and all holders of Company Common Stock that were outstanding immediately prior to
the First Effective Time shall cease to have any rights as stockholders of the Company, and (b)&nbsp;the stock transfer books of the Company shall be closed with respect to all shares of Company Common Stock outstanding immediately prior to the
First Effective Time. No further transfer of any such shares of Company Common Stock shall be made on such stock transfer books after the First Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.10 <U>Surrender of Book-Entry Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, Parent shall select a reputable bank, transfer agent, or trust company to act as exchange agent in the
Merger (the &#147;<B>Exchange Agent</B>&#148;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Common Stock and Parent Preferred Stock issuable pursuant to
<U>Section&nbsp;2.6(a)</U> in exchange for Company Common Stock (which, for the avoidance of doubt, shall consist of the Company Merger Shares and the Indemnity Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) For the avoidance of doubt. Parent shall not be required to deposit any funds related to any CVR, including with respect to any amounts
potentially payable under any CVR, with the Rights Agent unless and until such deposit is required pursuant to the express terms of the CVR Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.11 <U>Closing Cash Payments</U>. At the Closing, Parent shall deposit, or cause to be deposited, (a)(i) the Aggregate Cash Payments payable
to the Company Stockholders who are Unaccredited Investors in accordance with <U>Section&nbsp;2.6(a)(ii)</U>, and (ii)&nbsp;the Aggregate Cash-in-Lieu Payments payable to the Company Stockholders in accordance with <U>Section&nbsp;2.6(c)</U>, in
each case (a)&nbsp;and (b), with the Exchange Agent, for the benefit of such Company Stockholders, by wire transfer of immediately available funds to the account specified in writing by the Exchange Agent, (b)&nbsp;the Expense Fund Amount with the
Securityholder Agent, by wire transfer of immediately available funds to the account specified in writing by the Securityholder Agent and (c)&nbsp;the transaction expenses as set forth on <U>Schedule G</U> hereto to the extent unpaid at the Closing.
Any amounts deposited with the Exchange Agent pursuant to this Agreement shall not be used for any purpose except the payment of amounts due to the Company Holders in accordance with this Agreement. At the Closing, Parent shall deposit, or cause to
be deposited, the Aggregate Cash Payments payable to Company Holders who hold In-the-Money Company Options and Company Restricted Stock Units, with the Surviving Company, together with the amount of employer-funded employment Taxes in respect of
such Company Holders who are or were employed by the Company, for the benefit of such Company Holders, by wire transfer of immediately available funds to the account specified in writing by the Company prior to the First Effective Time. Parent shall
cause the Surviving Company to pay the amount determined under Sections 2.7 and 2.8 on or as soon as administratively practicable following the First Effective Time, such payment to be made under the Surviving Company&#146;s payroll for any such
Company Holder who is or was employed by the Company and under the Surviving Company&#146;s accounts payable for any such Company Holder who never was employed by the Company. At the Closing, Parent shall wire, or cause to be wired, the Expense Fund
Amount to the Securityholder Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.12 <U>Appraisal Rights</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding any provision of this Agreement to the contrary, shares of Company Common Stock that are outstanding immediately prior to
the First Effective Time and which are held by stockholders who have exercised and perfected appraisal rights for such shares of Company Common Stock in accordance with the DGCL (the &#147;<B>Dissenting Shares</B>&#148;) shall not be converted into
or represent the right to receive the applicable merger consideration described in <U>Section&nbsp;2.6</U> attributable to such Dissenting Shares. Such stockholders shall be entitled to receive payment of the appraised value of such shares of
Company Common Stock held by them in accordance with the DGCL, unless and until such stockholders fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders who shall
have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Common Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be
converted into and have become exchangeable for, as of the First Effective Time, the right to receive the applicable merger consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in
<U>Section&nbsp;2.6</U> and <U>Section&nbsp;2.10</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent shall give the Securityholder Agent prompt written notice of any
demands by dissenting stockholders received by the Company or Parent, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company or Parent in connection with such demands, and
Parent shall have the right to direct all negotiations and proceedings with respect to such demands; provided that the Securityholder Agent shall have the right to participate in such negotiations and proceedings. Neither the Parent nor the
Securityholder Agent shall, except with the other party&#146;s prior written consent, voluntarily make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of
the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.13 <U>Further Action</U>. If, at any time after the First Effective Time, any further action is determined by the
Surviving Company to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Company with full right, title, and possession of and to all rights and property of the Company, then the officers and manager of the
Surviving Company shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of Merger Subs, in the name of the Surviving Company and otherwise) to take such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.14 <U>Tax Consequences</U>. The Parties (i)&nbsp;acknowledge and agree that, for U.S. federal (and applicable state and local) income tax
purposes, the First Merger and the Second Merger, taken together, are intended to constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a reorganization within the meaning of Section&nbsp;368(a) of
the Code, and (ii)&nbsp;adopt this Agreement as a &#147;plan of reorganization&#148; within the meaning of Treasury Regulations Section&nbsp;1.368-2(g). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.15 <U>Withholding</U>. The Parties, the Exchange Agent, and each of their respective Affiliates (each, a &#147;<B>Withholding
Agent</B>&#148;) shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement such amounts as are required to be deducted or withheld from such consideration under the Code or under any other applicable Tax
Law; provided that if a Withholding Agent determines that any payment in connection with the Contemplated Transactions is subject to deduction and/or withholding under the Code or under any other applicable Tax Law, then, except with respect to
compensatory payments or as a result of a failure to deliver the certificate described in <U>Section&nbsp;5.5(c)</U>, such Withholding Agent shall use commercially reasonable efforts to (i)&nbsp;provide notice to such recipient after such
determination and (ii)&nbsp;cooperate with such recipient prior to Closing to reduce or eliminate any such deduction and/or withholding. To the extent such amounts are so deducted or withheld, and remitted to the appropriate Governmental Authority,
such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Representations and Warranties of the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to <U>Section&nbsp;3</U>, except as set forth in the written disclosure schedule delivered by the Company to Parent (the
&#147;<B>Company Disclosure Schedule</B>&#148;), the Company represents and warrants to Parent and Merger Subs as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1 <U>Due
Organization; Subsidiaries</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is a corporation duly incorporated, validly existing, and in good standing under the
Laws of the jurisdiction of its incorporation and has all necessary power and authority: (i)&nbsp;to conduct its business in the manner in which its business is currently being conducted, (ii)&nbsp;to own or lease and use its property and assets in
the manner in which its property and assets are currently owned or leased and used, and (iii)&nbsp;to perform in all material respects its obligations under all Contracts still in effect by which it is bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under
the Laws of all jurisdictions where the nature of its business requires such licensing or qualification, other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a
Company Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has no Subsidiaries and the Company does not own any capital stock or membership
interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant
in any partnership, joint venture, or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other
Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership, or other Entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2 <U>Organizational Documents</U>. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the
Company. The Company is not in breach or violation of its Organizational Documents in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3 <U>Authority; Binding
Nature of Agreement</U><B>. </B>The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company&#146;s board of directors has
(i)&nbsp;determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii)&nbsp;authorized, approved and declared advisable this Agreement and the Contemplated Transactions, and
(iii)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and approve the Contemplated Transactions. This Agreement has been duly
executed and delivered by the Company and, assuming the due authorization, execution, and delivery by Parent and Merger Subs, constitutes the legal, valid, and binding obligation of the Company, enforceable against the Company in accordance with its
terms, subject to the Enforceability Exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4 <U>Vote Required</U>. The affirmative vote (or written consent) of (i)&nbsp;the
holders of a majority of the shares of Company Common Stock each outstanding on the record date for the Company Stockholder Written Consent and entitled to vote thereon, voting as a single class; (ii)&nbsp;the holders of a majority of the shares of
Company Class&nbsp;A Common Stock each outstanding on the record date for the Company Stockholder Written Consent and entitled to vote thereon, voting as a single class, and (iii)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders of a majority of the shares of Company Class B Common Stock each outstanding on the record date for the Company Stockholder Written Consent and entitled to vote thereon, voting as a
single class (the &#147;<B>Required Company Stockholder Vote</B>&#148;), is the only vote (or written consent) of the holders of any class or series of Company Common Stock necessary to adopt and approve this Agreement and approve the Contemplated
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5 <U>Non-Contravention; Consents</U><B>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Company Stockholder Vote and the filing of the First Certificate of Merger, the Second Certificate of
Merger, and the Certificate of Designation required by the DGCL and DLLCA, neither (x)&nbsp;the execution, delivery, or performance of this Agreement by the Company, nor (y)&nbsp;the consummation of the Contemplated Transactions, will directly or
indirectly (with or without notice or lapse of time): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) contravene, conflict with or result in a violation of any of
the provisions of the Company&#146;s Organizational Documents; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) except as would not reasonably be expected to have a
Company Material Adverse Effect, contravene, conflict with, or result in a violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under,
any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) except as
would not reasonably be expected to have a Company Material Adverse Effect, contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel,
terminate or modify, any Governmental Authorization that is held by the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) except as would not reasonably be
expected to have a Company Material Adverse Effect, contravene, conflict with, or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&nbsp;declare a
default or exercise any remedy under any Company Material Contract, (B)&nbsp;any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C)&nbsp;accelerate the maturity or performance of any
Company Material Contract (excluding any compensatory payment or benefit payable under any Company Material Contract or an Employee Plan), or (D)&nbsp;cancel, terminate or modify any term of any Company Material Contract, except in the case of any
non-material breach, default, penalty or modification; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) except as would not reasonably be expected to have a
Company Material Adverse Effect, result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&nbsp;the Required Company Stockholder Vote, (ii)&nbsp;the filing of the First Certificate of Merger, the Second
Certificate of Merger and the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL and the DLLCA, (iii)&nbsp;such consents, waivers, approvals, orders, authorizations, registrations, declarations, and
filings as may be required under applicable federal and state securities laws and (iv)&nbsp;as otherwise disclosed in <U>Section&nbsp;3.5(b)</U> of the Company Disclosure Schedule, the Company was not, is not, nor will be required to make any filing
with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&nbsp;the execution, delivery or performance of this Agreement, or (y)&nbsp;the consummation of the Contemplated Transactions, in each case, except as would
not reasonably be expected to have a Company Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Assuming the accuracy of <U>Section&nbsp;4.17</U>, the Company board of directors has
taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL and any similar provisions of the Company&#146;s Organizational Documents are, and will be,
inapplicable to the execution, delivery, and performance of this Agreement and to the consummation of the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6
<U>Capitalization.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock as of the date of this Agreement consists of 144,341,247 shares of the
Company&#146;s common stock, par value $0.0001 per share (such stock, whether designated as Class&nbsp;A Common Stock, par value $0.0001 per share of the Company or Class B Common Stock, par value $0.0001 per share of the Company, the
&#147;<B>Company Common Stock</B>&#148;). The Company does not hold any shares of its capital stock in its treasury. <U>Section&nbsp;3.6(a)</U> of the Company Disclosure Schedule sets forth an accurate and complete capitalization table of the
Company, including each record holder of issued and outstanding Company Equity Securities and the number and type of shares of Company Equity Securities held by such holder, as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Company Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable
and are free of any Encumbrances, other than Permitted Encumbrances or as set forth on <U>Section&nbsp;3.6(b)</U> of the Company Disclosure Schedule. None of the outstanding Company Common Stock is entitled or subject to any preemptive right, right
of participation, right of maintenance or any similar right and none of the outstanding Company Common Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to
the voting or registration of, or restricting any Person from purchasing, selling, pledging, or otherwise disposing of (or granting any option or similar right with respect to), any Company Common Stock, in each case except as set forth on
<U>Section&nbsp;3.6(b)</U> of the Company Disclosure Schedule. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem, or otherwise acquire any outstanding Company
Common Stock or other securities. <U>Section&nbsp;3.6(b)</U> of the Company Disclosure Schedule accurately and completely lists all repurchase rights held by the Company with respect to Company Common Stock (including shares issued pursuant to the
exercise of Company Options) and specifies which of those repurchase rights are currently exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except for the Company&#146;s
2015 Equity Incentive Plan (the &#147;<B>Company Plan</B>&#148;), the Company does not have any stock option plan or any other plan, program, agreement, or arrangement providing for any equity or equity-based compensation for any Person. As of the
date of this Agreement, the Company has reserved 11,013,188 shares of Company Common Stock for issuance under the Company Plan, of which 2,079,238 shares have been issued and are currently outstanding, 7,370,233 shares have been reserved for
issuance upon exercise of Company Options and 389,500 shares for settlement of Company Restricted Stock Units previously granted and currently outstanding under the Company Plan, and 1,174,217 shares of Company Common Stock remain available for
future issuance of awards pursuant to the Company Plan. <U>Section&nbsp;3.6(b)</U> of the Company Disclosure Schedule sets forth the following information with respect to each Company Option and award of Company Restricted Stock Units outstanding as
of the date of this Agreement: (i)&nbsp;the name of the grantee; (ii)&nbsp;the number of shares of Company Common Stock subject to such Company Option or award of Company Restricted Stock Units at the time of grant; (iii)&nbsp;the number of shares
of Company Common Stock subject to such Company Option or award of Company Restricted Stock Units as of the date of this Agreement; (iv)&nbsp;the exercise price of such Company Option; (v)&nbsp;the date on which such Company Option or Company
Restricted Stock Unit was granted; (vi)&nbsp;the date on which such Company Option expires; and (vii)&nbsp;whether such Company Option is intended to constitute an &#147;incentive stock option&#148; (as defined in the Code) or a non-qualified stock
option. The Company has delivered to Parent an accurate and complete copy of the Company Plan and a form of stock option and restricted stock unit agreement that is consistent with the stock option agreements and restricted stock unit agreements
evidencing outstanding Company Options and awards of Company Restricted Stock Units, respectively, granted thereunder and any other forms of award agreements evidencing outstanding equity awards granted under the Company Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except for the Company Options and Company Restricted Stock Units set forth in
<U>Section&nbsp;3.6(d)</U> of the Company Disclosure Schedule, there is no: (i)&nbsp;outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of
the Company, (ii)&nbsp;outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of the Company, or (iii)&nbsp;condition or circumstance that may
give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock
appreciation, phantom stock, profit participation, or other similar rights with respect to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) All outstanding shares of
Company Common Stock, Company Options, Company Restricted Stock Units and other securities of the Company have been issued and granted in material compliance with (i)&nbsp;the Organizational Documents of the Company in effect as of the relevant
time, (ii)&nbsp;all applicable securities laws and other applicable Law, and (iii)&nbsp;all requirements set forth in applicable Contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) All distributions, dividends, repurchases, and redemptions of the Company Equity Securities or other equity interests of the Company were
undertaken in material compliance with (i)&nbsp;the Organizational Documents of the Company in effect as of the relevant time, (ii)&nbsp;all applicable securities laws and other applicable Law and (iii)&nbsp;all requirements set forth in applicable
Contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.7 <U>Financial Statements.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section&nbsp;3.7(a)</U> of the Company Disclosure Schedule includes true and complete copies of (i)&nbsp;the Company&#146;s audited
consolidated balance sheets at December&nbsp;31, 2022 and December&nbsp;31, 2021, (ii)&nbsp;the Company Unaudited Interim Balance Sheet, (iii)&nbsp;the Company&#146;s audited consolidated statements of income, cash flow and members&#146; equity for
the years ended December&nbsp;31, 2022 and December&nbsp;31, 2021, and (iv)&nbsp;the Company&#146;s unaudited statements of income, cash flow and shareholders&#146; equity for the six months ended June&nbsp;30, 2023 (collectively, the
&#147;<B>Company Financials</B>&#148;). The Company Financials (A)&nbsp;were prepared in accordance with United States generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) (except as may be indicated in the footnotes to such Company
Financials and that unaudited financial statements may not have notes thereto and other presentation items that may be required by GAAP and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in
amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (B)&nbsp;fairly present, in all material respects, the financial position and operating results of the Company as of the dates and for the
periods indicated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company maintains accurate books and records reflecting its assets and liabilities in all material
respects and maintains a system of internal accounting controls designed to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations, (ii)&nbsp;transactions are
recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#146;s assets, (iii)&nbsp;access to the Company&#146;s assets is permitted only in
accordance with management&#146;s general or specific authorization, and (iv)&nbsp;the recorded accountability for the Company&#146;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to
any differences. The Company maintains internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
GAAP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth on <U>Section&nbsp;3.7(c)</U> of the Company Disclosure Schedule,
since July&nbsp;1, 2020, there have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by, or initiated at the direction of the chief executive officer, chief financial
officer of the Company, the Company&#146;s board of directors, or any committee thereof. Except as set forth on <U>Section&nbsp;3.7(c)</U> of the Company Disclosure Schedule, since July 1, 2020, neither the Company nor, to the Knowledge of the
Company, its independent auditors have identified (i)&nbsp;any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii)&nbsp;any fraud, whether or not
material, that involves the Company, the Company&#146;s management or other employees who have a role in the preparation of financial statements, or the internal accounting controls utilized by the Company, or (iii)&nbsp;any claim or allegation
regarding any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.8 <U>Absence of Changes.</U> Except as set forth on <U>Section&nbsp;3.8</U> of the Company Disclosure
Schedule, between the date of the Company Unaudited Interim Balance Sheet and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and
the discussions, negotiations and transactions related thereto) and there has not been any (x)&nbsp;Company Material Adverse Effect or (y)&nbsp;actions to do any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) declare, accrue, set aside, or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase,
redeem or otherwise reacquire any equity interests in the Company or other securities (except for equity interests in the Company from terminated employees, directors or consultants of the Company in accordance with agreements in effect on the date
of this Agreement providing for the repurchase of shares at no more than the purchase price thereof in connection with any termination of services to the Company or any of its Subsidiaries); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be
a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) (A)&nbsp;lend money to any Person, (B)&nbsp;incur or guarantee any indebtedness for borrowed money (excluding any indebtedness reflected
on the Company Unaudited Interim Balance Sheet) or (C)&nbsp;make any commitment for capital expenditure; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) make, change or revoke any
material Tax election; file any amendment to any material Tax Return; settle or compromise any material Tax claim; waive or extend any statute of limitations in respect of a period within which an assessment or reassessment of material Taxes may be
issued (other than any extension pursuant to an extension to file any Tax Return); enter into any &#147;closing agreement&#148; as described in Section&nbsp;7121 of the Code (or any similar Law) with any Governmental Authority ; or adopt or change
any accounting method in respect of material Taxes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) waive, settle or compromise any pending or threatened Legal Proceeding against
the Company, other than waivers, settlements or agreements (A)&nbsp;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&nbsp;that do not impose any
material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) agree, resolve, or commit to do any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.9 <U>Absence of Undisclosed Liabilities.</U> The Company does not have any liability, indebtedness, obligation, expense, claim, deficiency,
guaranty, or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured, or otherwise (whether or not required to be reflected in the financial statements in accordance with GAAP) (each a &#147;<B>Liability</B>&#148;), in
each case, of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, or any securitization transactions or &#147;off balance sheet arrangements&#148; (as defined in Item&nbsp;303(c) of Regulation S-K
under the Exchange Act), except for: (a)&nbsp;Liabilities disclosed, reflected or reserved against in the Company Unaudited Interim Balance Sheet, (b)&nbsp;normal and recurring current Liabilities that have been incurred by the Company since the
date of the Company Unaudited Interim Balance Sheet in the Ordinary Course of Business, (c)&nbsp;Liabilities for performance of obligations of the Company under Company Contracts, (d)&nbsp;Liabilities incurred in connection with the Contemplated
Transactions, and (e)&nbsp;Liabilities listed in <U>Section&nbsp;3.9</U> of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.10 <U>Title to Assets.</U>
The Company owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or assets and equipment used or held for use in its business or operations or purported to be
owned by it, including: (a)&nbsp;all assets reflected on the Company Unaudited Interim Balance Sheet and (b)&nbsp;all other assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in
the case of leased assets, leased by the Company free and clear of any Encumbrances, other than those Encumbrances that are Permitted Encumbrances or listed in<U> Section&nbsp;3.10</U> of the Company Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.11 <U>Real Property; Leasehold.</U> The Company does not own nor has ever owned any real property. The Company has made available to Parent
(a)&nbsp;an accurate and complete list of all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and
(b)&nbsp;copies of all leases under which any such real property is possessed (the &#147;<B>Company Real Estate Leases</B>&#148;), each of which is in full force and effect, with no existing material default thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.12 <U>Intellectual Property</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section&nbsp;3.12(a)</U> of the Company Disclosure Schedule is an accurate, true and complete listing of all Company Registered IP.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Section&nbsp;3.12(b)</U> of the Company Disclosure Schedule accurately identifies (i)&nbsp;all Company Contracts pursuant to
which any material Company IP Rights are licensed to the Company (other than (A)&nbsp;any non-customized software that (1)&nbsp;is so licensed solely in executable or object code form pursuant to a non-exclusive, internal use software license and
other Intellectual Property associated with such software and (2)&nbsp;is not incorporated into, or material to the development, manufacturing, or distribution of, any of the Company&#146;s products or services, (B)&nbsp;any Intellectual Property
licensed on a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis ancillary to the purchase or use of equipment, reagents or other materials, (C)&nbsp;any confidential information provided under confidentiality agreements and
(D)&nbsp;agreements between Company and its employees in Company&#146;s standard form thereof) and (ii)&nbsp;whether the license or licenses granted to the Company are exclusive or non-exclusive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Section&nbsp;3.12(c)</U> of the Company Disclosure Schedule accurately identifies each Company Contract pursuant to which any Person
has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any material Company IP Rights (other than (i)&nbsp;any confidential information
provided under confidentiality agreements and (ii)&nbsp;any Company IP Rights non-exclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service
providers to provide services for the Company&#146;s benefit). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company is not bound by, and no material Company IP Rights are subject to, any
Contract containing any covenant or other provision that in any way materially limits or restricts the ability of the Company to use, exploit, assert, or enforce any material Company IP Rights anywhere in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Except as set forth in <U>Section 3.12(e)</U> of the Company Disclosure Schedule, the Company exclusively owns all right, title, and
interest to and in all Company IP Rights, (other than (i)&nbsp;Company IP Rights licensed to the Company, or co-owned rights, (ii)&nbsp;any non-customized software that (A)&nbsp;is licensed to the Company solely in executable or object code form
pursuant to a non-exclusive, internal use software license and other Intellectual Property associated with such software and (B)&nbsp;is not incorporated into, or material to the development, manufacturing, or distribution of, any of the
Company&#146;s products or services and (iii)&nbsp;any Intellectual Property licensed on a non-exclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than
Permitted Encumbrances). Without limiting the generality of the foregoing: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To the
Knowledge of the Company, all documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental
Authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To the Knowledge of the Company, each Person who is or was an employee
or contractor of the Company and who is or was involved in the creation or development of any material Intellectual Property for the Company has signed a valid, enforceable agreement assigning all rights in such Intellectual Property to the Company
and includes confidentiality provisions protecting trade secrets and confidential information of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To the Knowledge of the Company, no current or former officer, director, or employee
of the Company has any claim, right (whether or not currently exercisable), or interest to or in any material Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a)&nbsp;bound by or
otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b)&nbsp;in breach of any Contract with any former employer or other Person concerning material Company IP Rights purported to be owned by
the Company or confidentiality provisions protecting trade secrets and confidential information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) No funding, facilities, or personnel of any Governmental Authority were used, directly
or indirectly, to develop or create, in whole or in part, any material Company IP Rights in which the Company has an ownership interest. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) The Company has taken reasonable steps to maintain the confidentiality of and otherwise
protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret where the failure to be so individually or in the aggregate would not be reasonably expected to be material
to the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) The Company has not assigned or otherwise transferred ownership
of, or agreed to assign or otherwise transfer ownership of, any material Company IP Rights in which the Company has an ownership interest to any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) To the Knowledge of the Company,
the Company IP Rights constitute all Intellectual Property necessary for the Company to conduct its material business as currently conducted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) To the Knowledge of the Company, the Company has delivered or made available to Parent, a complete and accurate copy of all material
Company IP Rights Agreements. With respect to such Company IP Rights Agreements: (i)&nbsp;each such agreement is valid and binding on the Company and in full force and effect, (ii)&nbsp;the Company has not received any written notice of termination
or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived, and (iii)&nbsp;the Company is not, and to the Knowledge of the Company, no other party to any
such agreement is, in breach or default thereof in any material respect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The manufacture, marketing, license, sale, offering for
sale, importation, use or intended use or other disposal of any product or technology as currently licensed or sold or under development by the Company does not violate any Contract between the Company and any other Person in any material respect,
and does not infringe or misappropriate and has not infringed or misappropriated any Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to be material to the Company. To the Knowledge of
the Company, no third party is infringing upon any Patents owned by or exclusively licensed to the Company within the material Company IP Rights, or violating any Contract with the Company relating to any material Company IP Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any
patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any material Company IP Rights. The Company has not received any written notice
asserting that any material Company IP Rights or its past, current or proposed use, sale, offer for sale, license or disposition of products, methods, or processes claimed or covered thereunder conflicts with or infringes or misappropriates the
rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the material Company IP Rights is subject to any outstanding order of, judgment of, decree
of any court, tribunal or judicial authority of competent jurisdiction or agreement with any Governmental Authority that materially limits the ability of the Company to exploit any material Company IP Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) All Company Registered IP that is issued or granted is valid and enforceable except where the failure to be so individually or in the
aggregate would not be reasonably expected to be material to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) To the Knowledge of the Company, no trademark (whether
registered or unregistered) or trade name owned, used, or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used, or applied for by any other Person where the failure to
be so individually or in the aggregate would not be reasonably expected to be material to the Company. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to
have an ownership interest, has been materially impaired as determined by the Company in accordance with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Except as set forth
in <U>Sections 3.12(b)</U> or <U>3.12(c)</U> of the Company Disclosure Schedule or as contained in license, distribution or service agreements entered into in the Ordinary Course of Business by the Company (i)&nbsp;to the Knowledge of the Company,
the Company is not bound by any Contract to indemnify, defend, hold harmless, or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole
and (ii)&nbsp;to the Knowledge of the Company, the Company has never assumed, or agreed to discharge or otherwise take responsibility for in writing, any liability of another Person for infringement, misappropriation, or violation of any
Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement, except where, in each case of (i)&nbsp;and (ii), such obligation individually or in the aggregate would not be reasonably
expected to be material to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company is not party to any Contract that, as a result of such execution, delivery
and performance of this Agreement, will cause the grant of any license or other right to any material Company IP Rights, result in breach of, default under or termination of such Contract with respect to any material Company IP Rights, or impair the
right of the Company or the Surviving Company and its Subsidiaries to use, sell or license or enforce any material Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the
aggregate, reasonably be expected to be material to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.13 <U>Agreements, Contracts and Commitments.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section&nbsp;3.13(a)</U> of the Company Disclosure Schedule lists the following Company Contracts in effect as of the date of this
Agreement (each, a &#147;<B>Company Material Contract</B>&#148; and collectively, the &#147;<B>Company Material Contracts</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) each Company Contract relating to any bonus, deferred compensation, severance,
retention or incentive compensation, under which the Company has any actual or potential liability in excess of $50,000; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) each Company Contract requiring payments by the Company after the date of this
Agreement in excess of $50,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Person, including any employee, consultant or independent contractor, or Entity providing
employment related, consulting or independent contractor services, not terminable by the Company on ninety (90)&nbsp;calendar days&#146; or less notice without liability, except to the extent applicable Law or general principles of wrongful
termination Law may limit the Company&#146;s, or such successor&#146;s ability to terminate employees at will; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) each Company Contract relating to any agreement or plan, including any option plan,
stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased, or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction
with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) each Company Contract relating to any agreement of indemnification or guaranty not
entered into in the Ordinary Course of Business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) each Company Contract containing
(A)&nbsp;any covenant which would limit the freedom of the Surviving Company to engage in any line of business or compete with any Person, or would limit the development, manufacture, distribution or commercialization by the Surviving Company of any
of the Company&#146;s products, technology or services, (B)&nbsp;any most-favored nation or other preferred pricing arrangement in favor of a Person other than the Company or any similar term by which any Person is or could become entitled to any
benefit, right or privilege that must be at least as favorable to such Person as those offered to any other Person, (C) any exclusivity provision, right of first refusal or right of first negotiation or similar covenant in favor of a Person other
than the Company, or (D)&nbsp;any non-solicitation provision; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) each Company Contract
(A)&nbsp;pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, (B)&nbsp;pursuant to which the Company granted any Person an exclusive license under any Company IP Rights, (C)&nbsp;required to be
scheduled on <U>Section&nbsp;3.12(b)</U> of the Company Disclosure Schedule, or (D)&nbsp;required to be scheduled on <U>Section&nbsp;3.12(c)</U> of the Company Disclosure Schedule; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) each Company Contract relating to capital expenditures and requiring payments after
the date of this Agreement in excess of $50,000 pursuant to its express terms and not cancelable without penalty; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) each Company Contract relating to the disposition or acquisition of material assets
or any ownership interest in any Entity; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) each Company Contract relating to any
mortgages, indentures, loans, notes or credit agreements, security agreements, or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $50,000, or creating any material Encumbrances, other than
Permitted Encumbrances, with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) each Company Contract requiring payment by or to the Company after the date of this
Agreement in excess of $50,000 pursuant to its express terms relating to: (A)&nbsp;any distribution agreement (identifying any that contain exclusivity provisions), (B)&nbsp;any agreement involving provision of services or products with respect to
any pre-clinical or clinical development activities of the Company, (C)&nbsp;any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development, or other agreement currently in force under which the Company has continuing
obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company, or
(D)&nbsp;any Contract to license any patent, trademark registration, service mark registration, trade name, or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any
Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for material Company Contracts entered into in the Ordinary Course of Business; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) each Company Contract with any Person, including any financial advisor, broker,
finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) each Company Real Estate Lease; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) each Company Contract that is a material contract as defined in Item&nbsp;601(b)(10)
of Regulation S-K as promulgated under the Securities Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) each Company Contract
to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $50,000; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) any other Company Contract that is
not terminable at will (with no penalty or payment) by the Company, and (A)&nbsp;which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $50,000 in the
aggregate, or obligations after the date of this Agreement in excess of $50,000 in the aggregate or (B)&nbsp;that is material to the business or operations of the Company taken as a whole. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all
amendments thereto, other than the Company Material Contracts relating to any bonus, deferred compensation, severance, retention or incentive compensation, which have been provided to Parent or its counsel via email and are listed on
<U>Section&nbsp;3.13(a)</U> or <U>3.17(a)</U> of the Company Disclosure Schedule. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#146;s Knowledge, as of the date of this Agreement has
any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such manner as would permit
any other party to cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As of the date of this Agreement, each Company
Material Contract is valid, binding, enforceable, and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material
amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract, and to the Knowledge of the Company, no Person has indicated to the Company in writing that it
desires to renegotiate, modify, not renew or cancel any Company Material Contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.14 <U>Compliance; Permits; Restrictions.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company is, and its Subsidiaries are, and since July&nbsp;1, 2020, have been, in material compliance with all applicable Laws. No
investigation, claim, suit, proceeding, audit, Order, or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company or any of its Subsidiaries. To the Knowledge of
the Company, there is no agreement or Order binding upon the Company or any of its Subsidiaries which (i)&nbsp;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company or any
of its Subsidiaries, any acquisition of material property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently conducted, (ii)&nbsp;is reasonably likely to have an adverse effect
on the Company&#146;s ability to comply with or perform any covenant or obligation under this Agreement, or (iii)&nbsp;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated
Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Company is and, since July&nbsp;1, 2020, has been in compliance with all applicable Health Care Laws in all
material respects. Since July&nbsp;1, 2020, the Company has not received any written notice or, to the Knowledge of the Company, other communication alleging any violation in any material respect with respect to any applicable Health Care Laws. To
the Knowledge of the Company, there are no restrictions upon the Company that have resulted from conduct in violation of any Health Care Law in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company and its Subsidiaries hold all required Governmental Authorizations which are material to the operation of the business of the
Company and its Subsidiaries as currently conducted (the &#147;<B>Company Permits</B>&#148;) and required for the Company to comply in all material respects with all applicable Laws, including Health Care Laws. <U>Section&nbsp;3.14(a)</U> of the
Company Disclosure Schedule identifies each Company Permit. Each such Company Permit is valid and in full force and effect, and the Company and its Subsidiaries are in material compliance with the terms of the Company Permits. No Legal Proceeding is
pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend, or materially modify any Company Permit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on <U>Section 3.16(l)</U> or <U>3.17(h)</U> of the Company
Disclosure Schedule, there are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged material violation by the Company of any applicable Health Care Law promulgated by the FDA or other comparable
Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#147;<B>Drug
Regulatory Agency</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) The Company and each of its Subsidiaries held, since July&nbsp;1, 2020, all required Governmental
Authorizations issuable by any Drug Regulatory Agency necessary for the conduct of the business of the Company, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or
exportation, of any of the Company Product Candidates (collectively, the &#147;<B>Company Regulatory Permits</B>&#148;) and no such Company Regulatory Permit has been (i)&nbsp;revoked, withdrawn, suspended, cancelled or terminated by a Drug
Regulatory Agency. The Company and each of its Subsidiaries has timely maintained and is compliance in all material respects with the Company Regulatory Permits and has not, since July&nbsp;1, 2020, received any written notice or other written
communication from any Drug Regulatory Agency regarding (A)&nbsp;any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B)&nbsp;any revocation, withdrawal, suspension,
cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#146;s possession or control relating to the Company Product Candidates
and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following
(to the extent there are any): (x)&nbsp;adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other
written correspondence to and from any Drug Regulatory Agency; and meeting minutes with any Drug Regulatory Agency and (y)&nbsp;similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other
Governmental Authority. All such information is accurate and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) All clinical and pre-clinical tests
conducted by or on behalf of, or sponsored by, the Company or its Subsidiaries, or in which the Company or its Subsidiaries or their respective products or product candidates, including the Company Product Candidates, have participated, were and, if
still pending, are being conducted in all material respects with applicable Law, and in compliance in all material respects with applicable Law. Neither the Company nor any of its Subsidiaries have received any written notices, correspondence, or
other communications from any Drug Regulatory Agency requiring, or to the Knowledge of the Company threatening to terminate or materially delay, or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or its
Subsidiaries or in which the Company or its Subsidiaries or their products or product candidates, including the Company Product Candidates, have participated. Further, since July&nbsp;1, 2020, to the Knowledge of the Company, (1)&nbsp;no clinical
investigator, researcher, or clinical staff participating in any clinical study conducted by or, on behalf of the Company or its Subsidiaries has been disqualified from participating in studies involving the Company Product Candidates, and
(2)&nbsp;no such administrative action to disqualify such clinical investigators, researchers or clinical staff is pending or has been threatened. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Neither the Company nor any of its Subsidiaries, and to the Knowledge of the Company,
no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products by the FDA pursuant to its &#147;Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug Regulatory Agency under a comparable policy. Neither the Company
nor any of its Subsidiaries, and, to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate has committed any acts, made any statement, or failed to make any statement, in each case in respect of its
business or products that would violate the FDA&#146;s &#147;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#148; Final Policy, and any amendments thereto or by any other Drug Regulatory Agency under a comparable policy.
Since July&nbsp;1, 2020, none of the Company, any of its Subsidiaries, or any of their respective officers, employees or, to the Knowledge of the Company, agents or any contract manufacturer with respect to any Company Product Candidate, has been
debarred or excluded or convicted of any crime that could result in a debarment or exclusion under (i)&nbsp;21 U.S.C. Section&nbsp;335a or (ii)&nbsp;any similar applicable Health Care Law. No debarment or exclusionary claims, actions, proceedings or
investigations in respect of their business or Company Product Candidates are pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries, any of their respective officers, employees, or, to the Knowledge of the
Company, agents or any contract manufacturer with respect to any Company Product Candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) All manufacturing operations conducted
by, or to the Knowledge of the Company, for the benefit of, the Company or its Subsidiaries in connection with any Company Product Candidate, since July&nbsp;1, 2020, have been and are being conducted in compliance in all material respects with
applicable Laws, including the FDA&#146;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211, 600-680, 820 and 1271, and the respective counterparts thereof promulgated by
Governmental Authorities in countries outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) No manufacturing site owned by the Company or its Subsidiaries, and
to the Knowledge of the Company, no manufacturing site of a contract manufacturer, with respect to any Company Product Candidate, (i)&nbsp;is or has been subject to a Drug Regulatory Agency shutdown or import or export prohibition or (ii)&nbsp;has
received any Form FDA 483, notice of violation, warning letter, untitled letter, or similar correspondence or notice from the FDA or other Governmental Authority alleging or asserting noncompliance with any applicable Law, in each case, that have
not been complied with or closed to the satisfaction of the relevant Governmental Authority, and, to the Knowledge of the Company, neither the FDA nor any other Governmental Authority is considering such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.15 <U>Legal Proceedings; Orders.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) There is no ongoing Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal
Proceeding: (i)&nbsp;that involves the Company, any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or (ii)&nbsp;that challenges, or that may have the effect of preventing, delaying,
making illegal, or otherwise interfering with, the Contemplated Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which the Company, or any of the
material assets owned or used by the Company, is subject. To the Knowledge of the Company, no officer or other Key Employee of the Company is subject to any Order that prohibits such officer or employee from engaging in or continuing any conduct,
activity, or practice relating to the business of the Company or to any material assets owned or used by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.16 <U>Tax Matters.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company has timely filed all income and other material Tax Returns that were required to be filed under applicable Law. All such Tax
Returns are correct and complete in all material respects and have been prepared in compliance with applicable Law in all material respects. No claim has ever been made in writing by a Governmental Authority in a jurisdiction where the Company does
not file Tax Returns that the Company is subject to taxation by that jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All income and other material Taxes required to
be paid by the Company (whether or not shown on any Tax Return) have been paid. Since the date of the Company Unaudited Interim Balance Sheet, the Company has not incurred any Liability for income or other material Taxes, except in the Ordinary
Course of Business or otherwise consistent with past custom and practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company has withheld and paid all material Taxes
required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, member, or other third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) There are no Encumbrances for Taxes (other than Permitted </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Encumbrances) upon any of the assets of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) No deficiencies for material Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in
writing. There are no pending (or, to the Knowledge of the Company, threatened) audits, assessments or other actions for or relating to any liability in respect of material Taxes of the Company. The Company (or any of its predecessors) has not
waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a material Tax assessment or deficiency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company is not a party to any material Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other
than customary indemnification provisions in commercial contracts entered into in the Ordinary Course of Business the principal purpose of which does not relate to Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) The Company has never been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the
common parent of which is the Company). The Company has no Liability for Taxes of any Person (other than the Company) under Treasury Regulations Section&nbsp;1.1502-6 (or any similar provision of state, local, or foreign law) or as a transferee or
successor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) The Company will not be required to include any material item of income or gain or exclude any material item of deduction
or loss from taxable income for any Tax period or portion thereof ending after the Closing as a result of (A)&nbsp;any adjustment under Section&nbsp;481 of the Code (or any corresponding provision of state, local or non-U.S. Tax Law) by reason of a
change in a method of accounting, or use of an improper method of accounting for a taxable period that ends on or prior to the Closing Date, (B)&nbsp;any &#147;closing agreement&#148; within the meaning of Section&nbsp;7121 of the Code (or any
similar provision of applicable U.S. state or local or non-U.S. Law) entered into on or prior to the Closing, (C)&nbsp;any installment sale or open transaction disposition made on or prior to the Closing, or (D)&nbsp;any deferred revenue or prepaid
amount received on or prior to the Closing Date. Neither the Company nor any of its Subsidiaries has made an election under Sections 108(i) or 965(h) of the Code (or any corresponding or similar provision of U.S. state or local or non-U.S. Law).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Company uses the accrual method of accounting for U.S. federal income (and other applicable) Tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) During the two (2)&nbsp;year period ending on the date hereof, the Company has not
distributed membership interests of another Person, or has had its membership interests distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&nbsp;355 of the Code or
Section&nbsp;361 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company has not entered into any transaction identified as a &#147;listed transaction&#148; for
purposes of Treasury Regulations Sections 1.6011-4(b)(2) or 301.6111-2(b)(2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The per share exercise price of each Company Option is
no less than the fair market value of a share of Company Common Stock on the date of grant of such Company Option determined in a manner consistent with Section&nbsp;409A of the Code. Each Company Employee Plan that constitutes in any part a
nonqualified deferred compensation plan within the meaning of Section&nbsp;409A of the Code has been operated and maintained in all material respects in operational and documentary compliance with Section&nbsp;409A of the Code and applicable
guidance thereunder. No payment to be made under any Company Employee Plan is, or to the knowledge of the Company, will be, subject to the penalties of Section&nbsp;409A(a)(1) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) Any transfer of property which was subject to a substantial risk of forfeiture and which would otherwise have been subject to taxation
under Section&nbsp;83(a) of the Code is covered by a valid and timely filed election under Section&nbsp;83(b) of the Code, and a copy of such election has been provided to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) The Company is not subject to income Tax in any country other than its country of incorporation by virtue of having a permanent
establishment or other place of business in such other country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) No current or former employee, officer, director or independent
contractor of the Company has any &#147;gross up&#148; or similar &#147;make-whole&#148; arrangements with the Company or other assurance of reimbursement by the Company for any Taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) The Company has not taken or agreed to take any action that would reasonably be expected to prevent or impede the Merger from qualifying
for the Intended Tax Treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) Neither the execution of this Agreement, the shareholder approval of this Agreement, nor the
consummation of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment) could result any payment or benefit that is or could be characterized as
a &#147;parachute payment&#148; (within the meaning of Section&nbsp;280G of the Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision of this Agreement, nothing in
this<U> Section&nbsp;3.16</U> shall be construed as providing a representation or warranty with respect to the existence, amount, expiration date or limitations on (or availability of) any Tax attribute (including methods of accounting) of the
Company for any taxable period beginning after the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.17 <U>Employee and Labor Matters; Benefit Plans.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Section&nbsp;3.17(a)</U> of the Company Disclosure Schedule is a list of all of the Company&#146;s material Employee Plans
(&#147;<B>Company Employee Plans</B>&#148;), other than at-will employment offer letters on the Company&#146;s standard form and other individual compensatory equity award agreements made pursuant to the Company&#146;s standard forms, in which case
only representative standard forms of such agreements shall be scheduled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) As applicable with respect to each of the Company Employee Plans, the Company has
delivered to Parent, true, complete and correct copies of (i)&nbsp;all documents embodying or governing each Company Employee Plan, including all amendments thereto, and in the case of an unwritten Company Employee Plan, a written description of the
material terms of such Company Employee Plan thereof, and any funding medium for the Company Employee Plans, (ii)&nbsp;all current trust documents, investment management Contracts, custodial agreements, administrative services agreements and
insurance and annuity Contracts relating thereto, (iii)&nbsp;the current summary plan description and each summary of material modifications thereto, (iv)&nbsp;the annual reports with any Governmental Authority (<I>e.g.</I> Form 5500 and all
schedules thereto) for the last three years, (v)&nbsp;the most recent IRS determination, opinion or advisory letter, (vi)&nbsp;the most recent summary annual reports, nondiscrimination testing reports, actuarial reports, financial statements and
trustee reports for the last three years, and (vii)&nbsp;all non-routine correspondence to and from the IRS or Department of Labor or other Governmental Authority, including correspondence concerning audits or investigations, or &#147;prohibited
transactions&#148; within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Each Company Employee Plan has
been established, maintained, operated, and administered in all material respects in accordance with its terms and the applicable provisions of ERISA, the Code, the Affordable Care Act, and all other Laws. No Company Employee Plan is, or within the
past six years has been, the subject of an application or filing under a government sponsored amnesty, voluntary compliance, or similar program, or been the subject of any self-correction under any such program. The Company Employee Plans satisfy in
all material respects the minimum coverage, affordability and non-discrimination requirements under the Code. No Company Employee Plan provides major medical health or long-term disability benefits that are not fully insured through an insurance
contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company Employee Plans which are &#147;employee pension benefit plans&#148; within the meaning of Section&nbsp;3(2) of
ERISA and which are intended to meet the qualification requirements of Section&nbsp;401(a) of the Code have received determination or opinion letters from the IRS on which they may currently rely to the effect that such plans are qualified under
Section&nbsp;401(a) of the Code and the related trusts are exempt from federal income Taxes under Section&nbsp;501(a) of the Code, respectively, and, to the Knowledge of the Company, there has been no event or omission that would be expected to
affect the qualification of such Company Employee Plan or the tax exempt status of the related trust or require corrective action to the IRS or Employee Plan Compliance Resolution System to maintain such qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Neither the Company nor any of its ERISA Affiliates maintains, contributes to, is required to contribute to, or has ever maintained,
contributed to, or been required to contribute to or had any actual or contingent liability or obligation (including on account of any ERISA Affiliate) with respect to, (i)&nbsp;any &#147;employee pension benefit plan&#148;(within the meaning of
Section&nbsp;3(2) of ERISA) that is subject to Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code, (ii)&nbsp;any &#147;Multiemployer Plan&#148;, (iii)&nbsp;any Multiple Employer Arrangement or (iv)&nbsp;any &#147;Multiple Employer
welfare Arrangement&#148; (within the meaning of Section&nbsp;3(40) of ERISA), and neither the Company nor any ERISA Affiliate has ever incurred any liability under Title IV of ERISA that has not been paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) There are no pending audits or investigations by any Governmental Authority involving any Company Employee Plan, and no pending or
threatened claims (except for routine individual claims for benefits), suits or proceedings involving any Company Employee Plan, or any fiduciary thereof or service provider thereto. All contributions and premium payments required to have been made
under any of the Company Employee Plans or by applicable Law (without regard to any waivers granted under Section&nbsp;412 of the Code), have been timely made and the Company has no liability for any unpaid contributions with respect to any Company
Employee Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) None of the Company, or any of its ERISA Affiliates or any fiduciary, trustee, or
administrator of any Company Employee Plan, has engaged in, or in connection with the Contemplated Transactions will engage in, any transactions with respect to any Company Employee Plan which would subject any such Company Employee Plan, the
Company, or Parent to a Tax, penalty or liability for a &#147;prohibited transaction&#148; under Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) No Company Employee Plan provides death, medical, dental, vision, life insurance or other welfare benefits beyond termination of service
or retirement (other than as required by Part 6 of Subtitle B of Title I of ERISA or similar state law) and the Company has never promised to provide such post-termination benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Except as set forth on <U>Section 3.17(i)</U> of the Company Disclosure Schedule, neither the execution of this Agreement, the
shareholder approval of this Agreement, nor the performance of the Contemplated Transactions (either alone or when combined with the occurrence of any other event, including without limitation, a termination of employment), could: (a)&nbsp;result in
any payment becoming due to any current or former employee, director, officer, or independent contractor of the Company thereof, pursuant to any Company Employee Plan; (ii)&nbsp;increase any amount of compensation or benefits otherwise payable under
any Company Employee Plan; (iii)&nbsp;result in the acceleration of the time of payment, funding or vesting of any benefits under Company Employee Plan, (iv)&nbsp;require any contribution or payment to fund any obligation under any Company Employee
Plan or (v)&nbsp;further restrict any rights to amend or terminate any Company Employee Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Each Company Employee Plan may be
amended, terminated, or otherwise modified (including cessation of participation) by the Company to the greatest extent permitted by applicable law, including the elimination of any and all future benefit accruals thereunder and no employee
communications or provision of any Company Employee Plan has failed to effectively reserve the right of the Company or the ERISA Affiliate to so amend, terminate or otherwise modify such Company Employee Plan. Neither the Company nor any of its
ERISA Affiliates has announced its intention to modify or terminate any Company Employee Plan or adopt any arrangement or program which, once established, would come within the definition of a Company Employee Plan. Each asset held under each
Company Employee Plan may be liquidated or terminated without the imposition of any redemption fee, surrender charge or comparable liability other than ordinary administration expenses. No Company Employee Plan provides health or long-term
disability benefits that are not fully insured through an insurance contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) The Company does not maintain any Company Employee
Plan for the benefit of any service providers located outside of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) The Company has made available to Parent the
names of all current full-time, part-time or temporary employees, and, as applicable: (i)&nbsp;such employee&#146;s base salary or base wage rate, (ii)&nbsp;such employee&#146;s target annual bonus opportunity, (iii)&nbsp;such employee&#146;s
location; (iv)&nbsp;such employee&#146;s visa status, if applicable; and (v)&nbsp;a designation of whether they are classified as exempt or <FONT STYLE="white-space:nowrap">non-exempt</FONT> for purposes of the Fair Labor Standards Act, as amended
and any similar state law. The Company has also made available to Parent the names of all current independent contractors and a description of such person&#146;s contracting services and compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) The Company is not and has not been a party to, bound by, or has a duty to bargain under, any collective bargaining agreement or other
Contract with a labor union or similar labor organization representing or purporting to represent or seeking to represent any employees of the Company, including through the filing of a petition for representation election. There is not and has not
been in the past five years, nor is there or has there been since the Company&#146;s inception any threat of, any strike, slowdown, work stoppage, lockout, union election petition, demand for recognition, or any similar activity or dispute or any
union organizing activity, affecting the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) The Company is, and since the Company&#146;s inception has been, in compliance with all
applicable Laws respecting labor, employment, employment practices, and terms and conditions of employment, including worker classification, discrimination, harassment and retaliation, equal employment opportunities, fair employment practices, meal
and rest periods, immigration, employee safety and health, payment of wages (including overtime wages), unemployment and workers&#146; compensation, leaves of absence, and hours of work. With respect to employees of the Company, the Company, since
the Company&#146;s inception, has withheld and reported all amounts required by Law to be withheld and reported with respect to wages, salaries and other payments, benefits, or compensation to employees. There is no, and since July&nbsp;1, 2020
there has not been any, Legal Proceeding pending or threatened or reasonably anticipated against the Company relating to any current or former employee, applicant for employment, or consultant of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) The Company currently classifies and has properly classified each of its employees as exempt or non-exempt for the purposes of the Fair
Labor Standards Act, as amended and any applicable state and local wage and hour laws, and is and has been otherwise in compliance with such laws. To the extent that any individual independent contractors are or were engaged by the Company, the
Company currently classifies and has properly classified and treated them as such (as distinguished from employees within the meaning of Section&nbsp;3402 of the Code) in accordance with applicable law and for the purpose of all employee benefit
plans and perquisites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Since the Company&#146;s inception, no allegations of sexual harassment have been made to the Company against
any employee or independent contractor of the Company and the Company has not otherwise become aware of any such allegations. To the Knowledge of the Company, there are no facts that would reasonably be expected to give rise to claim of sexual
harassment, other unlawful harassment or unlawful discrimination or retaliation against or involving the Company or any Company employee, director or independent contractor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) The Company has not experienced a &#147;plant closing&#148;, &#147;mass layoff&#148; or similar group employment loss as defined in the
federal Worker Adjustment and Retraining Notification Act (the &#147;<B>WARN Act</B>&#148;) or any similar state or local law or regulation affecting any site of employment of the Company or one or more facilities or operating units within any site
of employment or facility of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.18 <U>Environmental Matters.</U> Since July&nbsp;1, 2020, the Company has complied with all
applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for
any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received since July&nbsp;1, 2020, any written notice or other communication (in writing or otherwise),
whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or
interfere with the Company&#146;s compliance with any Environmental Law in the future, in each case, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company:
(i)&nbsp;no current or prior owner of any property leased or controlled by the Company has received since July&nbsp;1, 2020, any written notice or other communication relating to property owned or leased at any time by the Company, whether from a
Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii)&nbsp;the Company has no
material liability under any Environmental Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.19 <U>Insurance.</U> The Company has delivered to Parent accurate and complete copies of
all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities, and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in
compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since July&nbsp;1, 2020, the Company has not received any notice or other communication regarding any actual or
possible: (i)&nbsp;cancellation or invalidation of any insurance policy or (ii)&nbsp;refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.20 <U>No Financial Advisors.</U> Except as set forth on<U> Section&nbsp;3.20</U> of the Company Disclosure Schedule, no broker, finder, or
investment banker is entitled to any brokerage fee, finder&#146;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.21 <U>Transactions with Affiliates.</U> <U>Section&nbsp;3.21</U> of the Company Disclosure Schedule describes any material transactions
or relationships, since July&nbsp;1, 2020, between, on one hand, the Company and, on the other hand, any (a)&nbsp;executive officer or director of the Company or any of such executive officer&#146;s or director&#146;s immediate family members,
(b)&nbsp;owner of more than five percent (5%)&nbsp;of the voting power of the outstanding Company Common Stock, or (c)&nbsp;to the Knowledge of the Company, any &#147;related person&#148; (within the meaning of Item&nbsp;404 of Regulation S-K under
the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&nbsp;or (c)&nbsp;that is of the type that would be required to be disclosed under Item&nbsp;404 of Regulation S-K under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.22 <U>Privacy and Data Security.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the Company
complies and has for the past three (3)&nbsp;years complied with applicable Privacy Laws, its Privacy Policies, the applicable terms of any Company Contracts relating to privacy, security, collection or use of Personal Information and all applicable
requirements of industry standards or codes of conduct that concern the privacy or security of Personal Information and that are binding upon the Company (all of the foregoing, collectively, &#147;<B>Privacy Requirements</B>&#148;). The Company has,
for the past three (3)&nbsp;years, used commercially reasonable methods and technology to secure Company IT Systems, all Personal Information and other material Company data and information from loss, theft, unauthorized access, use, acquisition of,
disclosure of, processing of, or modification, which methods and technology comply in all material respects with applicable Privacy Requirements. To the extent required under applicable Privacy Laws, the Company has contractually obligated third
parties that process Personal Information on behalf of the Company to comply in all material respects with applicable Privacy Laws and to protect the privacy, security and confidentiality of all Personal Information. To the Knowledge of the Company,
such third parties, in their provision of services to Company, have not failed to comply in any material respect with relevant contracts. In the past three (3)&nbsp;years, no claims have been asserted or threatened against the Company by any Person
alleging a violation of any Privacy Requirements, except as would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. In the past three (3)&nbsp;years, there have been no data security incidents
or data breaches affecting the Company IT Systems or any Personal Information that has been collected, maintained, processed or stored by or on behalf of the Company that would require notification of individuals, law enforcement, or any
Governmental Authority under any applicable Privacy Law. Neither the execution of this Agreement nor the performance of the Company&#146;s obligations under this Agreement will violate any applicable Privacy Requirements in any material respect.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) To the Knowledge of the Company, no Company IT System contains any &#147;back
door,&#148; &#147;drop dead device,&#148; &#147;time bomb,&#148; &#147;Trojan horse,&#148; &#147;virus,&#148; &#147;worm,&#148; &#147;spyware&#148; or &#147;adware&#148; (as such terms are commonly understood in the software industry) or any other
code designed or intended to have or capable of performing or facilitating, any of the following functions: (i)&nbsp;disrupting, disabling, harming or otherwise impeding in any manner the operation of, or providing unauthorized access to, a computer
system or network or other device on which such code is stored or installed; or (ii)&nbsp;compromising the privacy or data security of a user or damaging or destroying any data or file without the user&#146;s consent (collectively,
&#147;<B>Malicious Code</B>&#148;). The Company has implemented, and the Company maintains, commercially reasonable measures to prevent the introduction of Malicious Code into the Company IT Systems, including firewall protections and regular virus
scans and for taking and storing on-site and <FONT STYLE="white-space:nowrap">off-site</FONT> back-up copies of Company software and critical data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.23 <U>Anti Bribery.</U> Since July&nbsp;1, 2020, none of the Company nor, to the Knowledge of the Company, any of its directors, officers,
employees or agents or any other Person acting on behalf of the Company (each in their respective capacities as such) has directly or indirectly made any bribes, rebates, payoffs, influence payments, kickbacks, illegal payments, illegal political
contributions, or other payments, in the form of cash, gifts, or otherwise, or taken any other action in violation of the Foreign Corrupt Practices Act of 1977, the UK Bribery Act of 2010 or any other ani-bribery or anti-corruption Law
(collectively, the &#147;<B>Anti-Bribery Laws</B>&#148;). The Company is not, nor has ever been since July&nbsp;1, 2020, the subject of any investigation or inquiry by any Governmental Authority with respect to potential violations of Anti-Bribery
Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.24 <U>No Other Representations or Warranties.</U> The Company hereby acknowledges and agrees that, except for the representations
and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any
of its members or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in <U>Section&nbsp;4</U> (in each case as qualified and limited by
the Parent Disclosure Schedule)) none of the Company, or any of its Representatives or members, has relied on any such information (including the accuracy or completeness thereof). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Representations and Warranties of Parent and Merger Subs.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Except (i)&nbsp;as set forth in the written disclosure schedule delivered by Parent to the Company (the &#147;<B>Parent Disclosure
Schedule</B>&#148;) or (ii)&nbsp;as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#146;s Electronic Data Gathering Analysis and Retrieval system (but (A)&nbsp;without giving
effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B)&nbsp;excluding any disclosures contained under the heading &#147;Risk Factors&#148; and any disclosure of risks included in any
&#147;forward-looking statements&#148; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), Parent and Merger Sub represent and warrant to the Company as
follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 <U>Due Organization; Subsidiaries.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Each of Parent and its Subsidiaries (including Merger Subs) is a corporation or limited liability company duly incorporated or formed,
validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization, and has all necessary corporate power and authority: (i)&nbsp;to conduct its business in the manner in which its business is currently
being conducted, (ii)&nbsp;to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii)&nbsp;to perform its obligations under all Contracts by which it is bound. Each
of the Merger Subs was formed solely for the purpose of engaging in the Merger. Since the date of their formation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement. Merger Sub 2 is
disregarded as separate from Parent for U.S. federal income Tax purposes. All of Parent&#146;s Subsidiaries are wholly owned by Parent and Merger Subs are directly owned by Parent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in
good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business requires such licensing or qualification other than in jurisdictions where the failure to be so qualified
individually or in the aggregate would not be reasonably expected to have an Parent Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Except as set forth
on<U> Section&nbsp;4.1(c)</U> of the Parent Disclosure Schedule, Parent has no Subsidiaries other than Merger Sub and Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly
or indirectly, any other Entity other than Merger Sub. Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture, or similar business entity. Parent has not agreed and is
not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not
otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership, or other Entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2
<U>Organizational Documents.</U> Parent has delivered to the Company accurate and complete copies of Parent&#146;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3 <U>Authority; Binding Nature of Agreement.</U> Each of Parent and Merger Subs has all necessary corporate power and authority to enter
into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board (at meetings duly called and held, including written consents) has: (a)&nbsp;determined that the Contemplated Transactions are
fair to, advisable and in the best interests of Parent and its stockholders, (b)&nbsp;approved and declared advisable this Agreement, the CVR Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to
the Company Holders pursuant to the terms of this Agreement, and (c)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Conversion Proposal and
Charter Amendment Proposal pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub
1 and its sole member, (y)&nbsp;deemed advisable and approved this Agreement and the Contemplated Transactions, and (z)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of
Merger Sub 1 vote to adopt this Agreement and approve the Contemplated Transactions. The sole member of Merger Sub 2 has: (x)&nbsp;determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub 2 and
its sole member, (y)&nbsp;deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&nbsp;resolved to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the member of Merger Sub 2
vote to adopt this Agreement and approve the Contemplated Transactions. This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution, and delivery by the Company, constitutes the legal,
valid, and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4 <U>Vote Required.</U> The affirmative vote of a majority of the votes cast at the Parent
Stockholder Meeting is the only vote of the holders of any class or series of Parent&#146;s capital stock necessary to approve the Conversion Proposal and the affirmative vote of a majority of the shares of Parent Common Stock entitled to vote
thereon is the only vote of the holders of any class or series of Parent Capital Stock necessary to approve the Charter Amendment Proposal (the &#147;<B>Required Parent Stockholder Vote</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5 <U>Non-Contravention; Consents.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Subject to obtaining the Required Parent Stockholder Vote and the filing of the First Certificate of Merger, the Second Certificate of
Merger, and the Certificate of Designation required by the DGCL and DLLCA, neither (x)&nbsp;the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y)&nbsp;the consummation of the Contemplated Transactions, will
directly or indirectly (with or without notice or lapse of time): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) contravene,
conflict with, or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) contravene, conflict with, or result in a material violation of, or give any
Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent
or its Subsidiaries, is subject; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) contravene, conflict with, or result in a
material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that
otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) contravene, conflict with, or result in a violation or breach of, or result in a
default under, any provision of any Contract material to Parent, or give any Person the right to: (A)&nbsp;declare a default or exercise any remedy under any Contract material to Parent, (B)&nbsp;any material payment, rebate, chargeback, penalty or
change in delivery schedule under any such Contract, (C)&nbsp;accelerate the maturity or performance of any Contract material to Parent, or (D)&nbsp;cancel, terminate, or modify any term of any Contract material to Parent, except in the case of any
non-material breach, default, penalty, or modification; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) result in the
imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Except for (i)&nbsp;any Consent set forth on<U> Section&nbsp;4.5</U> of the Parent Disclosure Schedule under any Parent Contract,
(ii)&nbsp;the Required Parent Stockholder Vote, (iii)&nbsp;the filing of the First Certificate of Merger, the Second Certificate of Merger and the Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL
and DLLCA, and (iv)&nbsp;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, neither Parent nor any of its Subsidiaries was, is or
will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x)&nbsp;the execution, delivery, or performance of this Agreement, or (y)&nbsp;the consummation of the Contemplated
Transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Parent Board, the First Merger Sub Board, and the sole member of Merger Sub 2 have
taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&nbsp;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and
to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, or any of the other Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6 <U>Capitalization.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The authorized capital stock of Parent consists of (i)&nbsp;150,000,000 shares of Parent Common Stock, par value $0.001 per share, of
which 8,000,000 shares are designated as a <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, par value $0.001 per share (the &#147;<B>Non-Voting Common Stock</B>&#148;), of which 42,301,253 shares of Parent Common Stock have been
issued and are outstanding, 6,215,465 shares of which are Non-Voting Common Stock as of August&nbsp;2, 2023 (the &#147;<B>Capitalization Date</B>&#148;) and (ii) 10,000,000 shares of preferred stock, par value $0.001 per share, of which no shares
have been issued and are outstanding as of the Capitalization Date. As of the Capitalization Date, the total number of issued and outstanding shares of Parent Common Stock, including shares of Parent Common Stock underlying any Parent Options or
warrants to purchase Parent Common Stock, is as set forth on<U> Section&nbsp;4.6(a)</U> of the Parent Disclosure Schedule. Parent does not hold any shares of its capital stock in its treasury. From the Capitalization Date through the date of this
Agreement, neither Parent nor any of its Subsidiaries has issued any shares of Parent Common Stock or other equity interests of Parent or any Subsidiary of Parent, other than pursuant to Parent Options, in each case, that were outstanding as of the
Capitalization Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are
fully paid and nonassessable and are free of any Encumbrances. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance, or any similar right. None of the
outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing,
selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become
obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. <U>Section&nbsp;4.6(b)</U> of the Parent Disclosure Schedule accurately and completely describes all repurchase rights held by
Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All outstanding shares of Parent Common Stock, Parent Options and other securities of Parent have been issued and granted in material
compliance with (i)&nbsp;all applicable securities laws and other applicable Law and (ii)&nbsp;all requirements set forth in applicable Contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7 <U>SEC Filings; Financial Statements.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to
be filed or furnished by it with the SEC under the Exchange Act or the Securities Act since March&nbsp;26, 2021 (the &#147;<B>Parent SEC Documents</B>&#148;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior
to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and, to Parent&#146;s
Knowledge, as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. The certifications and statements required by (i)&nbsp;Rule 13a-14 under the Exchange Act and (ii)&nbsp;18 U.S.C. &#167;1350 (Section 906 of the Sarbanes-Oxley Act) relating to
the Parent SEC Documents (collectively, the &#147;<B>Certifications</B>&#148;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this<U> Section&nbsp;4.7</U>, the term &#147;file&#148; and variations
thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied, or otherwise made available to the SEC. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The financial statements (including any related notes) contained or incorporated by
reference in the Parent SEC Documents: (i)&nbsp;complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto, (ii)&nbsp;were prepared in accordance with GAAP (except as may be indicated in the
notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end
adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated, and (iii)&nbsp;fairly present, in all material respects, the financial position of
Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no
material change in Parent&#146;s accounting methods or principles that would be required to be disclosed in Parent&#146;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its
Subsidiaries are true and complete in all material respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent&#146;s auditor has at all times since the date of enactment of
the Sarbanes-Oxley Act been: (i)&nbsp;a registered public accounting firm (as defined in Section&nbsp;2(a)(12) of the Sarbanes-Oxley Act), (ii)&nbsp;to the Knowledge of Parent, &#147;independent&#148; with respect to Parent within the meaning of
Regulation S-X under the Exchange Act, and (iii)&nbsp;to the Knowledge of Parent, in compliance with subsections (g)&nbsp;through (l)&nbsp;of Section&nbsp;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public
Company Accounting Oversight Board thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Except as set forth on<U> Section&nbsp;4.7(d)</U> of the Parent Disclosure Schedule,
Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed
any unresolved comments in the Parent SEC Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) Since March&nbsp;26, 2021, there have been no formal internal investigations
regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer or chief financial officer of Parent, the Parent Board or any committee thereof, other than
ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)
Except as set forth on<U> Section&nbsp;4.7(f)</U> of the Parent Disclosure Schedule, Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act and the applicable listing and governance rules and
regulations of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) Parent maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and
15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and
procedures sufficient to provide reasonable assurance (i)&nbsp;that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#146;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as
necessary to permit preparation of financial statements in accordance with GAAP, (iii)&nbsp;that receipts and expenditures are made only in accordance with authorizations of management and the Parent Board, and (iv)&nbsp;regarding prevention or
timely detection of the unauthorized acquisition, use or disposition of Parent&#146;s assets that could have a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">material effect on Parent&#146;s financial statements. Parent has evaluated the effectiveness of
Parent&#146;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the
effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#146;s auditors and the Audit Committee of the Parent Board (and
made available to the Company a summary of the significant aspects of such disclosure) (A)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely
to adversely affect Parent&#146;s ability to record, process, summarize and report financial information and (B)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#146;s or its
Subsidiaries&#146; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent has not identified any material weaknesses in the design or operation of Parent&#146;s internal
control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Parent&#146;s &#147;disclosure controls and procedures&#148; (as defined in Rules 13a- 15(e) and
15d-15(e) of the Exchange Act) are reasonably designed to ensure that all information (both financial and non-financial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized, and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#146;s management as appropriate to allow timely decisions regarding required
disclosure and to make the Certifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8 <U>Absence of Changes.</U> Except as set forth on<U> Section&nbsp;4.8</U> of the Parent
Disclosure Schedule, between March&nbsp;31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations
and transactions related thereto) and there has not been any (x)&nbsp;Parent Material Adverse Effect or (y)&nbsp;actions to do any of the following: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) declare, accrue, set aside or pay any dividend, or make any other distribution in respect of any shares of its capital stock or
repurchase, redeem, or otherwise reacquire any shares of its capital stock or other securities (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent in accordance with agreements in effect on the
date of this Agreement providing for the repurchase of shares at no more than the purchase price thereof in connection with any termination of services to Parent or any of its Subsidiaries); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be
a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) lend money to any Person, (B)&nbsp;incur or guarantee any indebtedness for borrowed money or (C)&nbsp;make any commitment for capital
expenditure; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other
than waivers, settlements or agreements (A)&nbsp;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&nbsp;that do not impose any material restrictions
on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) agree, resolve, or commit to do any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9 <U>Absence of Undisclosed Liabilities</U>. Neither Parent nor any of its Subsidiaries
has any Liability of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for: (a)&nbsp;Liabilities disclosed, reflected or reserved against in the Parent Unaudited Interim Balance Sheet,
(b)&nbsp;normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Unaudited Interim Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract,
breach of warranty, tort, infringement, or violation of Law), (c)&nbsp;Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, and (d)&nbsp;Liabilities described in <U>Section&nbsp;4.9</U> of the
Parent Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10 <U>Title to Assets</U>. Each of Parent and its Subsidiaries owns, and has good and valid title to, or,
in the case of leased properties and assets, valid leasehold interests in, all tangible properties or assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&nbsp;all assets reflected on
the Parent Unaudited Interim Balance Sheet and (b)&nbsp;all other assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its
Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11 <U>Compliance; Permits; Restrictions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent and each of its Subsidiaries is, and since July&nbsp;1, 2020, has been in material compliance with all applicable Laws. No
investigation, claim, suit, proceeding, audit, Order, or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent
or any of its Subsidiaries which (i)&nbsp;has or could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent, any acquisition of material property by Parent or any of its Subsidiaries or the
conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii)&nbsp;is reasonably likely to have an adverse effect on Parent&#146;s ability to comply with or perform any covenant or obligation under this Agreement, or
(iii)&nbsp;is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12 <U>Legal Proceedings; Orders</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Except as set forth in <U>Section&nbsp;4.12</U> of the Parent Disclosure Schedule, there is no pending Legal Proceeding and, to the
Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i)&nbsp;that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used
by Parent or any of its Subsidiaries or (ii)&nbsp;that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its
Subsidiaries is subject. To the Knowledge of Parent, no officer or other Key Employee of Parent or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing any conduct, activity, or
practice relating to the business of Parent or any of its Subsidiaries or to any material assets owned or used by Parent or any of its Subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13 <U>Tax Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
Each of Parent and its Subsidiaries has timely filed all material Tax Returns that were required to be filed under applicable Law. All such Tax Returns are correct and complete in all material respects and have been prepared in compliance with
applicable Law in all material respects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) All material Taxes required to be paid by Parent and each of its Subsidiaries (whether
or not shown on any Tax Return) have been paid. Since the date of the Parent Unaudited Interim Balance Sheet, neither Parent nor any of its Subsidiaries has incurred any Liability for material Taxes, except in the Ordinary Course of Business or
otherwise consistent with past custom and practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) No deficiencies for material Taxes with respect to Parent or any of its
Subsidiaries have been claimed, proposed, or assessed by any Governmental Authority in writing. There are no pending (or, to the Knowledge of Parent or any of its Subsidiaries, threatened) audits, assessments or other actions for or relating to any
liability in respect of material Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries (or any of their predecessors) has waived any statute of limitations in respect of material Taxes or agreed to any extension of
time with respect to a material Tax assessment or deficiency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Neither Parent nor any of its Subsidiaries has taken or agreed to take
any action, in each case, that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.14 <U>Transactions with Affiliates</U>. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the
date of Parent&#146;s last proxy statement filed in 2023 with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item&nbsp;404 of Regulation S-K promulgated by the SEC. <U>Section&nbsp;4.14</U> of the Parent
Disclosure Schedule identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.15 <U>No Financial Advisors.</U> Except as set forth on <U>Section&nbsp;4.15</U> of the Parent Disclosure Schedule, no broker, finder or
investment banker is entitled to any brokerage fee, finder&#146;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.16 <U>Valid Issuance</U>. The Parent Capital Stock to be issued in the First Merger will, when issued in accordance with the provisions of
this Agreement, be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.17 <U>Ownership of Company Common Stock</U>. Neither Parent nor any of
its Affiliates or associates is, nor at any time during the last three years has Parent or any of its Affiliates or associates been, an &#147;interested stockholder&#148; of the Company as defined in Section&nbsp;203 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.18 <U>No Other Representations or Warranties</U>. Parent hereby acknowledges and agrees that, except for the representations and warranties
contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or
with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company
set forth in <U>Section&nbsp;3</U> (in each case as qualified and limited by the Company Disclosure Schedule)) none of Parent, Merger Subs, or any of their respective Representatives, stockholders, or members, has relied on any such information
(including the accuracy or completeness thereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Agreements of the Parties</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 <U>Proxy Statement</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) As promptly as practicable after the Closing Date (and in any event within thirty (30)&nbsp;days of the date of this Agreement), Parent
shall prepare and file with the SEC a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Conversion Proposal and Charter Amendment Proposal (together with any amendments thereof or supplements thereto, the
&#147;<B>Proxy Statement</B>&#148;). Parent shall use its reasonable best efforts to (i)&nbsp;cause the Proxy Statement to comply with applicable rules and regulations promulgated by the SEC and (ii)&nbsp;respond promptly to any comments or requests
of the SEC or its staff related to the Proxy Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent covenants and agrees that the Proxy Statement (and the letter to
stockholders, notice of meeting, and form of proxy included therewith) will (i)&nbsp;comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL, and (ii)&nbsp;will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Parent shall use reasonable best efforts to cause the definitive Proxy Statement to be filed, and mailed to Parent&#146;s stockholders,
as promptly as practicable after the preliminary Proxy Statement had been filed with the SEC pursuant to <U>Section&nbsp;5.1(a)</U> and either (i)&nbsp;the SEC has indicated that it does not intend to review such Proxy Statement or that its review
of such Proxy Statement has been completed or (ii)&nbsp;at least ten (10)&nbsp;days shall have passed since such Proxy Statement was filed with the SEC without receiving any communication from the SEC commenting upon, or indicating that it intends
to review, such Proxy Statement, all in compliance with applicable U.S. federal securities laws and the DGCL. If Parent, Merger Sub 1, Merger Sub 2, or the Company become aware of any event or information that, pursuant to the Securities Act or the
Exchange Act, should be disclosed in an amendment or supplement to the Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent
filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to the Parent stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Company Holders of shares of Parent Preferred Stock are express third party beneficiaries of the terms of this
<U>Section&nbsp;5.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 <U>Parent Stockholder Meeting</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common
Stock to consider and vote to approve the Conversion Proposal and the Charter Amendment Proposal pursuant to the terms of this Agreement (collectively, the &#147;<B>Parent Stockholder Matters</B>&#148; and such meeting, the &#147;<B>Parent
Stockholder Meeting</B>&#148;) as promptly as practicable. The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the definitive Proxy Statement is filed with the SEC, and in any event no later than forty-five
(45)&nbsp;days after such date. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the
contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i)&nbsp;it will not receive proxies sufficient to obtain
the Required Parent Stockholder Vote, whether or not a quorum would be present or (ii)&nbsp;it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the
business of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Parent Stockholder Meeting, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent
Stockholder Meeting is not postponed or adjourned more than an aggregate of fifteen (15)&nbsp;calendar days in connection with all postponements or adjournments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent agrees that: (i)&nbsp;the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent
Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <U>Section&nbsp;5.2(a)</U> above, (ii)&nbsp;the Proxy Statement shall include a statement to the effect that the Parent
Board recommends that Parent&#146;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#147;<B>Parent Board Recommendation</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Company Holders of shares of Parent Preferred Stock are express third party beneficiaries of the terms of this
<U>Section&nbsp;5.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3 <U>Employee Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Effective on the Closing Date, the Company shall terminate the employment of each employee of the Company other than the employees set
forth on <U>Schedule E</U> hereto (the &#147;<B>Continuing Employees</B>&#148;). The employees of the Company whose employment will be terminated on the Closing Date are referred to herein as the &#147;<B>Non-Continuing Employees</B>&#148;. The
Company shall provide a written notice of termination of employment to each Non-Continuing Employees and shall use commercially reasonable efforts to ensure that each Non-Continuing Employee enters into a separation agreement that includes a release
of claims against the Company, Parent and their respective Affiliates, in substantially the form attached hereto as <U>Exhibit F</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The Parent, the Surviving Company or Parent&#146;s Affiliate shall cause the Surviving Company to offer to continue to employ each
Continuing Employee effective as of the Closing. Parent shall, and shall cause Parent&#146;s Affiliates to maintain, while the Continuing Employee remains employed by the Surviving Company, Parent or a Parent Affiliate, the same annual base salary,
and not to require that any Continuing Employee relocate, in each case as provided by the Company immediately prior to the Closing Date for a period of 12 months following the Closing Date (or, if earlier, until the date of termination of the
applicable Continuing Employee&#146;s employment with the Surviving Company, the Parent or Parent&#146;s Affiliate). Furthermore, the Parent, Surviving Company or Parent&#146;s Affiliate shall comply with the terms of any employment, severance,
retention, change of control, or similar agreement specified on Section&nbsp;3.17(a) of the Company Disclosure Schedule, subject to the provisions of such agreements and perform all obligations set forth therein, subject to the terms and conditions
thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Nothing in this <U>Section&nbsp;5.3</U>, whether express or implied, shall (i)&nbsp;create any rights to continued
employment or service, any term or condition of employment or service with Parent or the Surviving Company or any of their Affiliates or in any way prohibit Parent, its Affiliates, the Surviving Company or any of their respective subsidiaries from
terminating the employment or service of any Continuing Employee or any other Person at any time and for any or no reason, (ii)&nbsp;be construed as an establishment, termination or amendment of any Company Employee Plan, Parent Employee Plan or any
other benefit or compensation plan, program, policy, contract, agreement or arrangement, or prohibit Parent, its Affiliates, the Surviving Company or any of their respective subsidiaries from establishing, amending or terminating any Company
Employee Program, Parent Employee Plan or any other benefit or compensation plan, program, policy, contract, agreement or arrangement or (iii)&nbsp;grant any rights or remedies whatsoever, including any third party beneficiary rights, by reason of
this <U>Section&nbsp;5.3</U> to any Person other than the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4 <U>Indemnification of Officers and Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the
Surviving Company shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the
&#147;<B>D&amp;O Indemnified Parties</B>&#148;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#146; fees and disbursements (collectively, &#147;<B>Costs</B>&#148;),
incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer
of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL and the DLLCA. Each D&amp;O Indemnified Party will be entitled to advancement of
expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Company, jointly and severally, upon receipt by Parent or the Surviving Company from the D&amp;O Indemnified Party of
a request therefor; <U>provided</U> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL and the DLLCA, to repay such advances if it is ultimately determined that such person
is not entitled to indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The provisions of the certificate of incorporation and bylaws of Parent with respect to
indemnification, advancement of expenses, and exculpation of present and former directors and officers of Parent that are presently set forth in the certificate of incorporation and bylaws of Parent shall not be amended, modified, or repealed for a
period of six years from the First Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the First Effective Time, were officers or directors of Parent, unless such modification is required
by applicable Law. The certificate of formation and bylaws of the Surviving Company shall contain, and Parent shall cause the certificate of formation and limited liability company agreement of the Surviving Company to so contain, provisions no less
favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) From and after the First Effective Time, (i)&nbsp;the Surviving Company shall fulfill and honor in all respects the obligations of the
Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#146;s Organizational Documents and pursuant to any indemnification agreements between the Company and
such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii)&nbsp;Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified
Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#146;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect
to claims arising out of matters occurring at or prior to the First Effective Time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) From and after the First Effective Time for a
period of six years, Parent shall maintain in effect directors&#146; and officers&#146; liability insurance covering those Persons who are currently covered by (x)&nbsp;the Company&#146;s directors&#146; and officers&#146; liability insurance
policies on terms not less favorable than the terms of such current insurance coverage, except that in no event shall Parent be required to pay an aggregate premium for such insurance in excess of 300% of the annual premium payable in the aggregate
by the Company for such insurance policy for the year ended December&nbsp;31, 2022; <U>provided</U>, <U>however</U>, that (i)&nbsp;Parent may cause coverage to be extended under the current directors&#146; and officers&#146; liability insurance by
obtaining a six-year &#147;tail&#148; policy containing terms not materially less favorable than the terms of such current insurance coverage with respect to claims existing or occurring at or prior to the First Effective Time (the &#147;<B>D&amp;O
Tail</B>&#148;) and (ii)&nbsp;if any claim is asserted or made within such six-year period, any insurance required to be maintained under this <U>Section&nbsp;5.4(d)</U> shall be continued in respect of such claim until the final disposition
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) From and after the First Effective Time, Parent shall pay all expenses, including
reasonable attorneys&#146; fees, that are incurred by the persons referred to in this <U>Section&nbsp;5.4</U> in connection with their enforcement of the rights provided to such persons in this <U>Section&nbsp;5.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The provisions of this <U>Section&nbsp;5.4</U> are intended to be in addition to the rights otherwise available to the current and former
officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives and all
such persons are express third party beneficiaries of this Agreement for purposes of this <U>Section&nbsp;5.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) In the event
Parent or the Surviving Company or any of their respective successors or assigns (i)&nbsp;consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or
(ii)&nbsp;transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Company, as the case may be, shall
succeed to the obligations set forth in this <U>Section&nbsp;5.4</U>. Parent shall cause the Surviving Company to perform all of the obligations of the Surviving Company under this<U> Section&nbsp;5.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5 <U>Tax Matters</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
Each of Parent and the Company shall use commercially reasonable efforts (and cause its Affiliates) to (i)&nbsp;cause the First Merger and Second Merger, taken together, to constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2
C.B. 321 that qualifies as a &#147;reorganization&#148; within the meaning of Section&nbsp;368(a)(1)(A) of the Code (the &#147;<B>Intended Tax Treatment</B>&#148;), and (ii)&nbsp;not take any actions, or fail to take or cause to be taken any action,
which action or failure to act would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. Without limiting the foregoing, Parent and its Affiliates (including the First Step Surviving Corporation
after the First Effective Time and the Surviving Company after the Second Effective Time) shall use commercially reasonable efforts to use PY314, PY159 and PY265 in the business development initiatives of Parent and its Affiliates, provided that,
for the avoidance of doubt, Parent and its Affiliates are not providing any guarantee hereunder that they will pursue internal development of PY314, PY159 or PY265 or that any such business development initiatives relating to PY314, PY159 and PY265
will be successful. The Parties further agree that, for tax purposes, the value of each share of Parent Preferred Stock issued at Closing is equal to the closing price of a share of Parent Common Stock on the last trading day ending prior to the
Closing. The Parties shall not file any U.S. federal, state or local Tax Return in a manner that is inconsistent with the Intended Tax Treatment or the other provisions of this <U>Section&nbsp;5.5(a)</U>, and shall not take any inconsistent position
during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a &#147;determination&#148; within the meaning of Section&nbsp;1313 of the Code. Notwithstanding anything to the
contrary in this Agreement, the Securityholder Agent shall have no obligation to prepare or file any Tax Returns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Parent, on the one
hand, shall be responsible for 50% of all transfer, documentary, sales, use, stamp, registration, excise, recording, registration value added and other such similar Taxes and fees (including any penalties and interest) that become payable in
connection with or by reason of the execution of this Agreement and the transactions contemplated hereby (collectively, &#147;<B>Transfer Taxes</B>&#148;) and all Company Holders on the other hand, shall be responsible for 50% of all Transfer Taxes.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) At the Closing, the Company shall deliver to Parent a certificate pursuant to Treasury
Regulations Sections 1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&nbsp;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;
provided, that Parent&#146;s only remedy for the Company&#146;s failure to provide such form or certificate will be to withhold from the payments to be made pursuant to this Agreement any required withholding Tax under Section&nbsp;1445 of the Code,
and the Company&#146;s failure to provide any such form or certificate will not be deemed to be a failure of the conditions set forth in <U>Section 7</U> to have been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) Following the filing of the Company&#146;s U.S. federal corporate income tax return (IRS Form 1120) for the tax year ending as of the
Closing Date, Parent will send to the Delaware Division of Corporation the signed page 1, page 4 and 5 of the Form 1120 (Schedule L), all ending consolidated balance sheet information (if consolidated) and the e-filed signature page (if e-filed).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6 <U>Legends</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
Parent shall be entitled to place the following legend on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company for purposes of Rules 144 and 145 under the
Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for Parent Capital Stock: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;THE OFFER AND SALE OF THESE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE
SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT OT THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR A VALID EXEMPTION FROM
REGISTRATION UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Upon issuance, until Released from Indemnity in accordance
with the terms hereof, the Indemnity Shares shall be issued in book entry form and shall bear the following legend, in addition to any legend required by <U>Section&nbsp;5.6(a)</U> above; provided, that the following legend shall be removed from any
such Indemnity Shares upon their Release from Indemnity: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;THE SHARES REPRESENTED HEREBY ARE INDEMNITY SHARES AND SUBJECT TO
RESTRICTIONS OF TRANSFER SET FORTH IN THAT CERTAIN AGREEMENT AND PLAN OF MERGER DATED AUGUST 4, 2023, AMONG THE ISSUER AND THE OTHER PARTIES THERETO, AND MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH SUCH AGREEMENT.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) Subject to receipt by Parent and its transfer agent of customary representations and other documentation reasonably acceptable to Parent
and Parent Transfer Agent, to the effect that the removal of such restrictive legends in such circumstances may be effected, upon request by a holder of Parent Capital Stock to be received in the Merger, Parent shall use commercially reasonable
efforts to remove or cause to be removed any legend from the certificates or book-entry position evidencing such Parent Capital Stock within a reasonable time following the earliest of such time as such Parent Capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock has been or is about to be sold or transferred pursuant to an effective registration statement. Further, Parent shall upon appropriate notice and receipt of customary representations from a
holder of Parent Capital Stock (i)&nbsp;following any sale or transfer pursuant to Rule 144 or (ii)&nbsp;if the shares of Parent Capital Stock may be sold by such holder of Parent Capital Stock without restriction under Rule 144, including without
limitation, any volume and manner of sale restrictions, use commercially reasonable efforts to promptly cause the restrictive legends to be removed and prepare and deliver certificate(s) or evidence of book-entry positions that are free from all
restrictive and other legends or, at the request of the holder, via DWAC transfer to such Holder&#146;s account. In connection with Parent&#146;s instruction to remove any legend pursuant to the preceding sentence, and subject to receipt from the
holder of Parent Capital Stock by Parent and its counsel of representations and documentation reasonably acceptable to Parent and its counsel, Parent shall cause its legal counsel to deliver an opinion, if necessary, to the transfer agent to the
effect that the removal of such restrictive legend in such circumstance may be effected under the Securities Act. If restrictive legends are no longer required for such shares of Parent Capital Stock pursuant to the foregoing, Parent shall, in
accordance with the provisions of this section and reasonably promptly following any request therefor from the holder accompanied by such customary and reasonably acceptable representations and other documentation referred to above establishing that
restrictive legends are no longer required, deliver to the transfer agent irrevocable instructions that the transfer agent shall make a new, unlegended entry for the shares of Parent Capital Stock. Parent shall be responsible for the fees of its
transfer agent, its legal counsel and all Depository Trust Company fees associated with the foregoing. The Company Holders of Parent Capital Stock shall be express third party beneficiaries of the terms of this<U> Section 5.6.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7 <U>Termination of Certain Agreements and Rights</U>. The Company shall cause any member agreements, voting agreements, registration rights
agreements, co-sale agreements and any other similar Contracts between the Company and any Company Holders, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director
registration rights (collectively, the &#147;<B>Investor Agreements</B>&#148;), to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of the Surviving Company, except as set forth in
<U>Section&nbsp;5.7</U> of the Company Disclosure Schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8 <U>Section&nbsp;16 Matters</U>. Prior to the First Effective Time, Parent
shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase or restricted stock units in respect of Parent Common Stock in connection with the Contemplated Transactions, by each
individual who is reasonably expected to become subject to the reporting requirements of Section&nbsp;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule 16b-3 promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9 <U>Allocation Certificate</U>. The Company will prepare and deliver to Parent prior to the Closing a certificate signed by the chief
financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company), in a form reasonably acceptable to Parent, setting forth (as of immediately prior to the First Effective
Time) (a)&nbsp;each holder of Company Common Stock, Company Option or Company Restricted Stock Unit, (b)&nbsp;such holder&#146;s name and email address (or mail address, to the extent an email address is unavailable), (c)&nbsp;whether such holder is
an Accredited Investor, (d)&nbsp;the number or percentage and type of Company Common Stock (including the Company Common Stock subject to Company Options and/or Company Restricted Stock Unit) held as of the Closing Date for each such holder,
(e)&nbsp;in the case of a Company Indemnitor, (i)&nbsp;the Pro Rata Share, and (ii)&nbsp;the Per Share Expense Fund Amount, (f)&nbsp;in the case of a holder that is an Accredited Investor, (i)&nbsp;the number of shares of Parent Common Stock or
Parent Preferred Stock to be issued to such holder pursuant to this Agreement (and indicating whether they are Company Merger Shares or Indemnity Shares), and (ii)&nbsp;any cash in lieu of fractional share interests to be paid to such holder
pursuant to this Agreement, in each case, in respect of the Company Common Stock held by such holder as of immediately prior to the First Effective Time and (g)&nbsp;in the case of a holder that is an Unaccredited Investor, the amount of cash
(rounded to the nearest whole cent) to be paid to such holder pursuant to this Agreement in respect of the Company Common Stock held by such holder as of immediately prior to the First Effective Time (the &#147;<B>Allocation Certificate</B>&#148;).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10 <U>CVR Agreement</U>. Parent shall deliver to the Company, at or prior to the Closing,
the CVR Agreement duly executed by Parent and the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11 <U>Resale Registration and Related Procedures</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Parent shall prepare and file with the SEC (i)&nbsp;a Registration Statement on Form S-3 if it is eligible to use such
form (or otherwise on Form S-1) or (ii)&nbsp;a prospectus supplement pursuant to Rule 424(b)(7) under the Act (the &#147;<B>Prospectus Supplement</B>&#148;) relating to an effective Registration Statement on Form S-3, in each such case covering the
resale of all Registrable Securities, specifically the Company Merger Shares, and when Released from Indemnity, the Indemnity Shares, as a secondary offering to be made on a continuous basis pursuant to Rule 415. The applicable Registration
Statement (including any preliminary or final prospectus or prospectus supplement contained therein) referenced in clause (i)&nbsp;is referred to herein as the &#147;<B>Registration Statement</B>.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Parent shall exercise commercially reasonable efforts to prepare and file either the Registration Statement under clause
(a)(i) above or the Prospectus Supplement under clause (a)(ii) above with the SEC no later than fifteen (15)&nbsp;days after the Closing Date; <U>provided</U>, <U>however</U>, that if Parent determines that the acquisition of the Company constitutes
the acquisition of a business that exceeds fifty percent (50%)&nbsp;under any of the significance tests under Article 3-05 of Regulation S-X, such date, such date shall be within two (2)&nbsp;Business Days following the date on which such financial
statements are filed with the SEC. Subject to the terms herein, Parent shall use commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable after such filing if not otherwise effective upon filing
and to keep the Registration Statement continuously effective and usable for resale of Registrable Securities covered thereby from the date of its initial effectiveness until such time as no Registrable Securities remain outstanding (such period,
the &#147;<B>Effectiveness Period</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The obligation of Parent to name a Company Holder as a selling
stockholder in a Registration Statement or Prospectus Supplement are subject to such Company Holder furnishing in writing to Parent a completed questionnaire substantially in form attached hereto as <U>Exhibit E</U>. At least five (5)&nbsp;Business
Days prior to the anticipated filing date of the Registration Statement or Prospectus Supplement, Parent shall notify each Company Holder of any additional information Parent requires from such Company Holder, and such Company Holder shall provide
such information to Parent at least two (2)&nbsp;Business Days prior to the anticipated filing date of the Registration Statement or Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Registration Procedures; Company Obligations</U>. Parent shall use commercially reasonable efforts to effect the registration of the
Registrable Securities in accordance with this <U>Section&nbsp;5.11</U>, and in connection therewith shall have the following obligations: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments
or supplements thereto, shall comply as to form and content with the applicable requirements of the Securities Act and shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or
necessary to make the statements therein, in light of the circumstances in which they were made, not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Subject to <U>Section&nbsp;5.11(b)(v)</U>, Parent shall prepare and
file with the SEC such amendments and supplements to the Registration Statement and the prospectus used in connection with the Registration Statement as may be necessary to keep the Registration Statement effective and usable for resale of the
Registrable Securities covered thereby at all times during the Effectiveness Period. Parent shall use commercially reasonable efforts to cause any post-effective amendment to the Registration Statement to become effective as soon as practicable
after such filing. No later than the first Business Day after the Registration Statement or a post-effective amendment to the Registration Statement becomes effective, Parent shall file with the SEC the final prospectus or prospectus supplement
included therein pursuant to Rule 424. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Parent shall use commercially reasonable efforts to register or qualify, and
cooperate with the Company Holders of Registrable Securities covered by the Registration Statement in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or &#147;blue sky&#148;
laws of each state and other jurisdiction of the United States as any such Company Holder reasonably requests in writing, and do any and all other things reasonably necessary or advisable to keep such registration or qualification in effect;
provided, however, that Parent shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified or take any action which would subject it to taxation or general service of process in any such
jurisdiction where it is not then so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Parent shall as promptly as practicable notify the Company Holders of
the time the Registration Statement or a post-effective amendment to the Registration Statement becomes effective and/or when an amendment or supplement to any prospectus forming a part of such Registration Statement has been filed. Parent shall
furnish to the Company Holders, without charge, such documents, including copies of any preliminary prospectus or final prospectus contained in the Registration Statement or any amendments or supplements thereto, as such Company Holder may
reasonably request from time to time in order to facilitate the disposition of the Registrable Securities covered by the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Parent shall promptly notify the Company Holders when a prospectus is required to be delivered under the Securities Act of
the happening of any event as a result of which any prospectus included in, or relating to, the Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated
therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading (<U>provided</U>, that in no event shall such notice contain any material, non-public information), and, subject to
<U>Section&nbsp;5.11(b)(vi)</U>, promptly prepare and file with the SEC a supplement to the related prospectus or amendment to such Registration Statement or any other required document so that, as thereafter delivered to the Company Holders, the
prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Parent shall use commercially reasonable efforts to prevent the issuance of any stop order or other
suspension of effectiveness of the Registration Statement, or the suspension of the qualification of any of the Registrable Securities for sale in any jurisdiction and, if such an order or suspension is issued, to obtain the withdrawal of such order
or suspension as soon as reasonably practicable and to notify the Company Holders of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or threat of any proceeding for such purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Notwithstanding anything in this Agreement to the contrary,
(A)&nbsp;Parent may delay effectiveness of the Registration Statement or any post-effective amendment thereto or (B)&nbsp;at any time after the Registration Statement is effective Parent may delay the disclosure of material, non-public information
concerning Parent or any of its subsidiaries if, in each case, the Board of Directors of Parent has a valid business reason for determining that disclosure of such information is not in the best interests of the Company and such disclosure is not
otherwise required, including under applicable laws or regulations or rules of any applicable securities exchange (a &#147;<B>Grace Period</B>&#148;); <U>provided</U>, <U>however</U>, that Parent shall promptly (1)&nbsp;provide written notice to the
Company Holders of the Grace Period (provided that in no event shall such notice contain any material, non-public information) and the date on which the Grace Period will begin, (2)&nbsp;use reasonable best efforts to terminate a Grace Period as
promptly as possible, and (3)&nbsp;provide written notice to the Holders of the date on which the Grace Period ends; <U>provided</U>, <U>further</U>, that no Grace Period shall exceed fifteen (15)&nbsp;consecutive days and such Grace Periods shall
not exceed an aggregate of forty-five (45)&nbsp;days in any twelve (12)&nbsp;month period in which Registrable Securities are outstanding. The provisions of <U>Section&nbsp;5.11(b)(v)</U> shall not be applicable during the pendency of any Grace
Period. Upon expiration of a Grace Period, Parent shall again be bound by the provisions of <U>Section&nbsp;5.11(b)(v)</U> with respect to the information giving rise thereto unless such material, non-public information is no longer applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) Parent shall cause the Registrable Securities covered by the Registration Statement to be (A)&nbsp;listed on the Nasdaq
and (B)&nbsp;reflected in the stock ledger maintained by Parent Transfer Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Current Public Information</U>. During the
Effectiveness Period, Parent shall use commercially reasonable efforts to (i)&nbsp;make and keep public information available, as those terms are defined in Rule 144, until all the Registrable Securities cease to be Registrable Securities, and so
long as a Company Holder owns any Registrable Securities, furnish to such Company Holder upon request a written statement by the Company as to its satisfaction of the current public information requirements of Rule 144, and (ii)&nbsp;file with the
SEC in a timely manner all reports and other documents required to be filed by the Company under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses of Registration</U>. All Registration Expenses incurred in connection with any registration, qualification or compliance
hereunder shall be borne by Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Parent shall indemnify and hold harmless each Company Holder of Registrable Securities and such Company Holder&#146;s
officers, directors, employees, partners, members, agents (including brokers), representatives and Affiliates and each person, if any, who controls such Company Holder within the meaning of the Securities Act or the Exchange Act (each, a
&#147;<B>Company Holder Indemnitee</B>&#148;), against any losses, claims, damages, liabilities or expenses to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims,
damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a &#147;<B>Violation</B>&#148;): (i)&nbsp;an untrue statement or alleged untrue statement
of a material fact contained in the Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto or any documents incorporated therein by reference; (ii)&nbsp;an omission
or alleged omission to state therein a material fact required to be stated therein, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
necessary to make the statements therein, in light of the circumstances in which they were made, not misleading; (iii)&nbsp;any liability of a Company Holder arising from any sales or
transactions made pursuant to the Registration Statement and/or Prospectus during the pendency of a Grace Period; and (iv)&nbsp;a violation or alleged violation by Parent or its Affiliates or Representatives of any rule or regulation promulgated
under the Securities Act or the Exchange Act applicable to Parent or its Affiliates or Representatives and relating to action or inaction required of Parent or its Affiliates or Representatives in connection with the Registration Statement, and
Parent will pay to each such Company Holder Indemnitee, as accrued, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, action or expense; <U>provided</U>,
<U>however</U>, that the indemnification contained in this <U>Section&nbsp;5.11(e)</U> shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, action or expense if such settlement is effected without the consent of
Parent (such consent not to be unreasonably withheld, conditioned or delayed), nor shall Parent be liable for any such loss, claim, damage, liability, action or expense to the extent that it arises out of or is based upon a Violation which occurs
(A)&nbsp;in reliance upon and in conformity with written information furnished by a Company Holder, (B)&nbsp;in connection with any failure of a Company Holder to deliver or cause to be delivered a prospectus made available by Parent in a timely
manner, or (C)&nbsp;as a result of offers or sales effected by or on behalf of any Company Holder by means of a free writing prospectus (as defined in Rule 405) that was not authorized in writing by Parent. Such indemnity shall remain in full force
and effect regardless of any investigation made by or on behalf of any such Company Holder Indemnitee, and shall survive the transfer of such securities by such Company Holder, and any termination of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) If the indemnification provided for in this <U>Section&nbsp;5.11(e)</U> is held by a court of competent jurisdiction to
be unavailable to any Company Holder Indemnitee with respect to any loss, liability, claim, damage, or expense referred to therein, then Parent, in lieu of indemnifying such Company Holder Indemnitee hereunder, shall contribute to the amount paid or
payable by such Company Holder Indemnitee as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of Parent on the one hand and of the Company Holder Indemnitee on the other
in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of Parent and of the Company Holder Indemnitee shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by Parent or by the Company Holder Indemnitee and the
parties&#146; relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. Notwithstanding the foregoing, the amount any Company Holder will be obligated to severally and not jointly contribute
pursuant to this <U>Section&nbsp;5.11(e)</U> will be limited to an amount equal to the gross proceeds received by a Company Holder for the sale of the Registrable Securities pursuant to the Registration Statement which gives rise to such obligation
to contribute and/or indemnify (less the aggregate amount of any damages which such Company Holder has otherwise been required to pay in respect of such loss, liability, claim, damage, or expense or any substantially similar loss, liability, claim,
damage, or expense arising from the sale of such Registrable Securities). No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution hereunder from any person
who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) The Company Holders of Registrable Securities shall be express third party
beneficiaries of the terms of this <U>Section&nbsp;5.11</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Conditions Precedent to Obligations of Each Party</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to
be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>No Restraints</U>. No temporary restraining order, preliminary or permanent injunction, or other Order preventing the consummation of
the Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation
of the Contemplated Transactions illegal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Stockholder Approval</U>. The Company shall have obtained the Required Company
Stockholder Vote and delivered evidence of a duly executed written consent evidencing approval by at least 75%-in-interest of the Company Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <U>Listing</U>. The shares of Parent Common Stock to be issued in the Merger pursuant to this Agreement shall have been approved for
listing (subject to official notice of issuance) on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Additional Conditions Precedent to Obligations of Parent and Merger
Sub</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are
subject to Parent receiving the following documents, each of which shall be in full force and effect, or written waiver by Parent of delivery: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <U>Company Stockholder Written Consent</U>. The Company Stockholder Written Consent executed by the Company Stockholders holding at least
seventy-five percent (75%)&nbsp;of the outstanding shares of Company Common Stock shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2 <U>Company
Valuation</U>. The Company Valuation shall not be below thirty-nine million and five hundred thousand (39,500,000)&nbsp;dollars as of immediately prior to the Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3 <U>Allocation Certificate</U>. The Company shall have delivered the Allocation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Certificate pursuant to Section&nbsp;5.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.4 <U>Accredited Investor Questionnaire</U>s. The Company shall have delivered to Parent duly completed and executed accredited investor
questionnaires in the form attached hereto as <U>Exhibit E</U> from the Company Stockholders holding at least eighty percent (80%)&nbsp;of the outstanding shares of Company Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.5 <U>Company Lock-Up Agreements</U>. The Company shall have delivered to Parent duly completed and executed Company Lock-Up Agreements,
which shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Additional Conditions Precedent to Obligation of the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the Company
receiving the following documents, each of which shall be in full force and effect, or the written waiver by the Company of delivery: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1
<U>Certificate of Designation</U>. A copy of the as-filed Certificate of Designation, certified by the Secretary of State of the State of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2 <U>Parent Stockholder Support Agreements</U>. Parent shall have delivered to the Company
duly completed and executed Parent Stockholder Support Agreements, which shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3 <U>CVR Agreement</U>.
Parent shall have delivered to the Company duly completed and executed CVR Agreement, which shall be in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.
<U>Indemnification</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1 <U>Indemnity Fund</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Promptly following the Closing, Parent shall give to the Parent Transfer Agent instructions for delivery of the Indemnity Shares to the
Company Indemnitors (which Indemnity Shares shall be delivered to the Company Indemnitors in accordance with their Pro Rata Share pursuant to <U>Section&nbsp;2.6(a)(ii))</U>. As used herein, the &#147;<B>Indemnity Fund</B>&#148; shall mean and refer
to, from time to time, such Indemnity Shares delivered to the Company Indemnitors (and any property or other securities issued upon conversion thereof or in exchange therefor) other than any such Indemnity Shares that shall have been Released from
Indemnity pursuant to the terms of this Agreement. The Indemnity Fund (and any Release from Indemnity of the Indemnity Shares comprising such Indemnity Fund) shall be governed by this Agreement and shall constitute partial security for the benefit
of Parent (on behalf of itself or any other Parent Indemnified Person) with respect to any Damages indemnifiable pursuant to the indemnification obligations of the Company Indemnitors under this <U>Section&nbsp;9</U>. During such time as the
Indemnity Shares are held in the Indemnity Fund, the Company Indemnitors shall be entitled to receive any dividends paid or payable, and to exercise any voting rights, with respect to their Pro Rata Shares of such Indemnity Shares and shall be
treated as the beneficial owners thereof for U.S. federal income tax purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Subject to <U>Section&nbsp;9.4</U>, the Company
Indemnitors shall hold the Indemnity Fund until 11:59 p.m. Eastern Time on February&nbsp;4, 2024 (the &#147;<B>Indemnity Release Date</B>&#148;). Neither the Indemnity Fund (including any portion thereof) nor any beneficial interest therein may be
pledged, subjected to any Encumbrance, sold, assigned or transferred by any Company Indemnitor or be taken or reached by any legal or equitable process in satisfaction of any debt or other Liability of any Company Indemnitor, in each case prior to
the Release from Indemnity of the Indemnity Fund (or any portion thereof) to any Company Indemnitor in accordance with <U>Section&nbsp;9.1(b)</U>, except that each Company Indemnitor shall be entitled to assign such Company Indemnitor&#146;s rights
to the cash, securities or other property distributable to such Company Indemnitor upon Release from Indemnity of the Indemnity Fund by will, by the laws of intestacy or by other operation of law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) On the Indemnity Release Date, Parent and the Securityholder Agent shall Release from Indemnity to the Company Indemnitors, the Indemnity
Fund less that portion of the Indemnity Fund (rounded down to the nearest whole share) that is necessary to satisfy all unsatisfied or disputed claims for indemnification specified in reasonable detail in any Claim Certificate delivered in good
faith to the Securityholder Agent on or prior to the Indemnity Release Date in accordance with this <U>Section&nbsp;9</U> (assuming that the value of each Indemnity Share equals the greater of the Parent Share Price and the volume weighted average
price (&#147;<B>VWAP</B>&#148;) of a share of Parent Common Stock on the Nasdaq Global Market in the 30 trading days prior to the Indemnity Release Date). Any portion of the Indemnity Fund not Released from Indemnity to the Company Indemnitors
pursuant to the prior sentence shall, other than any portion awarded to Parent in connection with the resolution thereof (which shall be paid in accordance with <U>Section&nbsp;9.7(a)</U>, <U>Section&nbsp;9.7(b)</U> or <U>Section&nbsp;9.7(c)</U>, as
applicable), be promptly Released from Indemnity to the Company Indemnitors upon the satisfaction or resolution of such claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2 <U>Survival of Company Fundamental Representations</U>. The Company Fundamental
Representations survive the Closing and remain in full force and effect until the Indemnity Release Date; <U>provided</U> that no right to indemnification pursuant to this <U>Section&nbsp;9</U> in respect of any claim that is set forth in a Claim
Certificate delivered to the Securityholder Agent on or prior to the expiration of such Company Fundamental Representations shall be affected by such expiration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3 <U>Indemnification</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
Subject to the limitations set forth in this <U>Section&nbsp;9</U>, from and after the Closing, each Company Indemnitor shall severally but not jointly, and in proportion to their Pro Rata Shares, indemnify, defend and hold harmless Parent, Merger
Subs, and the Company and their respective officers, directors, agents and employees and each Person, if any, who controls or may control Parent within the meaning of the Securities Act (each, an &#147;<B>Parent Indemnified Person</B>&#148;) from
and against, and shall compensate and reimburse each Parent Indemnified Person for, any and all losses, Liabilities, damages, fees, Taxes, interest, reasonable out-of-pocket costs and expenses, including costs of investigation, defense and
enforcement and reasonable fees and expenses of counsel, experts and other professionals, directly or indirectly, whether or not due to a Third Party Claim, experts and other professionals, directly or indirectly, other than any (i)&nbsp;punitive or
exemplary damages, or (ii)&nbsp;special, consequential, incidental, indirect or remote damages, unless and solely to the extent in each case (i)&nbsp;and (ii), an Indemnified Person is ordered to pay such Damages to a third party(collectively,
&#147;<B>Damages</B>&#148;), arising out of or resulting from: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any failure of any Company Fundamental Representation
to be true and correct as of the Closing Date (except in the case of representations and warranties that by their terms speak only as of a specified date or dates, which representations and warranties shall be true and correct as of such date or
dates); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any Third-Party Claim of gross negligence by the Company in connection with the conduct of its clinical
trials prior to the Closing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4 <U>Limitations</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Company Indemnitors shall not be required to make any indemnification payments unless and until the aggregate amount of such
indemnifiable Damages exceeds $653,569.14 (the &#147;<B>Basket</B>&#148;) in which case, subject to the limitations set forth in this <U>Section&nbsp;9</U>, the Parent Indemnified Persons shall recover from the Indemnity Fund for all the Damages in
excess of the Basket. In respect of each Company Indemnitor, his, her or its Pro Rata Share of indemnifiable Damages hereunder shall be recovered (i)&nbsp;first, from the shares of Parent Preferred Stock comprising the Indemnity Fund held by such
Company Indemnitor and if no such Indemnity Shares remain in the Indemnity Fund or after the Indemnity Release Date, (ii)&nbsp;second, from the shares of Parent Common Stock comprising the Indemnity Fund held by such Company Indemnitor and if no
such Indemnity Shares remain in the Indemnity Fund or after the Indemnity Release Date, then (iii)&nbsp;third, from the Company Merger Shares held by such Company Indemnitor (with any such Company Merger Shares surrendered pursuant to this clause
(iii)&nbsp;to be surrendered in the amounts and based on the valuations of such Company Merger Shares specified in <U>Section&nbsp;9.7</U>, applied as if such Company Merger Shares were Indemnity Shares); <U>provided</U>, that, (x)&nbsp;in no event
shall any Company Indemnitor be liable for Damages under this <U>Section&nbsp;9</U> in excess of his, her or its Pro Rata Share of such Damages and (y)&nbsp;in no event shall any Company Indemnitor be liable for any amount of Damages from and after
the time that such Company Indemnitor has (1)&nbsp;surrendered to any Parent Indemnified Person the Parent Capital Stock issued to such Company Indemnitor in the Merger pursuant to this Agreement to the extent any such Parent Capital Stock is held
by the Company Indemnitor as of such time, and (2)&nbsp;if any shares of Parent Capital Stock issued to such Company Indemnitor in the Merger pursuant to this Agreement have been sold by such Company Indemnitor, for the avoidance of doubt, excluding
any surrender thereof pursuant to this <U>Section&nbsp;9</U>, remitted to any Parent Indemnified Person pursuant to this <U>Section&nbsp;9</U> the amount of the lower of the Parent Share Price and the cash proceeds actually received from such
disposition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary herein, no Company Indemnitor shall have any
right of indemnification, compensation, reimbursement, contribution or right of advancement from Parent, the Surviving Company or any other Parent Indemnified Person (based upon such holder&#146;s position as an officer, director, employee or agent
of the Company or otherwise) with respect to any Damages owed to any Parent Indemnified Person pursuant to <U>Section&nbsp;9.3(a)</U> or any right of subrogation against the Company or the Surviving Company with respect to any such indemnification,
compensation or reimbursement of a Parent Indemnified Person by reason of such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) All Damages shall be calculated net of the
amount of any recoveries actually received by a Parent Indemnified Person prior to the Indemnity Release Date under any existing insurance policies and contractual indemnification or contribution provisions (in each case, calculated net of any
actual collection costs and reserves, expenses, deductibles or premium adjustments or retrospectively rated premiums (as determined in good faith by an Indemnified Person) incurred or paid to procure such recoveries) in respect of any Damages
suffered, paid, sustained or incurred by any Indemnified Person; provided that no Indemnified Person shall have any obligation to seek to obtain or continue to pursue any such recoveries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5 <U>Period for Claims</U>. The period (the &#147;<B>Claims Period</B>&#148;) during which claims may be made for Damages pursuant to clauses
(i)&nbsp;and (ii)&nbsp;of <U>Section&nbsp;9.3(a)</U> shall commence at the Closing and terminate at 11:59 p.m. Eastern Time on the Indemnity Release Date. No Company Indemnitor shall have any obligation to indemnify any Parent Indemnified Party for
any Damages that are not Claimed Damages contained in a Claim Certificate that is delivered to the Securityholder Agent prior to the expiration of the Claims Period. Notwithstanding anything to the contrary herein, such portion of the Indemnity Fund
(rounded down to the nearest whole share) that is reasonably necessary to satisfy any unresolved or unsatisfied claims for Damages specified in any Claim Certificate delivered to the Securityholder Agent on or prior to the Indemnity Release Date
(assuming that the value of each Indemnity Share equals the greater of the Parent Share Price and the VWAP of a share of Parent Common Stock on the Nasdaq Global Market in the 30 trading days prior to the Indemnity Release Date) shall not be
Released From Indemnity until such claims for Damages have been resolved or satisfied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.6 <U>Claims</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) From time to time during the Claims Period, Parent may deliver to the Securityholder Agent one or more certificates signed by any officer
of Parent (each, a &#147;<B>Claim Certificate</B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) stating that a Parent Indemnified Person has incurred,
paid, reserved or accrued, or in good faith believes that it may incur, pay, reserve or accrue, Damages (or that with respect to any Tax matters, that any Governmental Authority may raise such matter in audit of Parent or its subsidiaries, that
could give rise to Damages); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) stating the amount of such Damages (which, in the case of Damages not yet incurred,
paid, reserved or accrued, may be the maximum amount believed by Parent in good faith to be incurred, paid, reserved, accrued or demanded by a third party) (such amount, the &#147;Claimed Damages&#148;); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) specifying in reasonable detail (based upon the information then possessed by Parent) the individual items of such
Damages included in the amount so stated and the nature of the claim to which such Damages are related. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Such Claim Certificate (i)&nbsp;need only specify such information to the knowledge of
such officer of Parent or the Parent Indemnified Person as of the date thereof, (ii)&nbsp;shall not limit any of the rights or remedies of any Parent Indemnified Person with respect to the underlying facts and circumstances specifically set forth in
such Claim Certificate and (iii)&nbsp;may be updated and amended from time to time by Parent by delivering any updated or amended Claim Certificate, so long as the delivery of the original Claim Certificate is made within the applicable Claims
Period and such update or amendment relates to the underlying facts and circumstances specifically set forth in such original Claims Certificate; provided that all claims for Damages properly set forth in a Claim Certificate or any update or
amendment thereto shall remain outstanding until such claims have been resolved or satisfied, notwithstanding the expiration of such Claims Period. No delay in providing such Claim Certificate within the applicable Claims Period shall affect a
Parent Indemnified Person&#146;s rights hereunder, unless (and then only to the extent that) the Securityholder Agent or the Company Indemnitor are actually prejudiced thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.7 <U>Resolution of Objections to Claims</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If the Securityholder Agent does not contest, by written notice to Parent, any claim or claims by Parent made in any Claim Certificate
within the 60-day period following receipt of the Claim Certificate, then Parent and the Securityholder Agent shall Release from Indemnity to Parent a number of shares (rounded down to the nearest whole share) of Parent Capital Stock from the
Indemnity Fund having a total value, based on the greater of the Parent Share Price and the VWAP of a share of Parent Common Stock on the Nasdaq Global Market in the thirty (30)&nbsp;trading days prior to the last day of such 30-day period (assuming
that the value of each share of Parent Preferred Stock is equal to the value of each share of Parent Common Stock), equal to the amount of any Damages corresponding to such claim or claims as set forth in such Claim Certificate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the Securityholder Agent objects in writing to any claim or claims by Parent made in any Claim Certificate within the 60-day period set
forth in <U>Section&nbsp;9.7(a)</U>, Parent and the Securityholder Agent shall attempt in good faith for 45 days after Parent&#146;s receipt of such written objection to resolve such objection and the amount of Damages that are indemnifiable by the
Company Indemnitors pursuant to this <U>Section&nbsp;9</U> in connection with the claim or claims made by Parent in such Claim Certificate. If Parent and the Securityholder Agent shall so agree, in writing, Parent and the Securityholder Agent shall
Release from Indemnity to Parent from the Indemnity Fund a number of shares (rounded down to the nearest whole share) of Parent Capital Stock having a total value, based on the greater of the Parent Share Price and the VWAP of a share of Parent
Common Stock on the Nasdaq Global Market in the 30 trading days prior to the resolution by the Parent and the Securityholder Agent of such objection (assuming that the value of each share of Parent Preferred Stock is equal to the value of each share
of Parent Common Stock), equal to the amount of Damages, if any, so agreed by Parent and the Securityholder Agent in writing to be indemnifiable by the Company Indemnitors pursuant to this<U> Section&nbsp;9</U> in accordance with the terms of such
joint written instruction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) If no such agreement is reached during the 45-day period for good faith negotiation set forth in
<U>Section&nbsp;9.7(b)</U>, upon the expiration of such 45-day period, either Parent or the Securityholder Agent may bring an action in the applicable jurisdiction pursuant to <U>Section&nbsp;10.5</U> to resolve the matter. Any final, non-appealable
decision of a Governmental Authority as to the validity and amount of any claim in such Claim Certificate shall be conclusive and binding upon the parties hereto and the Company Indemnitors, and following such decision the Securityholder Agent and
Parent shall Release from Indemnity to Parent from the Indemnity Fund a number of shares (rounded down to the nearest whole share) of Parent Capital Stock having a total value, based on the greater of the Parent Share Price and the VWAP of a share
of Parent Common Stock on the Nasdaq Global Market in the 30 trading days prior to the decision regarding such matter by the Governmental Authority (assuming that the value of each share of Parent Preferred Stock is equal to the value of each share
of Parent Common Stock), equal to the amount of Damages, if any, so decided by the Governmental Authority to be indemnifiable by the Company Indemnitors pursuant to this <U>Section&nbsp;9</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.8 <U>Securityholder Agent</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) By approving the Merger and/or participating in the Merger and receiving any benefits hereunder, and without any further action of any of
the Company Holders or the Company, each Company Holder irrevocably approves the constitution and appointment of, and hereby irrevocably constitutes and appoints, Fortis Advisors LLC, a Delaware limited liability company, as the true and lawful
exclusive agent, representative and attorney-in-fact of all Company Holders (the &#147;<B>Securityholder Agent</B>&#148;) with respect to any and all matters relating to, arising out of, or in connection with, this Agreement, including for purposes
of taking any action or omitting to take any action on behalf of the Company Holders to: (i)&nbsp;execute, as the Securityholder Agent, this Agreement and any agreement or instrument entered into or delivered in connection with the Contemplated
Transactions, (ii)&nbsp;give and receive notices, instructions and communications permitted or required under this Agreement, or any other agreement, document or instrument entered into or executed in connection herewith, for and on behalf of the
Company Holders or any Company Holder, to or from Parent (on behalf of itself or any other Parent Indemnified Person) relating to this Agreement or any of the Contemplated Transactions and any other matters contemplated by this Agreement or by such
other agreement, document or instrument (except to the extent that this Agreement expressly contemplates that any such notice or communication shall be given or received by each such Company Holder individually), (iii)&nbsp;act for the Company
Holders with regard to all matters pertaining to indemnification under this Agreement, including the power to defend, compromise, or settle any claims and to otherwise prosecute or pursue any litigation claims, and the Release from Indemnity of any
of the Indemnity Fund, including to review, negotiate and agree to and authorize any Release from Indemnity to Parent of any amount from the Indemnity Fund in satisfaction of claims asserted by Parent (on behalf of itself or any other Parent
Indemnified Person, including by not objecting to such claims) pursuant to this <U>Section&nbsp;9</U>, (iv)&nbsp;object to such claims pursuant to <U>Section&nbsp;9.7</U>, (v)&nbsp;consent or agree to, negotiate, enter into, or, if applicable,
contest, prosecute or defend, settlements and compromises of, and demand arbitration and comply with Orders of courts and awards of arbitrators with respect to, such claims, resolve any such claims, take any actions in connection with the resolution
of any dispute relating hereto or to the Contemplated Transactions by arbitration, settlement or otherwise, and take or forego any or all actions permitted or required of the Company Holders or any Company Holder or necessary in the judgment of the
Securityholder Agent for the accomplishment of the foregoing and all of the other terms, conditions and limitations of this Agreement, (vi)&nbsp;consult with legal counsel, independent public accountants and other experts selected by it, solely at
the cost and expense of the Company Holders, (vii)&nbsp;consent or agree to any amendment to this Agreement or to waive any terms and conditions of this Agreement providing rights or benefits to the Company Holders (other than with respect to the
payment of the consideration contemplated in <U>Section&nbsp;2)</U> in accordance with the terms hereof and in the manner provided herein, and (viii)&nbsp;take or refrain from taking the foregoing and all other actions necessary or appropriate in
the judgment of the Securityholder Agent for the accomplishment of the foregoing or otherwise relating to the subject matter of this Agreement, in each case without having to seek or obtain the consent of any Person under any circumstance. Without
limiting the foregoing, by approving the Merger and/or participating in the Merger and receiving any benefits hereunder, and without any further action of any of the Company Holders or the Company, each Company Holder irrevocably grants to the
Securityholder Agent a power of attorney for such Company Holder for the purpose of taking any actions deemed necessary or advisable by the Securityholder Agent in connection with any Release from Indemnity of the Indemnity Fund pursuant to this
Agreement, and Parent and the Parent Transfer Agent shall each be an express third-party beneficiary of such power of attorney. Notwithstanding the foregoing or anything else herein, the Securityholder Agent shall have no obligation to act on behalf
of the Company Holders, except as expressly provided herein and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the Securityholder Agent Engagement Agreement, and for purposes of clarity, there are no obligations of the Securityholder Agent in any ancillary agreement (other than any Parent Stockholder
Support Agreement to which the Securityholder Agent is a party, to the extent expressly set forth therein), schedule, exhibit or the Company Disclosure Schedule. The powers, immunities and rights to indemnification granted to the Securityholder
Agent Group hereunder: (i)&nbsp;are coupled with an interest and shall be irrevocable and survive the death, incompetence, bankruptcy or liquidation of any Company Holder and shall be binding on any successor thereto, and (ii)&nbsp;shall survive the
delivery of an assignment by any Company Holder of the whole or any fraction of his, her or its interest in the Indemnity Fund. All actions, notices, communications, and determinations by or on behalf of the Company Holders in connection with this
Agreement may be given or made by the Securityholder Agent and all actions, notices, communications and determinations by the Securityholder Agent under this Agreement or the Securityholder Agent Engagement Agreement shall conclusively be deemed to
have been authorized by, and shall be binding upon, any of and all Company Holders and each such Company Holder&#146;s successors as if expressly confirmed and ratified in writing by such Company Holder, and no Company Holder shall have the right to
object, dissent, protest or otherwise contest the same. All defenses which may be available to any Company Holder to contest, negate or disaffirm the action of the Securityholder Agent taken in good faith under this Agreement or the Securityholder
Agent Engagement Agreement are waived. Parent, Merger Subs, and their respective Affiliates (including after the Second Effective Time, the Surviving Company) shall be entitled to rely on the appointment of Fortis Advisors LLC as the Securityholder
Agent and treat such Securityholder Agent as the duly appointed attorney-in-fact of each Company Holder and has having the duties, power and authority provided for in this <U>Section (c)</U>. The Company Holders shall be bound by all actions taken
and documents executed by the Securityholder Agent in connection with this <U>Section&nbsp;9</U>, and Parent and other Parent Indemnified Persons shall be entitled to rely exclusively on any action or decision of the Securityholder Agent. The Person
serving as the Securityholder Agent may be removed or replaced from time to time, or if such Person resigns from its position as the Securityholder Agent, then a successor may be appointed, by the holders of a majority in interest of the aggregate
amount of stock held in the Indemnity Fund, upon not less than thirty (30)&nbsp;days&#146; prior written notice to Parent. The immunities and rights to indemnification granted to the Securityholder Agent Group hereunder shall survive the resignation
or removal of the Securityholder Agent or any member of the Advisory Group and the Closing and/or any termination of this Agreement. No bond shall be required of the Securityholder Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) Certain Company Holders have entered into an engagement agreement (the &#147;<B>Securityholder Agent Engagement Agreement</B>&#148;) with
the Securityholder Agent to provide direction to the Securityholder Agent in connection with its services under this Agreement and the Securityholder Agent Engagement Agreement (such Company Holders, including their individual representatives,
collectively hereinafter referred to as the &#147;<B>Advisory Group</B>&#148;). Neither the Securityholder Agent nor its members, managers, directors, officers, contractors, agents and employees nor any member of the Advisory Group (collectively,
the &#147;<B>Securityholder Agent Group</B>&#148;) shall be liable to any Company Holder for any act done or omitted in connection with the acceptance or administration of the Securityholder Agent&#146;s responsibilities hereunder or under the
Securityholder Agent Engagement Agreement, including any hereunder as the Securityholder Agent while acting in good faith (and any act done or omitted pursuant to the advice of counsel shall be conclusive evidence of such good faith), unless and
only to the extent such act done or omitted constitutes gross negligence or willful misconduct. The Company Holders shall severally but not jointly indemnify and defend the Securityholder Agent Group and hold the Securityholder Agent Group harmless
against any loss, Liability, claim, damage, judgment, fine, amount paid in settlement, fee, cost or expense (collectively, the &#147;<B>Securityholder Agent Expenses</B>&#148;) incurred without gross negligence, willful misconduct or bad faith on
the part of the Securityholder Agent and arising out of, resulting from or in connection with the acceptance or administration of its duties hereunder or under the Securityholder Agent Engagement Agreement, including all reasonable out-of-pocket
costs and expenses and legal fees and other legal costs reasonably incurred by the Securityholder Agent. If not paid directly to the Securityholder Agent by the Company Holders, such losses, Liabilities or other Securityholder Agent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Expenses may be recovered by the Securityholder Agent first, from the Expense Fund, and second, from that portion of the Indemnity Fund otherwise to be Released from Indemnity to the Company
Holders (and not distributed or distributable to an Parent Indemnified Person or subject to a pending indemnification claim of an Parent Indemnified Person) on or after the Indemnity Release Date pursuant to the terms hereof, or any other
distribution to the Company Holders, in each case at the time of distribution, and/or directly from the Company Holders, and such recovery will be made from such Company Holders according to their respective Pro Rata Share of such losses,
Liabilities or other Securityholder Agent Expenses. The Company Holders acknowledge that the Securityholder Agent shall not be required to expend or risk its own funds or otherwise incur any financial liability in the exercise or performance of any
of its powers, rights, duties or privileges or pursuant to this Agreement, the Securityholder Agent Engagement Agreement or the transactions contemplated hereby or thereby. Furthermore, the Securityholder Agent shall not be required to take any
action unless the Securityholder Agent has been provided with funds, security or indemnities which, in its determination, are sufficient to protect the Securityholder Agent against the costs, expenses and liabilities which may be incurred by the
Securityholder Agent in performing such actions. The Securityholder Agent shall be entitled to: (i)&nbsp;rely upon the Allocation Certificate and any other document or information provided by or on behalf of the Company or the Advisory Group as to
the allocation of distributions to the Company Holders or other matters relating to the Company Holders, (ii)&nbsp;rely upon any signature believed by it to be genuine, and (iii)&nbsp;reasonably assume that a signatory has proper authorization to
sign on behalf of the applicable Company Holder or other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) After the Closing, any notice or communication given or received by,
and any decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of, the Securityholder Agent that is within the scope of the Securityholder Agent&#146;s authority under
<U>Section&nbsp;9.8(a)</U> shall constitute a notice or communication to or by, or a decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of all the Company Holders and shall
be final, binding and conclusive upon each such Company Holders; and each Parent Indemnified Person shall be entitled to rely exclusively upon any such notice, communication, decision, action, failure to act within a designated period of time,
agreement, consent, settlement, resolution or instruction as being a notice or communication to or by, or a decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of, each and
every such Company Holders. Parent, Merger Subs, the Surviving Company and the Parent Indemnified Persons are hereby relieved from any Liability to any Person for any acts done by them in accordance with such notice, communication, decision, action,
failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of the Securityholder Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Expense Fund Amount shall be held by the Securityholder Agent in a segregated client account and shall be used (i)&nbsp;for the
purposes of paying directly or reimbursing the Securityholder Agent for any Securityholder Agent Expenses incurred pursuant to this Agreement or the Securityholder Agent Engagement Agreement, or (ii)&nbsp;as otherwise determined by the Advisory
Group (the &#147;<B>Expense Fund</B>&#148;). The Securityholder Agent is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Expense Fund other than as a
result of its gross negligence or willful misconduct. The Securityholder Agent is not acting as a withholding agent or in any similar capacity in connection with the Expense Fund and has no tax reporting or income distribution obligations. The
Company Indemnitors will not receive any interest on the Expense Fund and assign to the Securityholder Agent any such interest. Subject to Advisory Group approval, the Securityholder Agent may contribute funds to the Expense Fund from any
consideration otherwise distributable to the Company Holders. As soon as reasonably determined by the Securityholder Agent that the Expense Fund is no longer required to be withheld, the Securityholder Agent shall distribute the remaining Expense
Fund (if any) to the Exchange Agent or Parent, as applicable, for further distribution to the Company Indemnitors in accordance with their respective Pro Rata Share. Upon deposit of the Expense Fund Amount with the Securityholder Agent in accordance
with <U>Section&nbsp;2.11</U>, for Tax purposes, Parent shall be deemed to have paid each Company Indemnitor its, his or her share of the Expense Fund Amount and then each Company Indemnitor shall be deemed to have voluntarily contributed such
amount to the Expense Fund held by the Securityholder Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.9 <U>Third-Party Claims</U>. In the event Parent becomes aware of a claim by a third party
(a &#147;<B>Third-Party Claim</B>&#148;) that Parent in good faith believes may result in a claim for Damages indemnifiable by the Company Indemnitors hereunder by or on behalf of an Parent Indemnified Person, Parent shall, promptly after receipt of
notice of any such Third-Party Claim, notify the Securityholder Agent of the commencement thereof. Parent shall have the right in its sole discretion to determine and conduct the defense of any Third-Party Claim and the settlement, adjustment or
compromise of such Third-Party Claim; <U>provided</U>, however, the Securityholder Agent and its counsel may participate in the defense of such Third-Party Claim or any action related to such Third-Party Claim (including any discussions or
negotiations in connection with the settlement, adjustment or compromise thereof), and receive copies of all pleadings, notices and communications with respect to such Third-Party Claim, in each case, in a manner that would not result in the loss of
any attorney-client privilege, attorney work product privilege or any other legal privilege, subject to execution by the Securityholder Agent of Parent&#146;s (and, if required, such third party&#146;s) standard non-disclosure agreement to the
extent that such materials contain confidential or propriety information. In the event that the Securityholder Agent has consented to the amount of any settlement, neither the Securityholder Agent nor any holder of Company Common Stock shall have
any power or authority to object under this <U>Section&nbsp;9</U> to the amount of any claim by or on behalf of any Parent Indemnified Person against the Indemnity Fund for indemnity with respect to such settlement or resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.10 <U>Treatment of Indemnification Payments</U>. The parties hereto and the Company Indemnitors agree to treat (and cause their respective
Affiliates to treat) any payment received by the Parent Indemnified Persons pursuant to <U>Section&nbsp;2.5</U> or this <U>Section&nbsp;9</U> as adjustments to the consideration contemplated in <U>Section&nbsp;2</U> for all Tax purposes to the
maximum extent permitted by Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.11 <U>Remedies</U>. From and after the Closing, except as expressly set forth in this
<U>Section&nbsp;9.11</U>, the sole and exclusive remedy of any Parent Indemnified Person for any claim under this Agreement or related to the transactions contemplated by this Agreement, including the Mergers, shall be indemnification in accordance
with this <U>Section&nbsp;9</U>. Notwithstanding the foregoing, this <U>Section&nbsp;9.11</U> shall not operate to limit the rights of the Parties to (1)&nbsp;enforce the terms of this Agreement, including the covenants that by their terms apply in
whole or in part after the Closing or (2)&nbsp;seek equitable remedies (including specific performance or injunctive relief) or any remedies available to it under applicable Law in the event of (a)&nbsp;a Party&#146;s failure to comply with its
indemnification obligations hereunder or (b)&nbsp;Fraud on the part of any Party. For the avoidance of doubt, nothing herein or otherwise shall limit or otherwise negatively affect any of the rights or remedies of the Securityholder Agent Group with
respect to the Company Holders pursuant to<U> Section&nbsp;9.7(c)</U> or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Miscellaneous Provisions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.1 <U>Non-Survival of Representations, Warranties and Pre-Closing Covenants; Survival of Post-Closing Covenants</U>. Except as provided in
<U>Section&nbsp;9.1(c)</U>, the representations and warranties of the Company, Parent, and Merger Subs (other than the Company Fundamental Representations (which shall survive until the Indemnity Release Date)) contained in this Agreement or any
certificate or instrument delivered pursuant to this Agreement shall terminate at the Closing (and there shall be no liability after the Closing in respect thereof), and only the covenants that by their terms apply in whole or in party after the
Closing shall survive the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.2 <U>Amendment</U>. This Agreement may be amended with the approval of the respective
boards of directors of the Company, Merger Subs and Parent at any time prior to the First Effective Time (whether before or after the adoption and approval of this Agreement by the Company&#146;s stockholders or before or after obtaining the
Required Parent Stockholder Vote); <U>provided</U>, <U>however</U>, that after any such approval of this Agreement by a Party&#146;s stockholders or members, no amendment shall be made which by Law requires further approval of such stockholders or
members without the further approval of such stockholders or members. Any provision of this Agreement may be amended (a)&nbsp;prior to the First Effective Time if, but only if, such amendment is in writing and is signed by each of the Company,
Merger Subs, and Parent; and (b)&nbsp;at or after the First Effective Time if but only if, such amendment is in writing and is signed by each of Parent and the Securityholder Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.3 <U>Waiver</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Any
provision hereof may be waived by the waiving Party solely on such Party&#146;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no
delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or
remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) No Party shall be
deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly
executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.4 <U>Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</U>. This Agreement and the other schedules,
exhibits, certificates, instruments and agreements referred to in this Agreement, including the Certificate of Designations, the CVR Agreement and the Parent Stockholder Support Agreement and the Lock-up Agreements, constitute the entire agreement
and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided, however, that the Confidentiality Agreement shall not be superseded
and shall remain in full force and effect in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of
a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in .PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.5 <U>Applicable Law; Jurisdiction</U>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of
Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated
Transactions, each of the Parties: (a)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter
jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b)&nbsp;agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in
accordance with clause (a)&nbsp;of this <U>Section&nbsp;10.5</U>, (c)&nbsp;waives any objection to laying venue in any such action or proceeding in such courts, (d)&nbsp;waives any objection that such courts are an inconvenient forum or do not have
jurisdiction over any Party, (e)&nbsp;agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <U>Section&nbsp;10.8</U> of this Agreement, and (f)&nbsp;irrevocably
waives the right to trial by jury. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.6 <U>Assignability</U>. This Agreement shall be binding upon, and shall be enforceable by
and inure solely to the benefit of, the Parties and their respective successors and assigns; provided, however, that neither this Agreement nor any of a Party&#146;s rights or obligations hereunder may be assigned or delegated by such Party without
the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#146;s prior written consent shall be void and of no effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.7 <U>Notices</U>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and
received hereunder (a)&nbsp;one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&nbsp;upon delivery in the case of delivery by hand or (c)&nbsp;on the date
delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. New York City time, otherwise on the next succeeding Business Day, in each case to the intended recipient as
set forth below; provided that with respect to notices delivered to the Securityholder Agent, such notices must be delivered solely by email: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if to
Parent or Merger Subs: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">645 Summer Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Jotin Marango </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jmarango@ikenaoncology.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which shall
not constitute notice): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: John T.
Haggerty, Stephanie Richards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jhaggerty@goodwinlaw.com, srichards@goodwinlaw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pionyr Immunotherapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 Tower Place, Unit 800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: steve@pionyrtx.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">140 Scott Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Menlo Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Mark M. Bekheit </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: Mark.Bekheit@lw.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if to the Securityholder Agent: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fortis Advisors LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Notices Department (Project
Portsmouth) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: notices@fortisrep.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.8 <U>Cooperation</U>. Each Party agrees to cooperate fully with the other Party and to
execute and deliver such further documents, certificates, agreements, and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent
and purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.9 <U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any
situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other
jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such
term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision,
and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and
enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.10 <U>Other Remedies; Specific Performance</U>. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a
Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree
that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an
injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they
are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.11 <U>No Third Party Beneficiaries</U>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person
(other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <U>Section&nbsp;5.4</U> (Indemnification of Officers and Directors), the Company Holders to the extent of their respective right
pursuant to <U>Section&nbsp;5.1</U> (Proxy Statement), <U>Section 5.2</U> (Parent Stockholder Meeting), <U>Section&nbsp;5.6</U> (Legends) and <U>Section&nbsp;5.11</U> (Resale Registration and Related Procedures)) any right, benefit or remedy of any
nature whatsoever under or by reason of this Agreement. Notwithstanding the immediately preceding sentence, following the First Effective Time, the provisions of Section&nbsp;2 shall be enforceable by holders of Company Common Stock solely to the
extent necessary to receive the merger consideration to which such holder is entitled to thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally
left blank] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the Parties have
caused this Agreement to be executed as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Ikena Oncology, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jotin Marango</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jotin Marango</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ORTSMOUTH</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> I, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jotin Marango</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jotin Marango</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>ORTSMOUTH</SMALL> M<SMALL>ERGER</SMALL> S<SMALL>UB</SMALL> II, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jotin Marango</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jotin Marango</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>IONYR</SMALL> I<SMALL>MMUNOTHERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven P. James</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Steven P. James</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ Signature Page to
Agreement and Plan of Merger] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SECURITYHOLDER AGENT</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>F<SMALL>ORTIS</SMALL> A<SMALL>DVISORS</SMALL> LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Richard Fink</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Richard Fink</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Merger
Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Parent Stockholder Support Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPORT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS SUPPORT
AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;), dated as of August&nbsp;4, 2023, is made by and among Ikena Oncology, Inc., a Delaware corporation (&#147;<U>Parent</U>&#148;), Pionyr Immunotherapeutics, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), Fortis Advisors LLC, a Delaware limited liability, as the Securityholder Agent (the &#147;<U>Securityholder Agent</U>&#148;), Steve James, an individual (the &#147;<U>Proxy</U>&#148;) and the undersigned holder
(&#147;<U>Stockholder</U>&#148;) of shares of capital stock (the &#147;<U>Shares</U>&#148;) of Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Parent, Portsmouth Merger Sub I,
Inc., a Delaware corporation and a wholly owned subsidiary of Parent (&#147;<U>Merger Sub&nbsp;1</U>&#148;), Portsmouth Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent (&#147;<U>Merger
Sub&nbsp;2</U>&#148;), the Company and the Securityholder Agent, have entered into an Agreement and Plan of Merger, dated of even date herewith (the &#147;<U>Merger Agreement</U>&#148;), providing for the merger of Merger Sub 1 with and into the
Company (the &#147;<U>First Merger</U>&#148;) and the merger of the Company with and into Merger Sub 2 (the &#147;<U>Second Merger</U>&#148; and, together with the First Merger, the &#147;<U>Merger</U>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Stockholder is the record and/or beneficial owner of, and has sole voting power with respect to, the number of Shares, and holds options to
purchase shares of Parent Common Stock (&#147;<U>Parent Options</U>&#148;), in the number of Shares indicated opposite Stockholder&#146;s name on <U>Schedule 1</U> attached hereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, as an inducement and a condition to the willingness of Parent, Merger Sub 1, Merger Sub 2 and the Company to enter into the Merger Agreement,
and in consideration of the substantial expenses incurred and to be incurred by them in connection therewith, Stockholder has agreed to enter into and perform this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, all capitalized terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of, and as a condition to, Parent, Merger Sub 1, Merger Sub 2 and the Company&#146;s entering into the Merger
Agreement and proceeding with the transactions contemplated thereby, and in consideration of the substantial expenses incurred and to be incurred by them in connection therewith, Stockholder, Parent, the Company, the Securityholder Agent and the
Proxy agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Agreement to Vote Shares</U>. Stockholder irrevocably and unconditionally agrees that, prior to the
Expiration Date (as defined in <U>Section&nbsp;2</U> below), at any meeting of the stockholders of Parent or any adjournment or postponement thereof, or in connection with any written consent of the stockholders of Parent, with respect to the
Conversion Proposal (defined below) and the Charter Amendment Proposal (defined below), Stockholder shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">appear at such meeting or otherwise cause the Shares and any New Shares (as defined in <U>Section&nbsp;3</U>
below) to be counted as present thereat (in person or by proxy) for purposes of calculating a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written
consent (or cause a written consent to be delivered) covering, all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i)&nbsp;in favor of (A)&nbsp;the approval of the conversion of the Parent Preferred Stock issued
pursuant to the Merger Agreement into shares of Parent Common Stock in accordance with Nasdaq Listing Rule 5635(a) (the &#147;<U>Conversion Proposal</U>&#148;) and (B)&nbsp;if determined to be necessary by Parent, the approval of an amendment to the
certificate of incorporation of Parent to authorize sufficient shares of Parent Common Stock for the conversion of the Parent Preferred Stock issued pursuant to the Merger Agreement (the &#147;<U>Charter Amendment Proposal</U>&#148;), and any matter
that could reasonably be expected to facilitate the Conversion Proposal and the Charter Amendment Proposal; (ii)&nbsp;against any other </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
proposed action, agreement, transaction or other matter that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or adversely affect the
approval or consummation of the Conversion Proposal, the Charter Amendment Proposal or the consummation of any or all of the other Contemplated Transactions, and (iii)&nbsp;to approve any proposal to adjourn or postpone the meeting to a later date,
if there are not sufficient votes for the approval of the Conversion Proposal, the Charter Amendment Proposal on the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the
foregoing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expiration Date</U>. As used in this Agreement, the term &#147;<U>Expiration Date</U>&#148; shall mean the
earlier to occur of (a)&nbsp;the effective time of the approval of the Conversion Proposal and Charter Amendment Proposal, (b)&nbsp;six (6)&nbsp;months from the date of the Merger Agreement, (c)&nbsp;the termination of the Merger Agreement in
accordance with its terms or (d)&nbsp;upon mutual written agreement of the parties to terminate this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Additional Purchases</U>. Stockholder agrees that any shares of capital stock or other equity securities of
Parent that Stockholder purchases or with respect to which Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Date, whether by the exercise of any Parent
Options or otherwise, including, without limitation, by receipt, gift, succession, in the event of a stock split, recapitalization, combination or exchange, or as a dividend or distribution of any Shares (&#147;<U>New Shares</U>&#148;), shall be
subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. Stockholder shall notify Parent and the Company in writing of the number of any New Shares of which Stockholder acquires beneficial or record
ownership on or after the date hereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Share Transfers</U>. From and after the date hereof until the Expiration Date, Stockholder shall not,
directly or indirectly, (a)&nbsp;sell, assign, transfer, pledge, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <U>Section&nbsp;5(c)</U> below)) any Shares or any New Shares or any right
or interest therein, (b)&nbsp;deposit any Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other
than this Agreement), (c)&nbsp;enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the
creation of any Liens) any Shares or New Shares, (d)&nbsp;grant or permit the grant of any proxy, power-of-attorney or other authorization or consent in or with respect to any Shares or New Shares (except as set forth in this Agreement) or
(e)&nbsp;take any action that would make any representation or warranty of Stockholder contained herein untrue or incorrect or in any way restrict, limit, impede, prevent, disable, delay or interfere with the performance of Stockholder&#146;s
obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null and void ab initio. Notwithstanding the foregoing, Stockholder may make (1)&nbsp;transfers by will or by operation of Law or other transfers for
estate-planning purposes, in which case this Agreement shall bind the transferee, (2)&nbsp;with respect to Stockholder&#146;s Parent Options which expire on or prior to the Expiration Date, transfers, sales, or other dispositions of Shares to Parent
as payment for the (i)&nbsp;exercise price of Stockholder&#146;s Parent Options and (ii)&nbsp;taxes applicable to the exercise of Stockholder&#146;s Parent Options, and (3)transfers, sales or other dispositions to any Affiliate of Stockholder;<U>
provided</U>, that, in each case (1) through (3), (A)&nbsp;prior to such transfer or disposition becoming effective, such transferee will execute a joinder to this Agreement in form and substance reasonably satisfactory to the Securityholder Agent
and which shall bind such transferee to all of the obligations of a Stockholder herein, and (B)&nbsp;the transferor Stockholder shall remain liable for any failure of such transferee to comply with or perform its obligations under this Agreement. If
any involuntary transfer of any Shares covered hereby shall occur (including a sale by a Stockholder&#146;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#146;s or court sale), the transferee (which term, as used herein, shall
include any and all transferees and subsequent transferees of the initial transferee) shall take and hold such Shares subject to all of the restrictions, Liabilities and rights under this Agreement, which shall continue in full force and effect,
notwithstanding that such transferee is not a Stockholder and has not executed a counterpart hereof or joinder hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties of Stockholder</U>. Stockholder hereby represents and warrants to Parent, the
Company, the Securityholder Agent and the Proxy as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Stockholder is not a natural person: (i)&nbsp;Stockholder is duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii) </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform Stockholder&#146;s obligations hereunder and to consummate the transactions contemplated
hereby, and (iii)&nbsp;the execution and delivery of this Agreement, performance of Stockholder&#146;s obligations hereunder and the consummation of the transactions contemplated hereby by Stockholder have been duly authorized by all necessary
action on the part of Stockholder and no other proceedings on the part of Stockholder are necessary to authorize this Agreement, or to consummate the transactions contemplated hereby. If Stockholder is an individual, Stockholder has the legal
capacity to execute and deliver this Agreement, to perform Stockholder&#146;s obligations hereunder and to consummate the transactions contemplated hereby; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Agreement has been duly executed and delivered by or on behalf of Stockholder and, to Stockholder&#146;s
knowledge and assuming this Agreement constitutes a valid and binding agreement of the Company, the Securityholder Agent, the Proxy and Parent, constitutes a valid and binding agreement with respect to Stockholder, enforceable against Stockholder in
accordance with its terms, except as enforcement may be limited by general principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#146; rights and remedies
generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Stockholder is, and at all times prior to the Expiration Date will be, the record and/or beneficial owner of
(within the meaning of Rule 13d-3 under the Exchange Act), and has good and marketable title to, the number of Shares indicated opposite Stockholder&#146;s name on<U> Schedule 1</U>, and will own and have good and marketable title to any New Shares,
in each case, free and clear of any liens, claims, charges or other encumbrances or restrictions of any kind whatsoever (&#147;<U>Liens</U>&#148;), and has sole and unrestricted voting power, sole power of disposition and sole power to issue
instructions with respect to, and to agree to, all of the matters set forth in this Agreement, in each case, with respect to such Shares or New Shares, with no limitations, qualifications or restrictions on such rights, except as contemplated by
this Agreement. None of the Shares are subject to any stockholders&#146; agreement, proxy, voting trust or other agreement or arrangement with respect to the voting of such Shares, except as provided pursuant to this Agreement. The number of Shares
listed on <U>Schedule 1</U> opposite Stockholder&#146;s name are the only equity interests in Parent beneficially owned or owned of record by such Stockholder as of the date hereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution and delivery of this Agreement by Stockholder and the consummation of the transactions
contemplated hereby do not, and the performance by Stockholder of his, her or its obligations hereunder and the compliance by Stockholder with any provisions hereof will not, (a)&nbsp;violate, contravene or conflict with, result in any material
breach of or constitute a default (or an event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or require any consent, waiver
or approval or result in the creation of any Liens on any Shares or New Shares pursuant to, any agreement, instrument, note, bond, mortgage, Contract, trust, lease, license, permit or other obligation or any order, arbitration award, judgment or
decree to which Stockholder is a party or by which Stockholder is bound, or any Law, statute, rule or regulation to which Stockholder is subject or (b)&nbsp;in the event that Stockholder is a corporation, partnership, trust or other Entity, any
bylaw or other Organizational Document of Stockholder; except in the case of clause (a)&nbsp;above, as would not reasonably be expected to prevent or delay the performance by Stockholder of his, her or its obligations under this Agreement in any
material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the execution and delivery of this Agreement by Stockholder does not, and the performance of this Agreement by
Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority or regulatory authority by Stockholder except for applicable requirements, if any, of the
Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by Stockholder of his, her or its obligations under this
Agreement in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Parent or
the Company in respect of this Agreement based upon any Contract made by or on behalf of Stockholder; </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of Stockholder,
threatened in writing against Stockholder, that would reasonably be expected to prevent or delay the performance by Stockholder of his, her or its obligations under this Agreement in any material respect </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Irrevocable Proxy</U>. Subject to the penultimate sentence of this<U> Section&nbsp;6</U>, by execution of
this Agreement, Stockholder does hereby appoint the Proxy and any of his designees with full power of substitution and resubstitution, as Stockholder&#146;s true and lawful attorney and irrevocable and unconditional proxy, to the fullest extent of
Stockholder&#146;s rights (including, for the avoidance of doubt, voting rights) with respect to the Shares, to vote and exercise all voting and related rights, including the right to sign Stockholder&#146;s name (solely in its capacity as a
stockholder) to any stockholder consent, if Stockholder is unable to perform or otherwise does not perform his, her or its obligations under this Agreement, with respect to such Shares solely with respect to the matters set forth in
<U>Section&nbsp;1</U> hereof, and the Proxy hereby accepts the obligations to vote and exercise all voting and related rights with respect to the Shares in accordance with<U> Section&nbsp;1</U> hereof. Stockholder intends this proxy to be
irrevocable and unconditional, and coupled with an interest hereunder until the Expiration Date, hereby revokes any proxy previously granted by Stockholder with respect to the Shares and represents that none of such previously-granted proxies are
irrevocable. Stockholder hereby affirms that the proxy set forth in this <U>Section&nbsp;6</U> is given in connection with, and granted in consideration of, and as an inducement to the Company, Parent and Merger Subs to enter into the Merger
Agreement and that such proxy is given to secure the obligations of the Stockholder under<U> Section&nbsp;1</U>. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of Stockholder and the obligations of
Stockholder shall be binding on Stockholder&#146;s heirs, personal representatives, successors, transferees and assigns. Stockholder hereby agrees not to grant any subsequent powers of attorney or proxies with respect to any Shares with respect to
the matters set forth in <U>Section&nbsp;1</U> until after the Expiration Date. Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Expiration Date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Other Remedies; Specific Performance; Certain Actions</U>. Except as otherwise provided herein, any and all
remedies herein expressly conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the
exercise of any other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is
accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the United
States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. Stockholder hereby agrees not to commence or participate in, and to take all actions necessary to opt out of any
class in any class action with respect to, any claim, derivative or otherwise, against Parent, the Company, the Securityholder Agent or any of their respective successors, directors or officers relating to the negotiation, execution or delivery of
this Agreement, the consummation of the Merger or the other Contemplated Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Directors and Officers</U>. This Agreement shall apply to Stockholder solely in Stockholder&#146;s capacity
as a stockholder of Parent and/or holder of Parent Options and not in Stockholder&#146;s capacity as a director, officer or employee of Parent or any of its Subsidiaries or in Stockholder&#146;s capacity as a trustee or fiduciary of any employee
benefit plan or trust. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of Parent in the exercise of his or her
fiduciary duties as a director and/or officer of Parent or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director and/or officer of
Parent or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee and/or fiduciary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Ownership Interest</U>. Nothing contained in this Agreement shall be deemed to vest in the Company or the
Proxy any direct or indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to Stockholder, and the Company or the
Proxy does not have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of Parent or exercise any power or authority to direct Stockholder in the voting of any of the Shares, except
as otherwise provided herein. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination</U>. This Agreement shall terminate and shall have no further force or effect as of the
Expiration Date. Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement;<I><U> provided</U></I>,<I><U> however</U></I>, nothing set forth in
this<U> Section&nbsp;10</U> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any willful and material breach of this Agreement prior to termination hereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Further Assurances</U>. Stockholder shall, from time to time, execute and deliver, or cause to be executed
and delivered, such additional or further consents, documents and other instruments as the Company, the Securityholder Agent, the Proxy or Parent may reasonably request for the purpose of effectively carrying out the transactions contemplated by
this Agreement and the Contemplated Transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Disclosure</U>. Stockholder hereby agrees that Parent and the Company may publish and disclose in the Proxy
Statement, any registration statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law,
Stockholder&#146;s identity and ownership of Shares and the nature of Stockholder&#146;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Proxy Statement, any registration
statement or prospectus or in any other filing made by Parent or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all subject to
prior review and an opportunity to comment by Stockholder&#146;s counsel. Prior to the Closing, Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make any press release,
public announcement or other public communication that criticizes or disparages this Agreement or the Merger Agreement or any of the Contemplated Transactions, without the prior written consent of Parent, the Company and the Securityholder Agent,
provided that the foregoing shall not limit or affect any actions taken by Stockholder (or any affiliated officer or director of Stockholder) that would be expressly permitted to be taken by Stockholder pursuant to the Merger Agreement; provided,
further, that the foregoing shall not effect any actions of Stockholder the prohibition of which would be prohibited under applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notice</U>. All notices and other communications hereunder shall be in writing and shall be deemed given if
delivered personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (providing confirmation of transmission) (a)&nbsp;to the Company,
Parent or the Securityholder Agent, as the case may be, in accordance with<U> Section&nbsp;10.7</U> of the Merger Agreement, (b)&nbsp;to Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on<U>
Schedule 1</U> attached hereto and (c)&nbsp;to the Proxy at his address or email address (providing confirmation of transmission) set forth below his signature hereto (in each case (a)-(c), or at such other address for a party as shall be specified
by such party by like notice). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. Any term or provision of this Agreement that is invalid or unenforceable in any situation
in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If
a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the power to limit such term or
provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and
enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assignability</U>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the
benefit of, the parties hereto and their respective successors and assigns;<I><U> provided</U></I>,<I><U> however</U></I>, that neither this Agreement nor any of a party&#146;s rights or obligations hereunder may be assigned or delegated by such
party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#146;s prior written consent shall be void
and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Waivers</U>. No waivers of any breach of this Agreement extended by the Securityholder Agent, the Proxy,
the Company or Parent to Stockholder shall be construed as a waiver of any rights or remedies of the Securityholder Agent, the Proxy, the Company or Parent, as applicable, with respect to any other stockholder of Parent who has executed an agreement
substantially in the form of this Agreement with respect to Shares held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other stockholder of Parent. No waiver of any provisions hereof by any
party shall be deemed a waiver of any other provisions hereof by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law; Jurisdiction</U>. This Agreement shall be governed by, and construed in accordance with, the
Laws of the state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of
the parties: (i)&nbsp;irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the Superior
Court of the State of Delaware or the United States District Court for the District of Delaware, (ii)&nbsp;agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance with clause
(i)&nbsp;of this<U> Section&nbsp;17</U>, (iii)&nbsp;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv)&nbsp;waives any objection that such courts are an inconvenient forum or do not have jurisdiction
over any party, and (v)&nbsp;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <U>Section&nbsp;13</U> of this Agreement. Each party irrevocably consents to
service of process inside or outside the territorial jurisdiction of the courts referred to in this<U> Section&nbsp;17</U> in the manner provided for notices in <U>Section</U> <U>13</U>. Nothing in this Agreement will affect the right of any party
to serve process in any other manner permitted by applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver of Jury Trial</U>. THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY HEREBY WAIVE ANY RIGHT TO TRIAL
BY JURY WITH RESPECT TO ANY ACTION OR LEGAL PROCEEDING RELATED TO OR ARISING OUT OF THIS AGREEMENT, ANY DOCUMENT EXECUTED IN CONNECTION HEREWITH AND THE MATTERS CONTEMPLATED HEREBY AND THEREBY. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Agreement Until Executed</U>. Irrespective of negotiations among the parties or the exchanging of drafts
of this Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a)the Merger Agreement is executed by all parties thereto and
(b)&nbsp;this Agreement is executed by all parties hereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement; Counterparts; Exchanges by Facsimile</U>. This Agreement and the other agreements referred
to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This Agreement may be
executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or
electronic transmission via &#147;.pdf&#148; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be
modified or waived, except by an instrument in writing signed on behalf of (a)&nbsp;prior to the First Effective Time if, each of the Stockholder, the Company, and Parent; and (b)&nbsp;at or after the First Effective Time, each of the Stockholder,
Parent and the Securityholder Agent;<I><U> provided</U></I>,<I><U> however</U></I>, that the rights or obligations of any Stockholder may be waived, amended or otherwise modified in a writing signed by Parent (for the avoidance of doubt, with the
prior written approval required by Section&nbsp;4.1 of Parent&#146;s Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock, as applicable), the Securityholder Agent and Stockholder.
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fees and Expenses</U>. Except as otherwise specifically provided herein, the Merger Agreement or any other
agreement contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">23)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Voluntary Execution of Agreement</U>. This Agreement is executed voluntarily and without any duress or undue
influence on the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i)&nbsp;it has read and fully understood this Agreement and the implications and consequences thereof; (ii)&nbsp;it has been
represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&nbsp;it is fully aware of the legal and
binding effect of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">24)<U></U></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Construction</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural,
and vice versa; the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved
against the drafting party shall not be applied in the construction or interpretation of this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and variations thereof,
shall not be deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#147;without limitation.&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise indicated, all references in this Agreement to &#147;Sections,&#148; and
&#147;Schedules&#148; are intended to refer to Sections of this Agreement and Schedules to this Agreement, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed
to be a part of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page has Intentionally Been Left Blank</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[STOCKHOLDER]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Signature:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name (if an Entity):</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title (if an Entity):</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Support Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EXECUTED as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IKENA ONCOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PIONYR IMMUNOTHERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>FORTIS ADVISORS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Steven P. James</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Steven P. James</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Address:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Email Address:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Support Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>of</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Parent</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Common</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Parent</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name, Address and Email Address of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Company Lock-Up Agreement </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT B </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF LOCK-UP AGREEMENT </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ikena Oncology, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">August&nbsp;4, 2023</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">645 Summer Street, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned signatory of this lock-up agreement (this &#147;<B><I>Lock-Up Agreement</I></B>&#148;) understands that Ikena Oncology, Inc., a
Delaware corporation (&#147;<B><I>Parent</I></B>&#148;), has entered into an Agreement and Plan of Merger, dated as of August&nbsp;4, 2023 (as the same may be amended from time to time, the &#147;<B><I>Merger Agreement</I></B>&#148;) with Portsmouth
Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, Portsmouth Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Pionyr Immunotherapeutics, Inc, a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the Contemplated Transactions, and
for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent and,
solely prior to the Closing, the Company, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 120 days after the Closing Date (the &#147;<B><I>Restricted Period</I></B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly (any of the foregoing, or any swap, short sale, hedge or other agreement or transaction that transfers, in whole or in part,
directly or indirectly, any of the economic consequences of ownership of the Undersigned&#146;s Shares, a &#147;<B><I>Transfer</I></B>&#148;), any shares of Parent Common Stock (including shares of Parent Common Stock issued upon conversion of
Parent Preferred Stock) or Parent Preferred Stock that are issued to the undersigned pursuant to the Merger Agreement (collectively, the &#147;<B><I>Undersigned&#146;s Shares</I></B>&#148;), or publicly disclose the intention to make any such offer,
sale, pledge, grant, transfer or disposition; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any swap, short sale, hedge or other agreement or any transaction that transfers, in whole or in
part, directly or indirectly, any of the economic consequences of ownership of the Undersigned&#146;s Shares regardless of whether any such transaction described in clause (i)&nbsp;above or this clause (ii)&nbsp;is to be settled by delivery of
shares of Parent Common Stock or other securities, in cash or otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions and obligations contemplated by this Lock-Up
Agreement shall not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfers of the Undersigned&#146;s Shares: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a<U> natural person</U>, (A)&nbsp;to any person who is an immediate family member of the
undersigned (for purposes of this Lock-Up Agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage, domestic partnership or adoption, not more </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
remote than first cousin) (a &#147;<B><I>Family Member</I></B>&#148;), or to a trust formed for the direct or indirect benefit of the undersigned or any of the undersigned&#146;s Family Members,
(B)&nbsp;to the undersigned&#146;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C)&nbsp;as a bona fide gift or a charitable contribution, as such term is described in Section&nbsp;501(c)(3) of the
Internal Revenue Code of 1986, as amended, (D)&nbsp;by operation of Law pursuant to a court order, qualified domestic order or in connection with a divorce settlement or (E)&nbsp;to any partnership, corporation or limited liability company which,
directly or indirectly, controls or manages, is controlled or managed by, or is under common control or management with, the undersigned and/or by any such Family Member(s); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a<U> corporation, partnership, limited liability company or other entity</U>, (A)&nbsp;to
another corporation, partnership, limited liability company or other entity that is an affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities under common control or management or
advisement with the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), (B)&nbsp;as a distribution or
dividend to equity holders, including, without limitation, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and
dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#146;s equity holders), (C)&nbsp;as a bona fide gift or a charitable contribution, as such term is described in Section&nbsp;501(c)(3) of the Internal
Revenue Code of 1986, as amended, (D)&nbsp;transfers or dispositions not involving a change in beneficial ownership or (E)&nbsp;with prior written consent of Parent; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a<U> trust</U>, to any grantors or beneficiaries of the trust; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>provided that</U></I>, in the case of any Transfer or distribution pursuant to this clause (a), such Transfer is not for value and each donee, heir,
beneficiary or other transferee or distributee shall sign and deliver to Parent a lock-up agreement in the form of this Lock-Up Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or
distributed; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act (a &#147;<B><I>10b5-1
Plan</I></B>&#148;) for the transfer of Parent Common Stock; <I><U>provided that,</U></I> such plan does not provide for any transfers of Parent Common Stock during the Restricted Period, or the sale of Parent Common Stock pursuant to a 10b5-1 Plan
existing as of the date of the Merger Agreement (which, for clarity, shall not be amended during the Restricted Period, but may be terminated during the Restricted Period); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfers, sales, dispositions, or the entering into of transactions (including, without limitation, any swap,
hedge or similar agreement) by the undersigned of or relating to shares of capital stock or other securities of Parent purchased or acquired by the undersigned on the open market, in a public offering by Parent, or that otherwise do not involve or
relate to shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfers pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction,
that is approved by or recommended to the Parent shareholders by the Board of Directors of Parent, made to all holders of Parent&#146;s capital stock involving a change of control of Parent, <I><U>provided that</U></I>, in the event that such tender
offer, merger, consolidation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
or other such transaction is not completed, the Undersigned&#146;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement (for purposes hereof, &#147;change of
control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock of
Parent if, after such transaction or transactions, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of Parent (or the surviving entity)); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfers in accordance with the terms of the Merger Agreement (it being understood that nothing in this
Lock-up Agreement shall abridge or otherwise impair the rights of the undersigned pursuant to Section&nbsp;5.6 or Section&nbsp;5.11 of the Merger Agreement or restrict a Release from Indemnity, as defined in the Merger Agreement) or, in the case of
Parent Preferred Stock, in accordance with the terms of the Certificate of Designation (it being understood that nothing in this Lock-up Agreement shall abridge the rights of the undersigned pursuant to, or otherwise impair the operation of,
Section&nbsp;6 of the Certificate of Designation, including any Conversion (as defined in the Certificate of Designation) thereunder); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Transfers pursuant to an order of a court or regulatory agency; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and <I><U>provided, further</U></I>, that, with respect to each of (a)&nbsp;and (b)&nbsp;above, no filing by any party (including any donor, donee,
transferor, transferee, distributor or distributee) under Section&nbsp;16 of the Exchange Act or other public announcement shall be made voluntarily in connection with such transfer or disposition during the Restricted Period; <I><U>provided
that</U></I>, (i)&nbsp;any filing under Section&nbsp;16 of the Exchange Act made during the Restricted Period shall clearly indicate in the footnotes thereto that such filing relates to the circumstances described in (a)&nbsp;or (b), as applicable
and (ii)&nbsp;the foregoing shall not prevent the undersigned from filing a Form 13F, Schedule 13G or Schedule 13D, or any amendment thereto, or from disclosing its holdings in Parent as required by law or regulation or its internal disclosure
policies in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null
and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the
foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would
constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the
undersigned&#146;s ownership of Parent Common Stock: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE
TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the
successors, assigns, heirs or personal representatives of the undersigned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that if the Merger Agreement is
terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent and the Company are proceeding with the Contemplated Transactions in reliance upon this Lock-Up
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all remedies herein expressly conferred upon Parent or the Company will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by Law or equity, and the exercise by Parent or the Company of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that irreparable
damage could occur to Parent and/or the Company in the event that any provision of this Lock-Up Agreement were not performed in accordance with its specific terms or were otherwise breached. It is accordingly agreed that Parent and the Company shall
be entitled to seek an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to
any other remedy to which Parent or the Company is entitled at Law or in equity, and the undersigned waives any bond, surety or other security that might be required of Parent or the Company with respect thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any holder of Parent&#146;s securities that are subject to a substantially similar agreement entered into by such holder,
other than the undersigned, is permitted by Parent, including through any written consent granted under subparagraph a(ii)(E) above, to sell or otherwise transfer or dispose of shares of Parent Common Stock or other shares of Parent capital stock
for value other than as permitted by this or a substantially similar agreement entered into by such holder or is granted an early release from the restrictions described herein during the Restricted Period, the same percentage of the
Undersigned&#146;s Shares shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#147;<B><I>Pro-Rata Release</I></B>&#148;). Parent shall notify the undersigned of any Pro-Rata Release of its
shares on the same day that any permission that triggers the Pro-Rata Release is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the release of any of the
Undersigned&#146;s Shares from this Lock-Up Agreement, Parent will cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned&#146;s Shares without the restrictive legend above or
the withdrawal of any stop transfer instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Lock-Up Agreement and any claim, controversy or dispute arising under or related
to this Lock-Up Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflict of Laws principles thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute
one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by Parent, the Company and the undersigned by facsimile, electronic mail (including any electronic signature covered by the U.S. federal
ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or electronic transmission in .pdf format shall be sufficient to bind such parties to the terms and
conditions of this Lock-Up Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print Name of Stockholder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Signature (for individuals):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">Signature (for entities):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted and Agreed</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">by IKENA
ONCOLOGY, INC.:</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">Accepted and Agreed by</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">PIONYR IMMUNOTHERAPEUTICS, INC.:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Lock-up Agreement] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d469204dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IKENA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RIGHTS AND LIMITATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERIES A <FONT
STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE PREFERRED STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pursuant to Section&nbsp;151 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ikena Oncology, Inc., a Delaware corporation (the &#147;<B>Corporation</B>&#148;), that the following
resolution was duly adopted by the Board of Directors of the Corporation (the &#147;<B>Board of Directors</B>&#148;) pursuant to and in accordance with the provisions of Sections 141(f) and 151 of the General Corporation Law of the State of Delaware
(the &#147;<B>DGCL</B>&#148;) on August&nbsp;4, 2023, which resolution provides for the creation of a series of the Corporation&#146;s Preferred Stock, par value $0.001 per share, which is designated as &#147;Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock,&#148; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>: the Fifth Amended and Restated Certificate of Incorporation (the &#147;<B>Certificate of
Incorporation</B>&#148;), provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.001 par value per share (the &#147;<B>Preferred Stock</B>&#148;), issuable from time to time in one or more series.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>: that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i)&nbsp;a series
of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&nbsp;the Board of Directors hereby authorizes the issuance of 5,000,000 shares of &#147;Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Convertible Preferred Stock&#148; pursuant to the terms of the Agreement and Plan of Merger, dated as of the date hereof, by and among the Corporation, Portsmouth Merger Sub I, Inc., Portsmouth Merger Sub II, Inc., Pionyr Immunotherapeutics, Inc.
and Fortis Advisors LLC, a Delaware limited liability company, solely in its capacity as Securityholder Agent thereunder (the &#147;<B>Merger Agreement</B>&#148;), and (iii)&nbsp;the Board of Directors hereby fixes the designations, powers,
preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation
that are applicable to the Preferred Stock of all classes and series, as follows: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERMS OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes hereof, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person, as such terms are used in and construed under Rule 405 of the Securities Act of 1933, as amended. With respect to a holder, any investment fund or managed account that is managed on a discretionary basis by the
same investment manager as such Holder will be deemed to be an Affiliate. A &#147;<B>controlled Affiliate</B>&#148; shall mean an Affiliate of any Person that is controlled by such Person; <U>provided</U>, <U>however</U>, that the Existing <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder shall not be deemed a &#147;controlled Affiliate&#148; of the Corporation (including Sections 4.1, 4.2, 7.2, 13 and 16). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148; shall have the meaning set forth in Section&nbsp;6.5.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Common Stock</B>&#148; means the Corporation&#146;s voting common stock, par value $0.001 per share, and stock of any other class of
securities into which such securities may hereafter be reclassified or changed. For the avoidance of doubt, Common Stock refers to the voting common stock under the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Conversion Shares</B>&#148; means, collectively, the shares of Common Stock or, solely if and to the extent provided in
Section&nbsp;6.1, 6.2 or 6.3 with respect to an Existing <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder, <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable, issuable upon conversion of the shares
of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance with the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange
Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder</B>&#148; means a holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Non-Voting Common Stock</B>&#148; means the Corporation&#146;s <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, par
value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means a day on which the principal Trading Market is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Market</B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the Nasdaq Global Market, the Nasdaq Capital Market, the Nasdaq Global Select Market, the NYSE American or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Designation, Amount and Par Value</U>. The series of Preferred Stock shall be designated as the Corporation&#146;s Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;<B>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</B>&#148;) and the number of shares so designated shall be 5,000,000. Each share of
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall have a par value of $0.001 per share. The shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall initially be issued and
maintained in the form of securities held in book-entry form. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Dividends</U>. Holders shall be entitled to receive, and the Corporation shall pay,
dividends on shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-Common-Stock</FONT></FONT></FONT></FONT> basis, without regard to the <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common
Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends
shall be paid on shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it
simultaneously complies with the previous sentence. Notwithstanding anything to the contrary herein, the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall not be entitled to any distribution made pursuant to the
Corporation&#146;s Contingent Value Rights Agreement dated as of August&nbsp;4, 2023 by and between the Corporation and Computershare Inc., as may be amended from time to time (the &#147;<B>CVR Agreement</B>&#148;). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Voting Rights</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1 Except as otherwise provided herein or as otherwise required by the DGCL, the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock shall have no voting rights. However, as long as any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock are outstanding, the Corporation shall not, in addition to any other requirements of the DGCL
or the Certificate of Incorporation, without the affirmative vote of the holders of a majority of the then issued and outstanding shares of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, voting as a single and
separate class (excluding, for the avoidance of doubt, any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are held by the Corporation or its controlled Affiliates (including in treasury), whether
repurchased, redeemed, acquired in connection with the indemnification obligations set forth in the Merger Agreement or otherwise which shall not be entitled to a vote): (i)&nbsp;(x) alter or change adversely the powers, preferences or rights given
to the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or alter or amend this Certificate of Designation, or (y)&nbsp;amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or bylaws
of the Corporation, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or
powers of, or restrictions provided for the benefit of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, regardless of whether, in the case of (x)&nbsp;and (y), any of the foregoing actions shall be by means of
amendment to the Certificate of Incorporation or by merger, consolidation or otherwise, (ii)&nbsp;issue further shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or increase or decrease (other than by conversion)
the number of authorized shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, (iii)&nbsp;prior to the Stockholder Approval (as defined below), consummate either: (A)&nbsp;any Fundamental Transaction (as defined
below) or (B)&nbsp;any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a
majority of the capital stock of the Corporation immediately after such transaction, (iv)&nbsp;authorize or issue any class or series of stock that has powers, preferences or rights that are senior to those of the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or (v)&nbsp;enter into any agreement to effect any of the foregoing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of shares of Common Stock acquired upon the conversion of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be entitled to the same voting rights as each holder of Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2 Any vote required or permitted under <U>Section</U><U></U><U>&nbsp;4.1</U> may be taken at a meeting of the Holders or through the
execution of an action by written consent in lieu of such meeting, provided that the consent is executed by Holders representing a majority of the issued and outstanding shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock (excluding, for the avoidance of doubt, any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are held by the Corporation or its controlled Affiliates (including in treasury), whether repurchased,
redeemed, acquired in connection with the indemnification obligations set forth in the Merger Agreement or otherwise which shall not be entitled to a vote). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Rank; Liquidation</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1 The Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall rank (i)&nbsp;senior to any class or series of
capital stock of the Corporation hereafter created specifically ranking by its terms junior to any Series A Preferred Stock and (ii)&nbsp;on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of
the Corporation, whether voluntarily or involuntarily. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2 Upon any liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, whether voluntary or involuntary (a &#147;<B>Liquidation</B>&#148;), each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation
the same amount that a holder of Common Stock would receive if such Holder&#146;s Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock Preferred Stock were fully converted (disregarding for such purpose the <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation) to Common Stock at the Conversion Ratio plus an additional amount equal to any dividends declared but unpaid to such shares, which amounts shall be paid pari passu with
all holders of Common Stock. For the avoidance of any doubt, a Fundamental Transaction shall be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall not be treated as if it were a Liquidation. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Conversion</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1 <U>Automatic Conversion on Stockholder Approval</U>. Effective as of 5:00 p.m. Eastern time on the third Business Day after the date that
the Corporation&#146;s stockholders approve the conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock into shares of Common Stock in accordance with the listing rules of the Nasdaq Stock Market LLC (the
&#147;<B>Stockholder Approval</B>&#148;), each share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then outstanding shall<B> </B>automatically convert into a number of shares of Common Stock equal to the Conversion
Ratio (as defined below), subject to the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation (the &#147;<B>Automatic Conversion</B>&#148;); <U>provided</U>, that only if such Holder already holds shares of <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common<B> </B>Stock prior to the Automatic Conversion (an &#147;<B>Existing <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder</B>&#148;), such Existing
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder shall receive shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock upon the Automatic Conversion in lieu of shares of Common Stock to the extent the issuance
of shares of Common Stock to such Holder would result in such Holder, when aggregated with affiliates with whom such Holder is required to aggregate beneficial ownership for purposes of Section&nbsp;13(d) of the Exchange Act, beneficially owning
(for purposes of Section&nbsp;13(d) of the Exchange Act) more than 9.99% of the Common Stock (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation</B>&#148;). The Corporation shall inform each Holder of
the<B> </B>occurrence of the Stockholder Approval within one Business Day of such Stockholder Approval. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the application of the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial
Ownership Limitation solely with respect to the Automatic Conversion, the Corporation shall calculate beneficial ownership for each Holder assuming beneficial ownership by such Holder of: (x)&nbsp;the number of shares of Common Stock issuable to
such Holder in such Automatic Conversion, plus (y)&nbsp;any additional shares of Common Stock that the Holder beneficially owns for which a Holder has provided the Corporation with prior written notice within 30 days prior to the date of Stockholder
Approval (a &#147;<B>Beneficial Ownership Statement</B>&#148;), and assuming the conversion of all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held by all other Holders into Common Stock less the aggregate
number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock held by all other Holders that will not convert into shares of Common Stock on account of the application of any
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation applicable to any such other Holders. If a Holder fails to provide the Corporation with a Beneficial Ownership Statement within 30 days prior to the date of
Stockholder Approval, then the Corporation shall presume the Holder&#146;s beneficial ownership of Common Stock (excluding the Conversion Shares) to be zero. The shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
that are converted in the Automatic Conversion are referred to as the &#147;Converted Stock&#148;. The Conversion Shares shall be issued as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.1 1 Converted Stock that is registered in book entry form shall be automatically cancelled upon the Automatic Conversion
and converted into the corresponding Conversion Shares, which shares shall be issued in book entry form and without any action on the part of the Holders and shall be delivered to the Holders within one Business Day of the effectiveness of the
Automatic Conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.2 Converted Stock that is issued in certificated form shall be deemed converted into the
corresponding Conversion Shares on the date of Automatic Conversion and the Holder&#146;s rights as a holder of such shares of Converted Stock shall cease and terminate on such date, excepting only the right to receive the Conversion Shares upon the
Holder tendering to the Corporation (or its designated agent) the stock certificate(s) (duly endorsed) representing such certificated Converted Stock and any remedies provided herein or otherwise available at law or in equity to such Holder because
of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#146;s failure to convert Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, including pursuant to <U>Section</U><U></U><U>&nbsp;6.5.3</U> hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1.3 Notwithstanding the cancellation of the Converted Stock upon the Automatic Conversion, Holders of Converted Stock shall
continue to have any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of
its rights and remedies for the Corporation&#146;s failure to convert the Converted Stock, including pursuant to <U>Section</U><U></U><U>&nbsp;6.5.3</U> hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2 <U>Conversion at Option of Holder</U>. Subject to <U>Section</U><U></U><U>&nbsp;6.1</U>, and <U>Section</U><U></U><U>&nbsp;6.4.3</U>, each
share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be convertible, at any time and from time to time following 5:00 p.m. Eastern time on the date of the Stockholder Approval, at the option of the Holder
thereof, at the office of the Corporation or any transfer agent for such shares, into a number of shares of Conversion Shares equal to the Conversion Ratio. Holders shall effect conversions by providing the Corporation with the form of conversion
notice attached hereto as Annex A (a &#147;<B>Notice of Conversion</B>&#148;), duly completed and executed. The </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Conversion Date</B>&#148;, or the date on which a conversion shall be deemed effective, shall be
defined as the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; <U>provided</U>, that, the original certificate(s) (if any) representing such
shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2)&nbsp;Trading Days thereafter. In all
other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly
endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3 <U>Conversion Ratio</U>. The &#147;<B>Conversion Ratio</B>&#148; for each share of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be one (1)&nbsp;share of Common Stock issuable upon the conversion (the &#147;<B>Conversion</B>&#148;) of each share of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (corresponding to a ratio of 1:1), subject to adjustment as provided herein; <U>provided</U>, that any Existing <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder
shall receive shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock upon the Conversion in lieu of shares of Common Stock to the extent the issuance of shares of Common Stock to the Holder would result in the Holder, when
aggregated with affiliates with whom such Holder is required to aggregate beneficial ownership for purposes of Section&nbsp;13(d) of the Exchange Act, beneficially owning (for purposes of Section&nbsp;13(d) of the Exchange Act) more than the <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Reserved</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5.1 <U>Delivery of Certificate or Book Entry Form</U>. Upon Conversion, not later than two (2)&nbsp;Trading Days after the applicable
Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&nbsp;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#147;<B>Share Delivery Date</B>&#148;), the Corporation shall either: (a)&nbsp;in the event that the
Holder has so elected in a Notice of<B> </B>Conversion, deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or (b)&nbsp;otherwise shall issue and deliver to such Holder or such Holder&#146;s nominees, documentation of the book entry for the number of Conversion Shares being
acquired. If in the case of any Notice of Conversion such certificate(s) or documentation of book entry are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the
applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for
Conversion Shares or receipt of evidence of book-entry form of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the reflection of such return of any shares of Common Stock in book entry form, representing the
shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock unsuccessfully tendered for conversion to the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5.2 <U>Obligation Absolute</U>. Subject to Holder&#146;s right to rescind a Notice of
Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U>, the Corporation&#146;s obligation to issue and deliver the Conversion Shares upon conversion of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in accordance
with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action
to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such
Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to Holder&#146;s right to rescind
a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> above, in the event a Holder shall elect to convert any or all of its Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, the Corporation may not
refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder,
restraining and/or enjoining conversion of all or part of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond
for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock which is subject to such injunction, which bond
shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall,
subject to Holder&#146;s right to rescind a Notice of Conversion pursuant to <U>Section</U><U></U><U>&nbsp;6.5.1</U> above, issue Conversion Shares upon a properly noticed conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5.3 <U>Cash Settlement</U>. If, at any time after the earlier of Stockholder Approval or six months after the initial issuance of the
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock pursuant to the Merger Agreement (the earliest such date, the &#147;Cash Settlement Date&#148;), the Corporation (x)&nbsp;has obtained the Stockholder Approval but fails to
or has failed to deliver to a Holder certificate or certificates representing the Conversion Shares, or deliver documentation of book entry form of (or cause its transfer agent to electronically deliver such evidence) Conversion Shares, pursuant to
<U>Section</U><U></U><U>&nbsp;6.5.1</U> on or prior to the third (3rd) Business Day after the date of the Shareholder Approval, or (y)&nbsp;has failed to obtain the Stockholder Approval, the Corporation shall, in either case, at the request of the
Holder (a &#147;<B>Request</B>&#148;) setting forth such Holder&#146;s request to cash settle a number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, pay to such Holder an amount in cash equal to the Fair
Value (defined below) of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock set forth in such Request, with such payment to be made within two Business Days from the date of the Request by the Holder,
whereupon, after payment in full thereon by the Corporation, the Corporation&#146;s obligations to deliver such shares underlying the Request shall be extinguished. For purposes of this <U>Section</U><U></U><U>&nbsp;6.5.3</U>, the &#147;<B>Fair
Value</B>&#148; of shares shall be fixed with reference to the last reported closing stock price on the principal Trading Market of the Common Stock on which the Common Stock is listed as of the Trading Day on which the Request is delivered to the
Corporation. For the avoidance of doubt, the cash settlement provisions set forth in this <U>Section</U><U></U><U>&nbsp;6.5.3</U> shall be available irrespective of the reason for the Corporation&#146;s failure to timely deliver Conversion Shares
(other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), including due to limitations set forth in <U>Section</U><U></U><U>&nbsp;6.7</U>, the lack of obtaining Stockholder Approval, or due to
applicable stock exchange rules or other applicable law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5.4 <U><FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver
Certificates</U>. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to provide documentation of book entry form, as applicable, by the Share Delivery Date pursuant to
<U>Section</U><U></U><U>&nbsp;6.5.1</U> (other than a failure caused by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in
an open market transaction or otherwise), or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the
conversion relating to such Share Delivery Date (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Corporation shall (A)&nbsp;pay in cash to such Holder (in addition to any other remedies available to or elected by such
Holder) the amount by which (x)&nbsp;such Holder&#146;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y)&nbsp;the product of (1)&nbsp;the aggregate number of shares of Common Stock
that such Holder was entitled to receive from the conversion at issue multiplied by (2)&nbsp;the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B)&nbsp;at the
option of such Holder, either reissue (if surrendered) the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock equal to the number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. For
example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted conversion of shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A)&nbsp;of the
immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3)&nbsp;Trading Days after the occurrence of a
<FONT STYLE="white-space:nowrap">Buy-In,</FONT> indicating the amounts payable to such Holder in respect of such <FONT STYLE="white-space:nowrap">Buy-In</FONT> together with applicable confirmations and other evidence reasonably requested by the
Corporation. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Corporation&#146;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock as required pursuant to the terms hereof or
the cash settlement remedy set forth in <U>Section</U><U></U><U>&nbsp;6.5.3</U>; provided, however, that the Holder shall not be entitled to receive both (i)&nbsp;reissued shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Preferred Stock representing the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that had been submitted for conversion for which such conversion was not timely honored and (ii)&nbsp;the number of shares of
Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under <U>Section</U><U></U><U>&nbsp;6.5.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Reservation of Shares Issuable Upon Conversion</U>. The Corporation covenants that at all times it will reserve and keep available out
of its authorized and unissued shares of Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock for the sole purpose of issuance upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, at least the aggregate number of shares of the
Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock as shall be issuable (taking into account the adjustments of <U>Section</U><U></U><U>&nbsp;7</U>) from time to time upon the conversion of all outstanding shares of
Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. The Corporation covenants that all shares of Common Stock and <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock that shall be so issuable shall, upon issue,
be duly authorized, validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Fractional Shares</U>. No fractional shares of Common Stock or <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock shall be issued upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be
entitled, the Corporation shall pay cash equal to such fraction multiplied by the closing price of a share of Common Stock on The Nasdaq Stock Market on such date. Whether or not fractional shares would be issuable upon such conversion shall be
determined on the basis of the total number of shares of Series A Non-Voting Preferred Stock the holder is at the time converting into Common Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock and the aggregate number of shares
of Common Stock and/or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock issuable upon such conversion pursuant to the Conversion Ratio. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Transfer Taxes</U>. The issuance of certificates for shares of the Common Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Common Stock upon conversion of the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or
delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that
of the registered Holder(s) of such shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons
requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Status as Stockholder</U>. Upon each Conversion Date, (i)&nbsp;the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock being converted shall be deemed converted into shares of Common Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable, and (ii)&nbsp;the
Holder&#146;s rights as a holder of such converted shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock or <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable, and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this
Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#146;s failure to convert Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. In no event shall the Series
A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock convert into shares of Common Stock or <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock prior to the Stockholder Approval. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Certain Adjustments</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1 <U>Stock Dividends and Stock Splits</U>. If the Corporation, at any time while this Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is outstanding: (A)&nbsp;pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Corporation upon conversion of this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock and shall not include any distribution made pursuant to the CVR Agreement with respect to the
then outstanding shares of Common Stock); (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of
shares, then the Conversion Ratio shall be multiplied by a fraction of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the
Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made
pursuant to this <U>Section</U><U></U><U>&nbsp;7.1</U> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision or combination. Upon the occurrence of each adjustment to the Conversion Ratio, the Corporation, at its expense, shall, as promptly as reasonably possible but in any event not later than two
(2)&nbsp;business days thereafter, compute such adjustment in accordance with the terms hereof and furnish to each Holder a certificate setting forth such adjustment and showing in detail the facts upon which such adjustment is based. The
Corporation shall, as promptly as reasonably practicable after the written request at any time of any Holder (but in any event not later than two (2)&nbsp;business days thereafter), furnish or cause to be furnished to such Holder a certificate
setting forth (i)&nbsp;the Conversion Price then in effect and (ii)&nbsp;the number of shares of Common Stock or, in the case of any Existing <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder,
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock which then would be received by such Holder upon conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2
<U>Fundamental Transaction</U>. If, at any time while this Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is outstanding, (A)&nbsp;the Corporation effects any merger or consolidation of the Corporation with or into
another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off,</FONT> share exchange or scheme of arrangement) with or into another
Person (other than such a transaction in which the Corporation is the surviving or continuing entity and holds at least a majority of the Common Stock after giving effect to the transaction and its Common Stock is not exchanged for or converted into
other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C)&nbsp;any tender offer or exchange
offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D)&nbsp;the
Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by <U>Section</U><U></U><U>&nbsp;7.1</U> above) to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then, in connection with such Fundamental Transaction, the Holders shall have<B> </B>the right
to receive in the Fundamental Transaction, , the same kind and amount of securities, cash or property that a holder of Common Stock would receive if such Holder&#146;s Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
Preferred Stock were fully converted (disregarding for such purpose the <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Beneficial Ownership Limitation) to Common Stock, plus an additional amount equal to any dividends declared but unpaid to such
shares, which amounts shall be paid pari passu with all holders of Common Stock in the Fundamental Transaction (the &#147;<B>Alternate Consideration</B>&#148;). If holders of Common Stock are given any choice as to the securities, cash or<B>
</B>property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives in such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions,
any successor to the Corporation or surviving entity in such Fundamental Transaction shall assume in writing all of the obligations of the Corporation under this Certificate of Designation in accordance with the provisions of this </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 pursuant to written agreements in form and substance approved by a majority of the holders
of issued and outstanding Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock prior to such Fundamental Transaction (excluding, for the avoidance of doubt, any shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are held by the Corporation or its controlled Affiliates (including in treasury), whether repurchased, redeemed, acquired in connection with the indemnification obligations set
forth in the Merger Agreement or otherwise which shall not be participate in such approval). The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any
such successor or surviving entity to comply with the provisions of this <U>Section</U><U></U><U>&nbsp;7.2</U>. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the
Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3 <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;7</U> shall be made to the nearest cent or the nearest
1/100<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of a share, as the case may be. For purposes of this <U>Section</U><U></U><U>&nbsp;7</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Redemption</U>. The shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock
shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law, nor shall the foregoing limit the
Holder&#146;s rights under <U>Section</U><U></U><U>&nbsp;6.5.3</U>. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Transfer</U>. A Holder may transfer such
shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock in whole, or in part, together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; <U>provided</U> that such
transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&nbsp;do and perform, or cause to be done and performed, all such further acts and things, and (ii)&nbsp;execute and deliver all such other agreements,
certificates, instruments and documents, in each case, as any holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this
<U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Register</U>. The
Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with <U>Section</U><U></U><U>&nbsp;11</U>), a register for the Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock, in which the Corporation shall record (i)&nbsp;the name, address, electronic mail address and facsimile number of each holder in whose name the shares of Series A <FONT
STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock have been issued and (ii)&nbsp;the name, address, electronic mail address and facsimile number of each transferee of any shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock. The Corporation may treat the Person in whose name any share of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock is registered on the register as the
owner and holder thereof for all purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock or
his, her or its legal representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Notices</U>. Any notice required or permitted by the provisions of this Certificate of
Designations to be given to a holder of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by
electronic communication in compliance with the provisions of the DGCL to the email address last shown on the records of the Corporation, and shall be deemed sent upon such mailing or electronic transmission. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Book Entry; Lost or Mutilated Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock Certificate</U>. Unless otherwise requested by a Holder, the Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock will be issued in book entry form; provided,
however, if a Holder shall have requested a certificate and such Holder&#146;s Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and
deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series A
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory
to the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Waiver</U>. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of
Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a
Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to
that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any
right of the Holders of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock granted hereunder may be waived as to all shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock (and the Holders
thereof) upon the written consent of the Holders of not less than a majority of the shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock then issued and outstanding (excluding, for the avoidance of doubt, any shares
of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock that are held by the Corporation or its controlled Affiliates (including in treasury), whether repurchased, redeemed, acquired in connection with the indemnification
obligations set forth in the Merger Agreement or otherwise, which shall not be entitled to provide such consent), unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher
percentage shall be required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Severability</U>. Whenever possible, each provision hereof shall be interpreted in a manner as to be
effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or
otherwise adversely affecting the remaining provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Headings</U>. The headings of the sections of this Certificate of
Designation are for convenience of reference only and shall not define, limit or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Status of
Converted Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock</U>. If any shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock shall be converted by the Corporation or acquired by the
Corporation or any of its controlled Affiliates, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred
Stock and shall no longer be outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left Blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Ikena Oncology, Inc. has caused this Certificate of Designation of Preferences, Rights
and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock to be duly executed by its Chief Executive Officer this 4<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of August, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IKENA ONCOLOGY, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Manfredi, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Mark Manfredi, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Certificate of Designation] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">NOTICE OF CONVERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(TO BE
EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF SERIES A <FONT STYLE="white-space:nowrap">NON-VOTING</FONT> CONVERTIBLE
PREFERRED STOCK) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned Holder hereby elects to convert the number of shares of Series A Non-Voting Preferred Stock indicated below,
[represented by stock certificate No(s). ] [represented in book-entry form], into shares of voting common stock, par value $0.001 per share (the &#147;<B>Common Stock</B>&#148;), of Ikena Oncology, Inc., a Delaware corporation (the
&#147;<B>Corporation</B>&#148;), or, if the<B> </B>undersigned is an Existing <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock Holder, <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock (as applicable), as of the date
written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning
ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock (the &#147;<B>Certificate of Designations</B>&#148;)
filed by the Corporation with the Secretary of State of the State of Delaware on August&nbsp;4, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONVERSION CALCULATIONS: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date to Effect Conversion:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock owned prior to
Conversion:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Number of shares of Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Preferred Stock to be
Converted:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Estimated Number of shares of Common Stock to be</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Issued (based on the Conversion Ratio last publicly disclosed by the Corporation):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Estimated Number of shares of <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock to be Issued (based on
the Conversion Ratio last publicly disclosed by the Corporation):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Address for delivery of physical certificates:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d469204dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS CONTINGENT VALUE RIGHTS AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;), dated as of August&nbsp;4, 2023, is entered into by and
among Ikena Oncology, Inc., a Delaware corporation (&#147;<B>Ikena</B>&#148;) and Computershare Inc., a Delaware corporation and its affiliate Computershare Trust Company, N.A., a federally chartered trust company, collectively, as initial Rights
Agent (as defined herein). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Ikena, Portsmouth Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Ikena (&#147;<B>Merger Sub 1</B>&#148;),
Portsmouth Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Ikena (&#147;<B>Merger Sub 2</B>&#148;), and Pionyr Immunotherapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;) and Fortis
Advisors LLC, a Delaware limited liability company, solely in its capacity as Securityholder Agent thereunder, have entered into an Agreement and Plan of Merger, dated as of the date herewith (the &#147;<B>Merger Agreement</B>&#148;), pursuant to
which (i)&nbsp;Merger Sub 1 will merge with and into Company (the &#147;<B>First Merger</B>&#148;), with Company surviving the First Merger as a wholly-owned subsidiary of Ikena and (ii) immediately following the First Merger, Company will merge
with and into Merger Sub 2 (the &#147;<B>Second Merger</B>&#148; and together with the First Merger, the &#147;<B>Merger</B>&#148;), with Merger Sub 2 surviving the Second Merger (after the Second Merger, Merger Sub 2 is sometimes referred to as the
&#147;<B>Surviving Company</B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to and in accordance with the terms and conditions of the Merger Agreement,
Ikena has agreed to provide to the Holders (as defined herein), who shall initially be Persons who are stockholders of the Company, in each case, as of immediately prior to the First Effective Time, contingent value rights as hereinafter described;
and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties have done all things necessary to make the contingent value rights, when issued hereunder, the valid obligations
of Ikena and to make this Agreement a valid and binding agreement of Ikena, in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in
consideration of the premises and the consummation of the transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.1 <I>Definitions.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement. The following terms have
the meanings ascribed to them as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Acting Holders</B>&#148; means, at the time of determination, Holders of at least 25%
of the outstanding CVRs as set forth on the CVR Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Assignee</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;7.5</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means any day other than a day on which banks in the State
of California or the State of New York are authorized or obligated to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Calendar Quarter</B>&#148; means the successive
period of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31, June&nbsp;30, September&nbsp;30, or December 31; provided, however that (a) the first Calendar Quarter shall commence on the date of this Agreement and shall end on the
first September&nbsp;30 thereafter, and (b)&nbsp;the last Calendar Quarter shall commence on the first day after the full Calendar Quarter immediately preceding the effective date of the termination of this Agreement and shall end on the effective
date of the termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Code</B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR</B>&#148; means a contingent contractual right of Holders to receive CVR Payments pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Payment</B>&#148; means the CVR Proceeds for a given payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Proceeds</B>&#148; means 50% of any excess of (i)&nbsp;of Gross Proceeds received by Ikena over (ii)&nbsp;the Permitted
Deductions, all as calculated, to the extent in accordance with GAAP, using the policies, methodologies, processes and procedures used to prepare Ikena&#146;s then most recent <FONT STYLE="white-space:nowrap">year-end</FONT> financial statements. To
the extent Permitted Deductions exceed Gross Proceeds for any period in which payments are to be made pursuant to <U>Section</U><U></U><U>&nbsp;2.4</U>, any excess Permitted Deductions shall be applied against Gross Proceeds with respect to any
subsequent payment to be made pursuant to <U>Section</U><U></U><U>&nbsp;2.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>CVR Register</B>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;2.3(b)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disposition Agreement</B>&#148; means any definitive agreement entered into
by Ikena within the Disposition Period pursuant to which Ikena may sell, assign, license, or dispose of, or transfer, in one or more transactions, some or all of the Legacy Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disposition Period</B>&#148; means the period beginning on the date of this Agreement and ending on the date which is twenty-four
(24)&nbsp;months following the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Gross Proceeds</B>&#148; means, without duplication, the net cash
consideration (other than royalties) paid to Ikena or its Affiliates during the Payment Period pursuant to any Disposition Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Holder</B>&#148; means, at the relevant time, a Person in whose name CVRs are registered in the CVR Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Legacy Assets</B>&#148; means the tangible and intangible assets owned or licensed by the Company as of the date of this Agreement
which are used in or related to the development and optimization of investigational drug products for which the Company is, or was, researching and developing, including PY314, PY159 and PY265. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.2(f)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Majority of Holders</B>&#148; means, at any time, the registered Holder or Holders
of more than 50% of the total number of CVRs registered at such time, as set forth on the CVR Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Notice</B>&#148; has the
meaning set forth in <U>Section</U><U></U><U>&nbsp;7.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Officer&#146;s Certificate</B>&#148; means a certificate signed by
the chief executive officer and the chief financial officer of Ikena, in their respective official capacities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent Common
Stock</B>&#148; means common stock, par value $0.001 per share, of Ikena. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Parent
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock</B>&#148; means Ikena&#146;s <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, par value $0.001 per share, and stock of any other class of securities into which such
securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Payment Information</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Payment Instructions</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.4(a)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Payment Period</B>&#148; means the period beginning immediately following the Second
Effective Time and ending on the second anniversary of the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Deductions</B>&#148; means the sum of the
following, without duplication: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) any applicable and <FONT STYLE="white-space:nowrap">non-recoverable</FONT> value added, sales or
similar taxes imposed on the Gross Proceeds and payable by Ikena or any of its Affiliates and any income or other Taxes payable by Ikena or any of its Affiliates that would not have been incurred by Ikena or its Affiliates for the taxable year of
receipt or accrual of the Gross Proceeds but for the Gross Proceeds having been received or accrued by Ikena or its Affiliates; <I>provided</I> that, for purposes of calculating income Taxes incurred by Ikena and its Affiliates with respect to Gross
Proceeds, any such income Taxes shall be computed: (i)&nbsp;after taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits) actually available to Ikena or its Affiliates, (A)&nbsp;which Tax attributes
were generated either prior to the Closing Date or with respect to the Legacy Assets after the Closing Date, (B)&nbsp;to the maximum extent permitted by law to offset such Gross Proceeds after taking into account any limits on the usability of such
attributes, including under Section&nbsp;382 or other applicable provisions of the Code or similar state, local, or other Tax laws, and (C)&nbsp;as reasonably determined by a nationally recognized tax advisor, and (ii)&nbsp;assuming for this purpose
that the last items of gross income of Ikena and its Affiliates after the Closing Date are the Gross Proceeds; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) any Loss (as
defined below) actually incurred, suffered, sustained, or paid by Ikena or any of its Affiliates arising out of, related to, or in connection with (1)&nbsp;distribution of CVRs to the initial Holders in accordance with
<U>Section</U><U></U><U>&nbsp;2.3(e)</U>, and (2)&nbsp;any Disposition Agreement (other than as a result of Ikena&#146;s failure to comply with the terms of such Disposition Agreement or as a result of Ikena&#146;s fraud, negligence, bad faith,
intentional breach or willful misconduct with respect to the performance of such Disposition Agreement) or any of the transactions contemplated thereby which, for the avoidance of doubt, shall include any Loss related to or arising out of any
contract or agreement entered into by Ikena with any third party acting in a consultant, broker or similar capacity relating to or involving the disposition of the Legacy Assets, pursuant to which Ikena is required to make a payment to such third
party as a result of entering into a Disposition Agreement or the receipt of Gross Proceeds, including (i)&nbsp;in respect of its performance of any Disposition Agreement, and (ii)&nbsp;any indemnification obligations set forth in any Disposition
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Transfer</B>&#148; means a Transfer of one or more CVRs (i)&nbsp;upon
death of a Holder by will or intestacy; (ii)&nbsp;by instrument to an <I>inter vivos</I> or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii)&nbsp;made pursuant to a court order of a court of
competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (iv) if the Holder is a partnership or limited liability company, a distribution by the transferring partnership or limited liability company to its partners or
members, as applicable; (v)&nbsp;made by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company, partnership or
other entity; (vi)&nbsp;in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary) or from such nominee to another nominee for the same beneficial owner, in each case as permitted by
The Depository Trust Company; (vii)&nbsp;to Ikena or its Affiliates; or (viii)&nbsp;as provided in <U>Section</U><U></U><U>&nbsp;2.6</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; shall mean any individual, partnership, joint venture, limited liability company, firm, corporation, unincorporated
association or organization, trust or other entity, and shall include any successor (by merger or otherwise) of any such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Record Time</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.3(c)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Rights Agent</B>&#148; means the Rights Agent named in the first paragraph of this Agreement, until a successor Rights Agent shall
have been appointed pursuant to <U>ARTICLE 3</U> of this Agreement, and thereafter &#147;Rights Agent&#148; will mean such successor Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer</B>&#148; means transfer, pledge, hypothecation, encumbrance, assignment or other disposition (whether by sale, merger,
consolidation, liquidation, dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition, and each contract, arrangement or understanding, whether or not in writing, to effect any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer Agent</B>&#148; means the transfer agent for the Parent Common Stock, the Parent
<FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock and the Parent Preferred Stock at the applicable time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTINGENT VALUE RIGHTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.1 <I>Holders of CVRs; Appointment of Rights Agent.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs represent the contractual rights of Holders to receive CVR Payments pursuant to this Agreement. In accordance with the Merger
Agreement and pursuant to the Contemplated Transactions, each share of Company Common Stock (as defined in the Merger Agreement) was cancelled in the First Merger and automatically converted into the right to receive, in addition to the other
consideration payable in accordance with the Merger Agreement, one CVR. The initial Holders shall be determined pursuant to the terms of this Agreement, and a list of the initial Holders shall be furnished to the Rights Agent by or on behalf of
Ikena in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Ikena hereby appoints the Rights Agent to act as rights agent for Ikena in accordance
with the express terms and conditions (and no implied terms and conditions) set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.2 <I><FONT STYLE="white-space:nowrap">Non-transferable.</FONT></I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Holder may not at any time Transfer CVRs, other than pursuant to a Permitted Transfer. Any attempted Transfer that is not a Permitted
Transfer, in whole or in part, will be void <I>ab initio</I> and of no effect. The CVRs will not be listed on any quotation system or traded on any securities exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.3 <I>No Certificate; Registration; Registration of Transfer; Change of Address.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The CVRs will be issued in book-entry form only and will not be evidenced by a certificate or other instrument. Holders&#146; rights and
obligations in respect of CVRs derive solely from this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to the delivery of the list of the initial Holders to the
Rights Agent by or on behalf of Ikena in accordance with <U>Section</U><U></U><U>&nbsp;4.1</U>, the Rights Agent will maintain an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> register (the &#147;<B>CVR
Register</B>&#148;) for the purposes of (i)&nbsp;identifying the Holders of CVRs, (ii)&nbsp;determining Holders&#146; entitlement to CVRs and (iii)&nbsp;registering the CVRs and Permitted Transfers thereof. The CVR Register will be created, and CVRs
will be distributed, effective as of the First Effective Time, in accordance with Section&nbsp;2.6(a) of the Merger Agreement. The Rights Agent will have no responsibility whatsoever directly to the street name holders with respect to transfers of
CVRs. Except for the obligations to the Rights Agent set forth herein, neither Ikena nor its Subsidiaries will have any responsibility or liability whatsoever to any Person other than the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to the restriction on transferability set forth in <U>Section</U><U></U><U>&nbsp;2.2</U>, every request made to Transfer CVRs must
be in writing and accompanied by a written instrument of Transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved by the
Securities Transfer Association (a &#147;<B>signature guarantee</B>&#148;) and other requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders
thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the Transfer. Upon receipt of such written notice, the Rights
Agent will, subject to its reasonable determination in accordance with its own internal procedures that the Transfer instrument is in proper form and the Transfer is a Permitted Transfer and otherwise complies on its face with the other terms and
conditions of this Agreement, register the Transfer of the applicable CVRs in the CVR Register. All Transfers of CVRs registered in the CVR Register will be the valid obligations of Ikena, evidencing the same right, and entitling the transferee to
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">same benefits and rights under this Agreement, as those held by the transferor. No transfer of CVRs shall be
valid until registered in the CVR Register and any transfer not duly registered in the CVR Register shall be void. Ikena and Rights Agent may require evidence of payment of any stamp or transfer taxes payable by reason of such Transfer (or
reasonable evidence that such taxes are not applicable). Neither Ikena nor Rights Agent shall be responsible for any other costs and expenses related to any transfer or assignment of the CVRs (including the cost of any transfer tax). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) A Holder may make a written request to the Rights Agent to change such Holder&#146;s address of record in the CVR Register. Such written
request must be duly executed by such Holder. Upon receipt of such written notice, the Rights Agent shall promptly record the change of address in the CVR Register. The Acting Holders may, without duplication, make a written request to the Rights
Agent for a list containing the names, addresses and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to
the Acting Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Ikena will provide written instructions to the Rights Agent for the distribution of CVRs to the Holders as of
immediately prior to the First Effective Time (the &#147;<B>Record Time</B>&#148;). Subject to the terms and conditions of this Agreement and Ikena&#146;s confirmation of the First Effective Time, the Rights Agent shall effect the distribution of
the CVRs, less any applicable tax withholdings, to each holder of Company Common Stock as of the Record Time by mailing of a statement of holding reflecting such CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.4 <I>Payment Procedures.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No later than forty-five (45)&nbsp;days following the end of each Calendar Quarter during the term of this Agreement, Ikena shall
(i)&nbsp;deliver to the Rights Agent, an Officer&#146;s Certificate certifying to and specifying in reasonable detail (A)&nbsp;the Holders that are Accredited Investors and those that are Unaccredited Investors, and (B)&nbsp;the aggregate amount of
(I)&nbsp;the Gross Proceeds received by Ikena or its Affiliates during such period, as the case may be; (II)&nbsp;the CVR Proceeds for such period, including the Permitted Deductions reflected in such CVR Proceeds; and (III)&nbsp;the CVR Payment
payable to Holders, if any, in respect of such CVR Proceeds (including, with respect to such CVR Payment, the amount of cash to be paid per CVR held by Unaccredited Investors, and the amount of cash and number of shares of Parent Common Stock,
Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock or Parent Preferred Stock, as the case may be, to be paid per CVR held by Accredited Investors (collectively, the &#147;<B>Payment Information</B>&#148;)), and (ii)&nbsp;deliver
to the Rights Agent, or as the Rights Agent directs, (A)&nbsp;the cash portion of the CVR Payment (if any) by wire transfer of immediately available funds to an account designated by the Rights Agent not less than ten (10)&nbsp;Business Days prior
to the date of the applicable payment, and, (B)&nbsp;directions, any other letter of instruction, opinions or other information requested by the Rights Agent or Transfer Agent (&#147;<B>Payment Instructions</B>&#148;) to enable the Rights Agent to
cause the Transfer Agent to issue to the Holders who are Accredited Investors, the stock portion of the CVR Payment in shares of Parent Common Stock, Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock or Parent Preferred Stock,
as applicable. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten (10)&nbsp;Business Days) pay, by check mailed, first-class postage prepaid, to the address of each
Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the Rights Agent, an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">amount in cash equal to such Holder&#146;s cash portion of the applicable CVR Payment. Subject to the other
provisions in this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>, for any CVR Payment, Ikena shall calculate the amount of cash to be paid to a Holder that is an Accredited Investor by employing the following formula:
<FONT STYLE="white-space:nowrap">one-half</FONT> of the product determined by multiplying (i)&nbsp;the quotient determined by dividing (A)&nbsp;the applicable CVR Payment by (B)&nbsp;the total number of CVRs registered in the CVR Register at such
time, by (ii)&nbsp;the number of CVRs registered to such Holder in the CVR Register at such time. For the avoidance of doubt, Ikena shall have no further liability in respect of the relevant CVR Payment (or the applicable Gross Proceeds or CVR
Proceeds) upon delivery in full of such CVR Payment in accordance with this <U>Section</U><U></U><U>&nbsp;2.4(a)</U> and the satisfaction of each of Ikena&#146;s obligations set forth in this <U>Section</U><U></U><U>&nbsp;2.4(a)</U>. Notwithstanding
anything in this Agreement to the contrary, except as set forth in the next sentence, each CVR Payment shall be made 50% in cash and 50% in shares of Parent Common Stock (with the number of shares of Parent Common Stock to be determined by Ikena
using a value per share of Parent Common Stock equal to the closing price of a share of Parent Common Stock on the Nasdaq Global Market for the last trading day preceding the CVR Payment); <U>provided</U>, that if a Holder of CVRs holds shares of
Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock prior to the Closing, such Holder shall receive, in lieu of shares of Parent Common Stock, shares of Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock to the
extent the issuance of shares of Parent Common Stock to such Holder would result in such Holder, when aggregated with affiliates with whom such Holder is required to aggregate beneficial ownership for purposes of Section&nbsp;13(d) of the Exchange
Act, beneficially owning (for purposes of Section&nbsp;13(d) of the Exchange Act) more than 9.99% of the Parent Common Stock; <U>provided</U>, <U>further,</U> provided that the Holders of CVRs who are Unaccredited Investors shall receive 100% cash
and the Holders of CVRs who are Accredited Investors shall receive such greater percentage of Parent Common Stock (or Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as set forth in the foregoing proviso) as is necessary to
ensure that the aggregate CVR Payment made to all former holders of Company Capital Stock consists 50% of cash and 50% of shares of Parent Common Stock. If the Conversion Proposal (as defined in the Merger Agreement) has not been approved by the
stockholders of Parent prior to payment being required on the CVRs, the Holders of CVRs shall be issued shares of Parent Preferred Stock (as defined in the Merger Agreement) in lieu of Parent Common Stock (in the same number) and Parent shall, in
furtherance of its covenants in the Merger Agreement, use reasonable best efforts to obtain stockholder approval permitting conversion of such shares of Parent Preferred Stock into Parent Common Stock as promptly as practicable after issuance (or
Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock, as applicable). For tax purposes, it is agreed that the value of a share of Parent Preferred Stock is equal to the value of a share of Parent Common Stock. Upon
(i)&nbsp;consummation of a Specified Transaction (as defined in Section&nbsp;6.1) or (ii)&nbsp;the delisting of the Parent Common Stock from The Nasdaq Stock Market, the CVR Payment shall be paid 100% in cash </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall be fully protected in relying on the Payment Information and Payment Instruction and shall have no duty or
obligation to investigate or confirm the accuracy of the calculations and statements contained therein, including, without limitation, the amount of cash or number of Parent Common Stock, Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT>
Common Stock or Parent Preferred Stock to be issued to any Holder in connection with any CVR Payment and whether any Holder is an Accredited Investor or Unaccredited Investor. The Rights Agent shall have no responsibilities whatsoever with regard to
the distribution of Parent Common Stock, Parent <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Common Stock or Parent Preferred Stock, as the case may be, to the Holders in connection with any CVR Payment by the Transfer Agent other than the
delivery of the Payment Instruction and Payment Information to the Transfer Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) For U.S. federal income and other applicable Tax purposes, the parties hereto agree that
(i)&nbsp;amounts payable pursuant to this Agreement are intended to be treated as deferred contingent purchase price in connection with the Merger and (ii)&nbsp;a portion of such amounts may be treated as interest pursuant to Section&nbsp;483 or
Section&nbsp;1274 of the Code (collectively, the &#147;<B>Intended Tax Treatment</B>&#148;). The parties hereto will not take any position contrary to the Intended Tax Treatment on any Tax Return or for other Tax purposes, except as may be required
by a change in applicable Law or pursuant to a final &#147;determination&#148; within the meaning of Section&nbsp;1313(a) of the Code, in each case, after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Ikena and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any CVR Payment otherwise
payable pursuant to this Agreement, such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of applicable Law relating to Taxes. To the extent that amounts are so deducted and withheld,
such deducted and withheld amounts will be treated for all purposes of this Agreement as having been paid to the Holder in respect of which such deduction and withholding was made. If instructed by Ikena, the Rights Agent shall solicit from each
Holder an IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or applicable IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable, at such time or times as is necessary to permit any payment under this Agreement to be made without
U.S. federal backup withholding. Prior to making any Tax deductions or withholdings or causing any such Tax deductions or withholdings to be made with respect to any Holder, the Rights Agent will, if instructed by Ikena, use commercially reasonable
efforts to provide notice to the Holder of any potential Tax deduction or withholding (other than backup withholding) and a reasonable opportunity for the Holder to provide any necessary Tax forms, including an IRS Form <FONT
STYLE="white-space:nowrap">W-9</FONT> or appropriate IRS Form <FONT STYLE="white-space:nowrap">W-8,</FONT> as applicable, in order to reduce such withholding amounts; <I><U>provided</U></I> that the time period for payment of a CVR Payment by the
Rights Agent set forth in <U>Section</U><U></U><U>&nbsp;2.4(a)</U> will be extended by a period equal to any delay caused by the Holder providing such forms, <I><U>provided</U></I><U>, </U><I><U>further</U></I>, that in no event shall such period be
extended for more than ten (10)&nbsp;Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. Ikena will provide Tax withholding and reporting instructions in writing to the
Rights Agent from time to time as relevant, and upon request of the Rights Agent. The Rights Agent shall have no responsibilities with respect to tax withholding, reporting or payment except as specifically instructed by Ikena pursuant to a Tax
Instruction Letter memorializing the Rights Agent&#146;s obligations under this Agreement as to IRS tax reporting and withholding with respect to the distribution of the CVRs as well as to CVR payments (if any). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any portion of a CVR Payment that remains undistributed to the Holders at such time as such portion could be properly delivered to a
public official pursuant to applicable abandoned property, escheat, or similar applicable Law (including by means of invalid addresses on the CVR Register) will be delivered by the Rights Agent to Ikena or a Person nominated in writing by Ikena
(with written notice thereof from Ikena to the Rights Agent), who shall be permitted to permanently retain such amounts and each of the applicable Holders will thereafter irrevocably forfeit any rights to such amounts. In addition to and not in
limitation of any other indemnity obligation herein, Ikena agrees to indemnify and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring
such property to Ikena or a public official. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.5 <I>No Voting, Dividends or Interest; No Equity or Ownership Interest.</I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) CVRs will not represent any equity or ownership interest in Ikena or any of its Affiliates (including in the Surviving Company). The sole
right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security of Ikena or any of its Subsidiaries
or of the Surviving Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The CVRs and the possibility of any payment hereunder with respect thereto are highly speculative and
subject to numerous factors outside of Ikena&#146;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. It is highly possible that there will not be any Gross Proceeds that
may be the subject of a CVR Payment. Neither Ikena nor its Affiliates owe, by virtue solely of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders in connection with the CVRs and the parties hereto intend
solely the express provisions of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this <U>Section</U><U></U><U>&nbsp;2.5(c)</U> is an essential and material term of this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any actions seeking the enforcement of the rights of Holders hereunder may be brought by the Acting Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.6 <I>Ability to Abandon CVR.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Holder may at any time, at such Holder&#146;s option, abandon all of such Holder&#146;s remaining rights represented by CVRs by transferring
such CVRs to Ikena or a Person nominated in writing by Ikena (with written notice thereof from Ikena to the Rights Agent) without consideration or compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly
notified in writing by Ikena of such transfer and cancellation. Nothing in this Agreement is intended to prohibit Ikena or its Affiliates from offering to acquire or acquiring CVRs, in private transactions or otherwise, for consideration in its sole
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.8 <I>No Implied Obligations of Ikena.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as specifically provided in <U>Section</U><U></U><U>&nbsp;4.4</U>, and subject to the terms of the Merger Agreement, Ikena shall have
the power and right to control all aspects of its and its subsidiaries&#146; businesses and operations (and all of their assets and products), and subject to its compliance with the terms of this Agreement and the Merger Agreement, Ikena may
exercise or refrain from exercising such power and right as it may deem appropriate and in the best overall interests of Ikena and its stockholders, rather than the interest of the Holders. Except as specifically provided in
<U>Section</U><U></U><U>&nbsp;4.4</U> and Section&nbsp;5.5(a) of the Merger Agreement, Ikena shall have no obligation to own, operate, use, sell, transfer, convey, license, develop, commercialize or otherwise exploit in any particular manner any of
its or its subsidiaries&#146; business or operations (or any of their assets or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">products) or to negotiate or enter into any agreement, including any Disposition Agreement, including in
order to obtain, maximize or expedite the receipt of any Gross Proceeds or minimize Permitted Deductions. None of Ikena or any of its Affiliates (or any directors, officer, employee, or other representative of the foregoing) owes any fiduciary duty
or similar duty to any Holder in respect of the CVRs. Notwithstanding anything to the contrary in this Agreement, including this <U>Section</U><U></U><U>&nbsp;2.8</U>, nothing in this Agreement shall limit, amend, affect or otherwise alter the terms
and<U> </U>provisions of the Merger Agreement, including Parent&#146;s obligations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE RIGHTS AGENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.1 <I>Certain Duties and Responsibilities.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to the extent
such liability arises as a result of the fraud, willful misconduct, bad faith, or gross negligence of the Rights Agent (in each case as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of court of competent
jurisdiction). Notwithstanding anything in this Agreement to the contrary, any liability of the Rights Agent under this Agreement will be limited to the amount of annual fees paid by Ikena to the Rights Agent in connection with this Agreement during
the twelve (12)&nbsp;months preceding the event for which recovery is sought by Ikena, except in the case of willful misconduct, bad faith or fraud of the Rights Agent (in each case as determined by a final
<FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of court of competent jurisdiction). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental or consequential
loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder with respect
to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Ikena or the
Surviving Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All funds received by the Rights Agent under this Agreement that are to be distributed or applied by the Rights
Agent in the performance of services hereunder (the &#147;<U>Funds</U>&#148;) shall be held by the Rights Agent as agent for Ikena and deposited in one or more bank accounts to be maintained by the Rights Agent in its name as agent for Ikena. Until
paid pursuant to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&nbsp;billion or with an average rating above investment grade by
S&amp;P (LT Local Issuer Credit Rating), Moody&#146;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall have no responsibility or liability for any diminution
of the Funds that may result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank or financial institution or other Person. If at any time the Funds are insufficient
to pay the Holders the amounts then required to be paid pursuant to this Agreement as a result of any diminution of the Funds, Parent shall promptly replenish the Funds so that the Funds are sufficient to pay the Holders the amounts then required to
be paid pursuant to this Agreement. The Rights Agent may from time to time receive interest, dividends or other earnings in connection with such deposits. The Rights Agent shall not be obligated to pay such interest, dividends or earnings to Ikena,
any Holder or any other Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.2 <I>Certain Rights of Rights Agent.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and no implied
covenants or obligations will be read into this Agreement against the Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Rights Agent may rely and will be protected
by Ikena in acting or refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it in the absence of bad faith to be
genuine and to have been signed or presented by or on behalf of Ikena or a Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Whenever the Rights Agent deems it desirable that
a matter be proved or established prior to taking or omitting any action hereunder, the Rights Agent may rely upon an Officer&#146;s Certificate, which certificate shall be full authorization and protection to the Rights Agent, and the Rights Agent
shall, in the absence of bad faith, gross negligence or willful misconduct (each as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) on its part, incur no liability and be
held harmless by the Company for or in respect of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#146;s Certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Rights Agent may engage and consult with counsel of its selection, and the advice or opinion of such counsel will, in the absence of
bad faith on the part of the Rights Agent, be full and complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Ikena agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any claim, loss,
liability, damage, deficiency, Tax, judgment, award, settlement, fine, penalty, interest, fee, cost, or expense, including reasonable and documented fees, costs, or expenses of attorneys, accountants, financial advisors, brokers, finders,
consultants, and other professionals (each, a &#147;<B>Loss</B>&#148;) suffered or incurred by the Rights Agent and arising out of, related to, or in connection with the Rights Agent&#146;s performance of its obligations under this Agreement,
including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of, related to, or in connection with the execution, acceptance, administration, exercise and
performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent such Loss has been
determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision of a court of competent jurisdiction to have resulted from any willful misconduct, bad faith, or gross negligence of the Rights Agent (in each case, as determined
by a final, <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Ikena agrees (i)&nbsp;to pay the fees of the Rights Agent in connection with the Rights
Agent&#146;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and Ikena on or prior to the date of this Agreement, and (ii)&nbsp;to reimburse the Rights Agent for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise
and performance of its duties hereunder, including all Taxes (other than income, receipt, franchise or similar Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not reasonably assured to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but has not
received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder either itself or
by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Ikena or the Surviving Company resulting from any such
act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final <FONT STYLE="white-space:nowrap">non-appealable</FONT> judgment of a court of competent jurisdiction) in the selection and
continued employment thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) Ikena shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all
such further and other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Without limiting the usage of terms defined in this Agreement or in the Merger Agreement, the Rights Agent shall not be liable for or by
reason of any of the statements of fact or recitals contained in this Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Ikena only.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) The Rights Agent shall act hereunder solely as agent for Ikena and shall not assume any obligations or relationship of agency or
trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by Ikena, including, without
limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Ikena. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) The Rights Agent may rely on and be fully authorized and protected in acting or failing
to act upon (a)&nbsp;any guaranty of signature by an &#147;eligible guarantor institution&#148; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#147;signature guarantee program&#148; or
insurance program in addition to, or in substitution for, the foregoing; or (b)&nbsp;any Law or any interpretation of the same even though such Law may thereafter have been altered, changed, amended or repealed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) The Rights Agent shall not be liable or responsible for any failure of Ikena to comply with any of its obligations relating to any
registration statement filed with the SEC or this Agreement, including without limitation obligations under applicable Law. The Rights Agent shall not be subject to, nor be required to comply with, or determine if any Person has complied with, the
Merger Agreement or any other agreement between or among any of the Company, Surviving Company or Holders, even though reference thereto may be made in this Agreement, or to comply with any notice, instruction, direction, request or other
communication, paper or document other than as expressly set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) In the event the Rights Agent reasonably
believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request or other communication, paper or document received by the Rights Agent hereunder, the Rights Agent shall, as soon as practicable, provide notice
to Ikena, and the Rights Agent may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to Ikena or any Holder or any other Person for refraining from taking such action, unless the
Rights Agent receives written instructions from Ikena or such Holder or other Person which eliminate such ambiguity or uncertainty to the reasonable satisfaction of the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) The obligations of Ikena and the rights of the Rights Agent under this <U>Section</U><U></U><U>&nbsp;3.2</U>,
<U>Section</U><U></U><U>&nbsp;3.1</U> and <U>Section</U><U></U><U>&nbsp;2.4</U> shall survive the expiration of the CVRs and the<U> </U>termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 <I>Resignation; Appointment of Successor.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Rights Agent may resign at any time by written notice to Ikena. Any such resignation notice shall specify the date on which such
resignation will take effect (which shall be at least thirty (30)&nbsp;days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (x)&nbsp;the date so specified and (y)&nbsp;the
appointment of a successor Rights Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Rights Agent resigns or becomes incapable of acting, Ikena will promptly appoint a
qualified successor Rights Agent. Notwithstanding the foregoing, if Ikena fails to make such appointment within a period of thirty (30)&nbsp;days after it has been notified in writing of such resignation or incapacity by the resigning or
incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance of such appointment in
accordance with this <U>Section</U><U></U><U>&nbsp;3.3(c)</U> and <U>Section</U><U></U><U>&nbsp;3.4</U>, become the Rights Agent for all purposes hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Ikena will give notice to the Holders of each resignation of the Rights Agent and each
appointment of a successor Rights Agent in accordance with <U>Section</U><U></U><U>&nbsp;7.2</U>. Each notice will include the name and address of the successor Rights Agent. If Ikena fails to send such notice within ten (10)&nbsp;Business Days
after acceptance of appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Ikena. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Notwithstanding anything to the contrary in this <U>Section</U><U></U><U>&nbsp;3.3</U>, unless consented to in writing by the Acting
Holders, Ikena will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Rights Agent will reasonably cooperate with Ikena and any successor Rights Agent in connection with the transition of the duties and
responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be required to make any
additional expenditure or assume any additional liability in connection with the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.4 <I>Acceptance of Appointment
by Successor.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every successor Rights Agent appointed hereunder will, at or prior to such appointment, execute, acknowledge and
deliver to Ikena and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor Rights Agent, without any further act, deed or conveyance, will become vested with all the
rights, powers, trusts and duties of the Rights Agent; <I><U>provided</U></I> that upon the request of Ikena or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor
Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent, except such rights which survive its resignation or removal under the terms hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.1 <I>List of Holders.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ikena will furnish or cause to be furnished to the Rights Agent, in such form as Ikena receives from Ikena&#146;s transfer agent (or other
agent performing similar services for Ikena), the names and addresses of the initial Holders (and for each such Holder, identifying if it is an Accredited Investor or Unaccredited Investor) within two (2)&nbsp;Business Days following the Closing
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.2 <I>Books and Records.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the termination of this Agreement and for a period of one (1)&nbsp;year thereafter, Ikena shall, and shall cause its Affiliates to, keep
true, complete and accurate records in sufficient detail to support the applicable CVR Payments payable hereunder (including the calculation of the Permitted Deductions) in accordance with the terms specified in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.3 <I>Audits.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the termination of this Agreement and for a period of one (1)&nbsp;year thereafter, Ikena shall keep complete and accurate records in
sufficient detail to permit the Acting Holders to confirm the accuracy of the payments due hereunder. Subject to reasonable advance written notice from the Acting Holders and prior execution and delivery by Ikena and an independent accounting firm
of national reputation chosen by the Acting Holders (the &#147;<B>Accountant</B>&#148;) of a reasonable and customary confidentiality/nonuse agreement, which confidentiality/nonuse agreement shall not prohibit the Acting Holders from communicating
any such information with the Holders who have a need to know such information, provided that any such recipients are subject to confidentiality obligations with respect thereto, Ikena shall permit the Acting Holders and the Accountant, acting as
agent of the Acting Holders, to have access during normal business hours to the books and records of Ikena as may be reasonably necessary to audit the calculation of any CVR Payment, Gross Proceeds and the Permitted Deductions. Notwithstanding
anything in this Agreement to the contrary, in no event shall Ikena be required to provide any Tax returns or any other Tax information it deems confidential to the Acting Holders or any other party pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.4 <I>Diligent Efforts.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to Section&nbsp;5.5(a) of the Merger Agreement, Ikena and its Affiliates shall have the right, in their sole and absolute
responsibility, authority and discretion during the Disposition Period with respect to (i)&nbsp;managing, directing and controlling the research, development, commercialization and other exploitation of the Legacy Assets in all respects, including
any determination to test, develop, pursue, market, make any regulatory filings or seek regulatory approval with respect to the Legacy Assets, and (ii)&nbsp;conducting any sale process (including engagement of advisors) with respect to any Legacy
Assets during the Disposition Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Ikena and Ikena&#146;s Board of Directors shall not owe fiduciary duties to the Holders in
their capacity as such and shall not, subject to Section&nbsp;5.5(a) of the Merger Agreement and its compliance with the terms of this Agreement, have any liability to the Holders for any actions taken or not taken in connection with the matters set
forth herein. No provision of this Agreement shall require the Ikena or Ikena&#146;s Board of Directors or any members thereof to expend or risk its, his or her own funds or otherwise incur any financial liability in the performance of any duties
hereunder or in the exercise of any rights or powers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to Section&nbsp;5.5(a) of the Merger Agreement, none of Ikena or any of
its Subsidiaries shall have any obligation or liability whatsoever to any Person relating to or in connection with any action, or failure to act, with respect to the sale of the Legacy Assets, except for the obligation to make CVR Payments to the
Holders of CVRs pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.1 <I>Amendments Without Consent of Holders or Rights Agent.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Ikena, at any time and from time to time, may (without the consent of any Person, other than the Rights Agent, with such consent not to be
unreasonably withheld, conditioned or delayed) enter into one or more amendments to this Agreement for any of the following purposes, without the consent of any of the Holders: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of the
covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to
<U>Section</U><U></U><U>&nbsp;6.1</U>, to evidence the succession of another Person to Ikena and the assumption of any such successor of the covenants of Ikena outlined herein in a transaction contemplated by <U>Section</U><U></U><U>&nbsp;6.1</U>;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) as Ikena may reasonably determine, on advice of counsel, to be necessary to ensure that CVRs are not subject to registration under
the Securities Act or the Exchange Act and the rules and regulations made thereunder, or any applicable state securities or &#147;blue sky&#148; laws; <U>provided</U> that such amendments do not affect the payment terms or the amount or calculation
of the CVR Payment (or the components thereof); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) as Ikena may reasonably determine to be necessary or appropriate to ensure that
Ikena is not required to produce a prospectus or an admission document in order to comply with applicable Law; <U>provided</U> that, such amendments do not adversely affect the interests of the Holders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) in respect of a specific Holder, (i)&nbsp;to cancel CVRs in the event that such Holder has abandoned its rights in accordance with
<U>Section</U><U></U><U>&nbsp;2.6</U>, or (ii)&nbsp;to cancel CVRs of transferor following a transfer of such CVRs in accordance with <U>Section</U><U></U><U>&nbsp;2.2</U> or <U>Section</U><U></U><U>&nbsp;2.3</U>; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) as Ikena may reasonably determine to be necessary or appropriate to ensure that Ikena complies with applicable Law; <U>provided</U>
that, such amendments do not adversely affect the interests of the Holders; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) as Ikena may reasonably determine to facilitate the
administration or performance of obligations under this Agreement; <U>provided</U> that, such amendments do not adversely affect the interests of the Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by Ikena of any amendment pursuant to this <U>Section</U><U></U><U>&nbsp;5.1</U>, Ikena will (or will cause
the Rights Agent to) notify the Holders in general terms of<U> </U>the substance of such amendment in accordance with <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.2 <I>Amendments with Consent of Holders.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In addition to any amendments to this Agreement that may be made by Ikena without the consent of any Holder pursuant to
<U>Section</U><U></U><U>&nbsp;5.1</U>, with the consent of the Majority of Holders, Ikena and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of this
Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders, unless such addition, elimination or amendment disproportionately adversely impacts any Holders relative to the Majority of Holders in which case
such addition, elimination or amendment must be approved by a majority of the CVRs held by such disproportionately affected group of Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the execution by Ikena and the Rights Agent of any amendment pursuant to the provisions of this
<U>Section</U><U></U><U>&nbsp;5.2</U>, Ikena will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <U>Section</U><U></U><U>&nbsp;7.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.3 <I>Effect of Amendments.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the execution of any amendment under this <U>ARTICLE 5</U>, this Agreement will be modified in accordance therewith, such amendment will
form a part of this Agreement for all purposes and every Holder will be bound thereby. As a condition precedent to the execution of any supplement or amendment to this Agreement, Ikena shall deliver the Rights Agent an Officer&#146;s Certificate
which states that the proposed supplement or amendment is in compliance with the terms of this <U>ARTICLE 5</U>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the contrary, the Rights
Agent shall not be required to execute any supplement or amendment to this Agreement that it has determined would adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement
shall be effective unless duly executed by the Rights Agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATION, MERGER, SALE OR CONVEYANCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.1 <I>Ikena May Not Consolidate, Etc.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ikena shall not (a)&nbsp;convey, transfer, lease, sell or other dispose of all or substantially all (which, for the purposes of this
definition, shall mean at least fifty percent (50%)) of Parent&#146;s assets or business, (b)&nbsp;engage in or effect any merger or consolidation involving Parent in which Parent is not the surviving entity or (c)&nbsp;engage in or effect any other
transaction involving Parent in which Parent is the surviving entity but in which the stockholders of Parent immediately prior to such transaction own less than fifty percent (50%) of Parent&#146;s voting power immediately after the transaction (any
of the foregoing, a &#147;<B>Specified Transaction</B>&#148;), unless: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Person formed by such consolidation or into which Ikena is
merged, the Person that acquires the properties and assets of Ikena substantially as an entirety or the Person that acquires by conveyance or transfer, or that leases, Ikena substantially as an entirety (the &#147;<B>Surviving Person</B>&#148;)
shall expressly assume payment of amounts on all CVRs (when and as due hereunder) and the performance of every duty and covenant of this Agreement on the part of Ikena to be performed or observed (including pursuant to the last sentence of
<U>Section</U><U></U><U>&nbsp;2.4(a)</U>); and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Ikena has delivered to the Rights Agent an Officer&#146;s Certificate, stating that such
consolidation, merger, conveyance, transfer or lease complies with this <U>ARTICLE 6</U> and that all conditions precedent herein provided for relating to such transaction have been complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.2 <I>Successor Substituted.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any Specified Transaction in accordance with <U>Section</U><U></U><U>&nbsp;6.1</U>, the Surviving Person shall succeed
to, and be substituted for, and may exercise every right and power of, and shall assume all of the obligations of Ikena under this Agreement with the same effect as if the Surviving Person had been named as Ikena herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.1 <I>Notices to Rights Agent and to Ikena.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All notices, requests and other communications (each, a &#147;<B>Notice</B>&#148;) to any party hereunder shall be in writing. Such Notice
shall be deemed given on the date of delivery, if delivered in person, by FedEx or other internationally recognized overnight courier service (upon proof of delivery) or, (except with respect to any Person other than the Rights Agent), by e-mail
(upon confirmation of receipt) prior to 5:00 p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m. in the time zone of the receiving party, addressed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to the Rights Agent, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Computershare Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Computershare Trust Company, N.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">150 Royall Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Canton, MA
02021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Client Services </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">if to Ikena, to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Ikena Oncology,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">645 Summer Street, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Jotin Marango </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email:
jmarango@ikenaoncology.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John T. Haggerty, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;David C. Lee, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;jhaggerty@goodwinlaw.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;srichards@goodwinlaw.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address or email address as such party may hereafter specify for the purpose by notice to
the other parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.2 <I>Notice to Holders.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Notices required to be given to the Holders will be given (unless otherwise herein expressly provided) in writing and mailed, first-class
postage prepaid, to each Holder at such Holder&#146;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest date, prescribed for the sending of such Notice, if any, and will be deemed given on
the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other
Holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.3 <I>Entire Agreement.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As between Ikena and the Rights Agent, this Agreement constitutes the entire agreement between the parties with respect to the subject matter
of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior and contemporaneous agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.4 <I>Merger or Consolidation or Change of Name of Rights Agent.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person into which the Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting
from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall
be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the parties hereto, provided that such Person would be eligible for appointment as a successor Rights
Agent under the provisions of <U>Section</U><U></U><U>&nbsp;3.3</U>. The purchase of all or substantially all of the Rights Agent&#146;s assets employed in the<U> </U>performance of transfer agent activities shall be deemed a merger or consolidation
for purposes of this <U>Section</U><U></U><U>&nbsp;7.4</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.5 <I>Successors and Assigns.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement will be binding upon, and will be enforceable by and inure solely to the benefit of, the Holders, Ikena and the Rights Agent
and their respective successors and assigns (the &#147;<B>Assignee</B>&#148;). Except for assignments pursuant to <U>Section</U><U></U><U>&nbsp;7.4</U>, the Rights Agent may not assign this Agreement without Ikena&#146;s prior written consent. Ikena
or an Assignee may not otherwise assign this Agreement without the prior consent of the Majority of Holders. Any attempted assignment of this Agreement in violation of this <U>Section</U><U></U><U>&nbsp;7.5</U> will be void <I>ab initio</I> and of
no effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.6 <I>Benefits of Agreement; Action by Acting Holders.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parent and the Rights Agent hereby agree that their respective covenants and agreements set forth herein are intended to be for the benefit
of, and shall be enforceable by, the Holders, who are intended third-party beneficiaries hereof. Nothing in this Agreement, express or implied, will give to any Person (other than Ikena, the Rights Agent, the Holders and their respective permitted
successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Ikena, the
Rights Agent, the Holders and their permitted successors and assigns. Any actions seeking the enforcement of the rights of Holders hereunder may be brought by the Acting Holders and/or the Majority of Holders. Except for the rights of the Rights
Agent set forth herein, the Majority of Holders and/or Acting Holders, in accordance with this agreement and as the case may be, will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute
any action or proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. In the event of a bankruptcy of Ikena, individual Holders shall be entitled to
assert claims in bankruptcy and take related actions in pursuit of such claims with respect to any Payment Amounts that may be claimed by the bankruptcy estate of Ikena or by any creditor of Ikena. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.7 <I>Governing Law.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement, the CVRs and all disputes or controversies arising out of or relating to this Agreement, the CVRs or the transactions
contemplated hereby shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to the laws of any other jurisdiction that might be applied because of the conflicts of laws principles of the
State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.8 <I>Jurisdiction.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties (and by accepting the CVRs, the Holders) irrevocably agrees that any legal action or proceeding arising out of or relating
to this Agreement or the CVRs brought by any party or its Affiliates against any other party or its Affiliates shall be brought and determined in the Court of Chancery of the State of Delaware; provided, that if jurisdiction is not then available in
the Court of Chancery of the State of Delaware, then any such legal action or proceeding may be brought in any federal court located in the State of Delaware or any other Delaware state court. Each of the parties (and by accepting the CVRs, the
Holders) hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally, with regard to any such action or proceeding arising out of or relating to this Agreement,
the CVRs and the transactions contemplated hereby. Each of the parties agrees not to commence any action, suit or proceeding relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction
to enforce any judgment, decree or award rendered by any such court in Delaware as described herein. Ikena (and by accepting the CVRs, the Holders) further agrees that notice as provided herein shall constitute sufficient service of process and the
parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action or
proceeding arising out of or relating to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">this Agreement, the CVRs or the transactions contemplated hereby, (a)&nbsp;any claim that it is not
personally subject to the jurisdiction of the courts in Delaware as described herein for any reason, (b) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether
through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) that (i)&nbsp;the suit, action or proceeding in any such court is brought in an inconvenient forum,
(ii)&nbsp;the venue of such suit, action or proceeding is improper or (iii)&nbsp;this Agreement or the subject matter hereof, or the CVRs, may not be enforced in or by such courts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.9 <I>WAIVER OF JURY TRIAL.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH OF THE PARTIES TO THIS AGREEMENT (AND BY ACCEPTING THE CVRS, THE HOLDERS) HEREBY IRREVOCABLY WAIVES ALL RIGHT TO A TRIAL BY JURY IN ANY
ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE CVRS OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (II) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III)&nbsp;EACH PARTY MAKES THIS
WAIVER VOLUNTARILY, AND (IV)&nbsp;EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION 7.9</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10 <I>Severability Clause.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, is for any
reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful,
void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible;
provided, however, that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Ikena. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11 <I>Counterparts; Effectiveness.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be signed in any number of counterparts, each of which will be deemed an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by facsimile copies or delivered by electronic communications by portable document format (.pdf), each of which shall be
deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto,
this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written agreement or any other communication). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12 <I>Term and Termination.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement will automatically terminate and be of no further force or effect and, except as provided in
<U>Section</U><U></U><U>&nbsp;3.2</U>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or compensation therefor, upon the payment of the final CVR Payment payable with respect to Gross
Proceeds received by Ikena pursuant to any Disposition Agreement. The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <U>Section</U><U></U><U>&nbsp;2.4</U> to the extent earned prior to
the termination of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13 <I>Force Majeure.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained herein, none of the Rights Agent, Ikena or any of its Subsidiaries (except as it relates to
the obligations of the Surviving Company under <U>ARTICLE 3</U>) will be liable for any delays or failures in performance resulting from acts beyond<U> </U>its reasonable control including acts of God, pandemics (including <FONT
STYLE="white-space:nowrap">COVID-19),</FONT> terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to power failures or mechanical difficulties with information
storage or retrieval systems, labor difficulties, war or civil unrest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14 <I>Specific Performance</I>. The parties hereto
hereby agree that irreparable damage would occur in the event that any provision of this Agreement were not performed in accordance with its specific terms or were otherwise breached, and that money damages or other legal remedies will not be an
adequate remedy for any such damages. Accordingly, the parties hereto acknowledge and hereby agree that in the event of any breach or threatened breach by Parent or its Assignee, on the one hand, or the Holders, on the other hand, of any of their
respective covenants or obligations set forth in this Agreement, Parent or Assignee, on the one hand, and the Holders, on the other hand, shall be entitled to an injunction or injunctions to prevent or restrain breaches or threatened breaches of
this Agreement, by the other(s) (as applicable), and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of the other(s) (as
applicable) under this Agreement. Parent, on the one hand, and the Holders, on the other hand, hereby agree not to raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened
breaches of this Agreement by such party (or parties), and to specifically enforce the terms and provisions of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of such party
(or parties) under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.15 <I>Construction.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the masculine
gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) As used in this Agreement, the words &#147;include&#148; and &#147;including,&#148; and
variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#147;without limitation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will
not be referred to in connection with the construction or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Unless stated otherwise,
&#147;Article&#148; and &#147;Section&#148; followed by a number or letter mean and refer to the specified Article or Section of this Agreement. The term &#147;Agreement&#148; and any reference in this Agreement to this Agreement or any other
agreement or document includes, and is a reference to, this Agreement or such other agreement or document as it may have been, or may from time to time be, amended, restated, replaced, supplemented or novated and includes all schedules to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on the last
day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day of the period is not a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States, unless
otherwise specified. The parties hereto and Ikena have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted
jointly by the parties and Ikena and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) All references herein to &#147;<B>$</B>&#148; are to United States Dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Remainder of Page Intentionally Left Blank</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the
day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Ikena Oncology, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jotin Marango</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Jotin Marango</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Chief Financial Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Contingent Value Rights Agreement</I>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the
day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPUTERSHARE INC.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COMPUTERSHARE TRUST COMPANY, N.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Collin Ekeogu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Collin Ekeogu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Manager, Corporate Actions</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to
Contingent Value Rights Agreement</I>] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d469204dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ikena Oncology Acquires Pionyr Immunotherapeutics in <FONT STYLE="white-space:nowrap">All-Stock</FONT> Transaction </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Ikena receives approximately $43&nbsp;million in net cash at closing </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>New capital will further accelerate and expand development of Ikena&#146;s targeted oncology pipeline </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BOSTON, MA and SOUTH SAN FRANCISCO, CA, August 07, 2023 &#151; Ikena Oncology, Inc. (Nasdaq: IKNA, &#147;Ikena&#148;), a targeted oncology company forging new
territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena&#146;s acquisition of Pionyr in an <FONT
STYLE="white-space:nowrap">all-stock</FONT> transaction. Ikena acquired all of Pionyr&#146;s assets, including approximately $43&nbsp;million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and <FONT
STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock priced at $7.15 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Ikena has made incredible strides this year,
and we are glad to welcome the Pionyr shareholders to the Ikena team as we head into a pivotal time for our targeted oncology programs,&#148; said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena. &#147;The capital from this acquisition allows
us to accelerate and expand our clinical efforts in <FONT STYLE="white-space:nowrap">IK-930</FONT> and further support our comprehensive clinical plan for <FONT STYLE="white-space:nowrap">IK-595</FONT> as we continue to build value through both
depth and breadth in our pipeline. We are looking forward to sharing more updates from across our business and pipeline, including initial clinical data from <FONT STYLE="white-space:nowrap">IK-930</FONT> later this year.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction further strengthens Ikena&#146;s financial position as the Company advances development of its targeted oncology programs. The new capital
will enable Ikena to expand and accelerate its targeted oncology programs, including both <FONT STYLE="white-space:nowrap">IK-930,</FONT> Ikena&#146;s clinical program targeting the Hippo pathway with initial clinical data expected this year, and <FONT
STYLE="white-space:nowrap">IK-595,</FONT> a <FONT STYLE="white-space:nowrap">MEK-RAF</FONT> complexing inhibitor expected to have an IND submitted this year. The new Ikena shareholders include New Enterprise Associates, SV Health Investors,
Sofinnova Investments, Vida Ventures, and Gilead Sciences. Gilead Sciences acquired an equity stake in Pionyr through their 2020 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">option-to-acquire</FONT></FONT> agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We have been highly rigorous and selective in our search for a buyer. Our attraction to Ikena was driven by not only the potential of their targeted
oncology programs, but by their company culture and the way their team has managed capital and developed their pipeline,&#148; commented Steven P. James, Pionyr&#146;s Chief Executive Officer. &#147;On behalf of our investors, board of directors,
and the Pionyr executive team, I want to thank and congratulate the entire Pionyr team for their efforts.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further details on the transaction are
described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transaction and Approval </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The transaction was unanimously approved by the boards of directors from both companies and closed following
signing of the definitive agreement </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ikena&#146;s acquisition of Pionyr was structured as a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stock-for-stock</FONT></FONT> transaction whereby all of Pionyr&#146;s outstanding common stock was exchanged for a combination of Ikena common stock and <FONT STYLE="white-space:nowrap">non-voting</FONT> convertible
preferred stock </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ikena acquired all of Pionyr&#146;s assets, including cash, cash equivalents, and investments as well as all
intellectual property and clinical and preclinical assets </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pionyr Programs </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ikena plans to include Pionyr&#146;s programs as part of Ikena&#146;s partnering portfolio, and to pursue
strategic business development opportunities, including <FONT STYLE="white-space:nowrap">out-licensing</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The transaction includes contingent value rights (CVRs) providing the legacy Pionyr shareholders with rights to
50% of the net proceeds, outside of royalties, for any potential monetization of the Pionyr programs within the next two years </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Details </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pionyr shareholders were collectively issued approximately 1.8&nbsp;million shares of Ikena common stock with the
remainder of the shares issued as Ikena <FONT STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stock </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pionyr&#146;s valuation for the transaction was determined solely by net cash available at closing
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The transaction price of $7.15 per share represents a premium to both Ikena&#146;s
<FONT STYLE="white-space:nowrap">twenty-day</FONT> volume-weighted average ending on the transaction date and its most recent underwritten public offering </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a result of the transaction, the Pionyr shareholders collectively hold approximately 12% of Ikena&#146;s
outstanding shares </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ikena&#146;s management team and board of directors remain unchanged </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ikena Oncology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ikena Oncology<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The
Company&#146;s lead targeted oncology program, <FONT STYLE="white-space:nowrap">IK-930,</FONT> is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The
Company&#146;s additional research spans other targets in the Hippo pathway as well as the RAS signaling pathway, including developing <FONT STYLE="white-space:nowrap">IK-595,</FONT> a novel <FONT STYLE="white-space:nowrap">MEK-RAF</FONT> inhibitor.
Additionally, <FONT STYLE="white-space:nowrap">IK-175,</FONT> an AHR antagonist, is being developed in collaboration with Bristol Myers Squibb. Ikena aims to utilize their depth of institutional knowledge and breadth of tools to efficiently develop
the right drug using the right modality for the right patient. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Pionyr Immunotherapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pionyr&#146;s programs exploit novel target discovery and antibody generation platform technologies to create the next
generation of immuno-oncology therapeutics after checkpoint inhibitors. Their initial approach, termed &#147;Myeloid Tuning<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>,&#148; is designed to enhance the immune system&#146;s anti-tumor
response by specifically altering the cellular infiltrate of the tumor microenvironment. Pionyr&#146;s clinical programs, PY314 and PY159, targeting TREM2 and TREM1 respectively, are designed to selectively deplete and in some cases reprogram
certain tumor-associated macrophages responsible for immunosuppression. PY314 and PY159 have demonstrated safety alone and in combination with pembrolizumab in Phase 1a/b trials. Pionyr&#146;s third program, PY265 (anti-MARCO) is <FONT
STYLE="white-space:nowrap">IND-ready.</FONT> In July 2020, Pionyr entered into an alliance with Gilead Sciences whereby Gilead acquired a minority interest in the company. The alliance and exclusive option to acquire Pionyr was terminated in 2023.
In addition to Gilead, Pionyr&#146;s investors include New Enterprise Associates, OrbiMed, SV Health Investors, Sofinnova Investments, and Vida Ventures. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including,
without limitation, implied and express statements regarding: the anticipated use of proceeds; projected cash runway; future development plans; stockholder approval of the conversion rights of the Series A preferred stock, potential future payouts
under the CVR, the timing and advancement of our targeted oncology programs, including the timing of updates, and our expectations regarding the therapeutic benefit of our targeted oncology programs. The words &#147;may,&#148; &#147;will,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;potential,&#148;
&#147;continue,&#148; &#147;target&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release
are based on management&#146;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of our targeted oncology programs; our expectations regarding the therapeutic benefit of
our targeted oncology programs; our ability to efficiently discover and develop product candidates; the implementation of our business model, and strategic plans for our business and product candidates; the sufficiency of our capital resources to
fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available, and other factors discussed in the &#147;Risk Factors&#148; section of Ikena&#146;s Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2023, which is on file with the SEC, as updated by any subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only
as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect
the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebecca Cohen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ikena Oncology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rcohen@ikenaoncology.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Luke Shiplo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LifeSci Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lshiplo@lifescicomms.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ikna-20230804.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/7/2023 10:55:58 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:ikna="http://www.ikenaoncology.com/20230804"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ikenaoncology.com/20230804"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20230804_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20230804_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>ikna-20230804_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/7/2023 10:55:58 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>ikna-20230804_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/7/2023 10:55:58 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ikna-20230804.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140095736519136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001835579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  04,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IKENA ONCOLOGY, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1697316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Ikena Oncology, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">645 Summer Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">273-8343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IKNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d469204d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ikna-20230804.xsd" xlink:type="simple"/>
    <context id="duration_2023-08-04_to_2023-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-08-04_to_2023-08-04">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-08-04_to_2023-08-04"
      id="Hidden_dei_EntityCentralIndexKey">0001835579</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="duration_2023-08-04_to_2023-08-04"
      id="Hidden_dei_CurrentFiscalYearEndDate_duration_2023-08-04_to_2023-08-04">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="duration_2023-08-04_to_2023-08-04">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-08-04_to_2023-08-04">2023-08-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-08-04_to_2023-08-04">IKENA ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-08-04_to_2023-08-04">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-08-04_to_2023-08-04">001-40287</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-08-04_to_2023-08-04">81-1697316</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-08-04_to_2023-08-04">Ikena Oncology, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-08-04_to_2023-08-04">645 Summer Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-08-04_to_2023-08-04">Suite 101</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-08-04_to_2023-08-04">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-08-04_to_2023-08-04">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-08-04_to_2023-08-04">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-08-04_to_2023-08-04">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-08-04_to_2023-08-04">273-8343</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-08-04_to_2023-08-04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-08-04_to_2023-08-04">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-08-04_to_2023-08-04">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-08-04_to_2023-08-04">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-08-04_to_2023-08-04">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-08-04_to_2023-08-04">IKNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-08-04_to_2023-08-04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-08-04_to_2023-08-04">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-08-04_to_2023-08-04">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " !=0 =7)!Z;HJT
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M2P$"% ,4    " !=0 =7!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %U !U<T!W5_[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M %U !U>97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 74 '5S>: HF_!   #1,  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M %U !U>?H!OPL0(  .(,   -              "  0,-  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ 74 '5Y>*NQS     $P(   L              ( !
MWP\  %]R96QS+RYR96QS4$L! A0#%     @ 74 '5QPX9>H_ 0  / (   \
M             ( !R!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %U
M!U<D'INBK0   /@!   :              "  302  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %U !U=ED'F2&0$  ,\#   3
M          "  1D3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(  &,4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>26</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d469204d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d469204d8k.htm">d469204d8k.htm</File>
    <File>d469204dex101.htm</File>
    <File>d469204dex21.htm</File>
    <File>d469204dex31.htm</File>
    <File>d469204dex991.htm</File>
    <File>ikna-20230804.xsd</File>
    <File>ikna-20230804_lab.xml</File>
    <File>ikna-20230804_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d469204d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d469204d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ikna-20230804_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ikna-20230804_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ikna-20230804.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 27,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 26,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ikna",
   "nsuri": "http://www.ikenaoncology.com/20230804",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d469204d8k.htm",
      "contextRef": "duration_2023-08-04_to_2023-08-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d469204d8k.htm",
      "contextRef": "duration_2023-08-04_to_2023-08-04",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ikenaoncology.com//20230804/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-204493-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-204493-xbrl.zip
M4$L#!!0    ( %U !U=;L:@,@2,  #+/   .    9#0V.3(P-&0X:RYH=&WM
M/6E3XTBRWS=B_T,%\V8#(FQC&VBN'E[0AIXEA@86Z-G9]V6B+)6QIF7)HY(
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M9QJ@I]Y?BZGZKL)472]V+@93*!.CLY5D[I4"2$,@8N&#105$'(1D7R52T%.
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M*1=SZMC,&KVG7SIW0 #!$B-/%T6F;MT8/TFD^[ZH<)E*R$V; ]?EA;RE2;U
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M,O;/G>F9?S4#Y:$R688R#6VK.(+K;7)T7<(]&-.+4/#1G^1!FJ#: @.ABZ]
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MGM=E"ML+0^XXPQF_&<'*8"U _R-)6$NN$R!3/,'53J0XVCF0:;)$#@?I]VY
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M]K_?_MV.=57&N[Z9GG09[U9/ZO8BSR?JD@V8OE((QBFP@-- Y<MP0J\"?X^
M%=L+/&-FR\>H+%?,MV*^.9FOO;#S$1@LV:U29#N?1+TLU[SX)GBO4C6,R^ T
MB9;"<ED% A\!:[87C#Y*K^,\2]&5 T?UTDC(_56YG$? ANT%I(_3HLK1I;,$
MK+=R)RX_Z^VV%W?^E 46%M8=7,=%M@2%N5=<^!BXL,76!+8M1A'<Q.55T!T.
MXR2.RF7 XJRX\3%P8WL!Z-,\OH[ZMV2O'$9E9!J2KEAQQ8KSL&*+0>BTC(/W
M>=Q3^3)PWZHBQ"/@OO9BS: <<K.U>CV(+ ]L.8@57SY9OOQ)E4KV?V6E$NE5
M@#]PWR&J%K%BVB?+M.T)T_V_4-&2%3L^ G;\*Q0MV5_EYR\_(_[UBI:LV/(1
ML.63+5JRXKY'P'U_D:(E^ZNB)<O/BT^W:,G^"CZV_.S7'GKL_.@@^! GC)]=
MS@HF*XY\!!SYM"N8[*^ B\O/@G^M"B;[JWSIY6?)IUS!9,6 CX$!6^RCMOR9
MT2N6? PLV5Z498E3 %>L^!A8L;TXRU*E *Z8[S$P7XN=U98;W_UJQ8W+SXUM
M1E<F<UY6;+ABP[G8L+W RM<H =H<%T6U)*E_*_Y[!/S77F3E\TT*RN!5/"9/
M-O?RH]IV61J<EUG_VXHE5RPY#TNV%UIY- D'*[Y\5 D'S]I+.+!E074;U-,H
M7PZN?+8J&['LTO)9BQD%IWGV_=8"(5;\M^*_.?BOQ31I3JPB51$KQ<.Q_5&I
M<BEZEZ]8\1&P8GO.;5-B;&D\W,]6B?K+SX#M.;B/82"C-![&?3)84#7\/(2_
M@!>YC$2<@SZZ%&[&9S^2Z/?V45?G7I7G7I7G7I7GUN)@59Z[]3ON/B=6Y;E;
M.;';"P(N%1[BV2J];_EYK[W(WXFZ5.E@&?ANE<JW_'S77L3O E&QJ;%0#E1>
M1G$:."YMM%7.D#>6@3E7:57+SYSMQ?XD8!/L/%^B<WG%@LO/@BVF525))@X<
ME(WLSED"9,Z*#1\!&[:82G7P]6R92M\\>[YBO^5GOS9;01=1@M5O+N.BS%D>
MDF*H$A"' \YG&53Y4F >5KSYJ) XS]M#XAQDZ2!F>-AIKH C,1I=9L'G7A)?
M:MS8,#B*^E>$T5F" LK/5KBQ99>DSUM$Z'S*./\4C.QE,*B?KT 1R\]][>%S
M7&!.=SS.L^LH63'AB@GG8,+VD#DGH$(N!2)LQ7>/2U%\T2)D>\!Z8I0$<^J,
MC37C5SS\9'FX/=GYHD7U4>=DN0?YGWE<EBK5Y4!7/+GBR3EXLCVE4O/DURBI
MEJ0@Z(H#'P$'ME@P?DF#-"LV? 1LV![BN]OOYPIT234(CM-K5919'OQ_%?P7
M&#.-XGS%D2N.G(<CVT,TZJ/Y!+3%S2]C!]:S8L4GRXH_R?I^N2#K6^=4"R^O
M&/?),FY[,O1EFR:WU2B1%0]5$5^F*SMGQ8KSLN)/3:\^K\;C+"^7ZV1?);HN
M/U>V9WTO&31MQ7V/2Z]\U9Y>64NY7O'BD^7%]B3AJQ951>&_\C;X4*5+T")P
MQ7Z/@/U:1/=4^75\#4:U4[P1&3'"@QDNURKH+0%_KAI,+S]_MJ<H+M_QO.*_
MY>>_]N(S)_$H7LF^%>_-SWOM16).51YG _A>'APD43Q:!@Y<59A8?@YLL6GO
MBNU6;#<OV[578.),%5E2F0IXO7\IZ?E29LLC"5<U3Y:?)5LM*U'E<7FK$V$N
ME\-OO<KH7WXF;*^PQ,55G \V*0EU>>3@J@?;\K-@F_UY@5 E.@?Q:*[7JSV-
M;I<EGKQBRT? EFT6FQBIP5*TS_@ASGO[N LCKRHCKRHC_U4J([]\:&7D'WW!
M['^_755&_NF5D5<:P2_$^.QLMP?R^1@7?94D4:JR"D'CV75<+$E(9Z6G+KN>
M"HS89BV?=-/%7-3P%6%@^Q-2W8#37&T>)%D1IY?!07:M4OBM>!.XKSC-BG+R
MGA5KKUA['M9N#TK4!=-_L"1XWE6!M$? >NVAA/Z,XFN5K_ANQ7?S\%U[Z* C
M.*AS93,9WL#Y6Z'1,8YR/*:/OO>OHO021M"[#8X24&_S+(W[P04<\<4H+@H*
M<>;!AZA?Q##>9<CV7K'P(V#A]D!&W?$XB?M1+U'!273S)O@_51X7@[B_)&C+
M%3<^ FYL#W#4+2A3MA<G\3(4VGVQRI5]!.S7'O#H4U;&_64((JT8[S$P7GOP
MHH,L&ZM\25(<7JQ2P!X!\[4'*SI78#POSYF[XKY'P'TM(HH^EU<J#S2 XTUP
M/E9]A!0%IRH?9CE\L;\$=O&*+1\%6[;:=8'PEMST(WBO4@5,&4?Y4J",?H@=
MX>9'C3.Z_BO C&A)'R4R9F?_H="89W]SQ=<O;4W]]OV[H^]7<2\NB]?S(46F
M2Q)^X<\^!7ZMB!?B!-T'$^8#G.E.=?R9E:F>*!'?MT;$J=4ZGRCE#MJCW.P:
M?4^/=(?MD6ZB>M?3H]91:]2:K\3STZ/@A]8H>*[&D=] 4D6%>K(L"*K(>?]*
M#:I$K721INEHZO"LNRX)'O*_#R:S/HS_D68WB1I<*G1A%!IG^O3HWX(>(TK@
M7X9B#]=?M-HLJO(3I]?#E9:ZAOS$"?9PO>6 4WX037PT&B?9K5)/EEH/UU$0
MT/TU*QE[/1J!BD(&;7!<%)7Q7#]!ROW^8,H1""XBH%%P]'VLTL+E,\=7V>AA
MW-EMP<6(JI:6#X=QT4^RHLI58"9Y1\9=:V,0F7['$)ZLQ_-7IE5V?S\[.OH(
MPPVZGPZ#TY/N)\RQ_'AT]OO1V0^OMQN[V/_;_=?_XNWYQ^[)R;L_CL_?_IW_
M&73EFAZO^4&NP_#-I5.Y!K.IW_;Y@[[26?LHUVBR^C+-6?]3GETOK^(B^)__
MVME_\09I9@VM]^_PZLLW&P'<,(H&BBPR(B_8MW%:9D%$O2^[U655E"P"]L-@
M=WMW+T04+-X>@9B\A/<&Q_+A?QQ]ZIJ/?Y:+GY#O?O^GOAZ:NS\=Z&M;.* P
MB()#E40WL(F"?I:#6D2V8F=MW<R -Y@S_## JYI&9Q?G'S]_N?C#C*&14L&Y
M7/WRWEPZAF'A>*8/@V9\<Y4ER6V0W:1 I:+J@5".H_S6<8/:L=I6H<&..V(D
MV-013UG<QB'#F$].)L><8*E#&%X2"Q8 9L&B\0$SV+4SP->$09E=*@KXWL3E
M5>#.-0P:7E"X%(!M:1?M^/.G?]IY:M[X^/'+I\\7?QR==4^/OEP<'YS/8I\&
MUI^ZBNO83\8,T#26<1@*J?0!5'+8&-W!=5QD>8%TGH_&(6X;_$13H:&MSAIZ
M*Z,X#?K1."Y!?OX'7@)[;E0$54$;+Z M:W9J@%\;J&&<\J]OO]2R*]_^_<N[
MK6!Z!*^5LZU!_IYI-CTXONB>6'&W$-';W7)[]#H=@U"2*;R4!6HX!,+!(HZ8
M*8'A7:YE/L;'2?BY[_!9YD.<%Z4\ZLE1$%11'UAM@.HBOZZ^EC*XP]\/3K:"
M+V-@QSZ8,-5HY'4[<K\0U@>9)$&?O&8XI>]Q,3EENJ>G@"%!J-^]WYEY?NER
MO=\*CD<($XE*!6,;P@BS&]2\Z[/G4Z8(, U#4Z>(8%X9(IU@FJ6C>\K&\ZDW
M01A:?;/8G35:;5?0U98;=EMF^C[/%H+-7Z\)0T_4U&7G+JR;ID-!J:'X%] 8
M)8S,WQO0 A;O8"NX@&$@F@*36_4&NXK*YN6;&#.0)?JF4D.\4+@:=@+,LRI1
M%:'77H+(1O'HK/% %?T\[K$L/%/7(%'/JF0+U)+MG<W]YR'_8S<XV (>V]O=
MX7']NP)).Z147/A_69%<9?EEE,;_H;TGJXH+0C)8 :/ CT!]\EL[$G?O^<OU
M:,-V)A/5"?_ FDJP;+<PLLLJT9G D26/)PUZBG\#$BA0J&*\=9"-<<K.,,=)
MA(*AL]8X7JPIBU\>5W#"@=W5--J)H38-TW]J9PN>V]Q=O]SXH:/E0?QUR/SU
M/HOR 4W\,,YA;'@*.SJ*M[/D(CWBBN0KH.-ZO,%S&B@\9^D<-<R*+A(U A(C
MT1T[MJ!C=QC%0-T,EP74 $JMX?.!GNTIX/.8%.:BK+>)C^%*80/BL+3KL1Y(
M-![G(+\&=.- ]9,(56[[#623SIKA$Y%A;JC.$?E3QA_"R/I)-=#")!8O!@ZS
MN((/N@/V_!V4K,[73W,U5#D.CG^J'8M_\-20]_#EI?Z=U1EBNHG3#ZB@R9!C
M<5 D SR6XVF%:<>@&E9X+-KWX%-P;&'I4/V!ONT;6*@2]P!(T0G-*;3+[*Z$
M,^_K#&0-[&4>#UH\O#+Z(W#&%,ZQ/(4J2%KXPZ>"-W$86ETQ^!05@^C?P0F<
MW[A$(,-49^W9\[UG*%KJ*JH9R&F>P2Z/$I?'B:H]F4,\!(9" &:0JKXJ"CSH
M0;3PR/&X"J*JO,IRV(I U"'BX'" LSDB3N4R?O+YFP+T#R_B#ISFZ-=:(LU+
M/SB![R1@C2 PVA)5:IVGWD277R^WCEAN>><?GNDLR$ 4@1W;IBP*9PLC3VTT
M(BE+O-UP7[%T/Q%$^M6=.S[XN1M^@A:XZZD",1VV3=-RQ<#4Z2U \_K '$:+
M.%*CWL3D=ML_\2:XC#3F1C;;]=F,1_C3.>SN(^6!#%8[BH6.4^C?-G.M7,4/
MWC6_^_IDX*F3T\U\?;5)J?RUDMP=8QNZY7VVV'+(\ DRD.;V&$7X'ULXG'Z5
MHRJ4W%J_@?JN^I5Q,P]4@H50;B>UZ%"[1")+46&?0=5G OAZNM;:T,@&73,%
MM1#NZ*S1AM7.KOH:H&('&AYQU\!L&%K69EW:KFF6OOWR+G"!$O GVKCPH74\
M&9);X778!_UH'/71N1$54]Z,7I(K,&TGE=1<E]SBU?X>C]B=M/OJ;YI?LJHL
M2A@UZMCF^<[:-<=Y^ZSETG?M>T/:I;(>^)P -"+391>'/XRNL[S.EG =/6PE
MUOV*T.N&/V+J4Q"59804T82("B22@\7^\J[9IKT#5>WXDES]^>8J[E_!6.!_
M!"8!8NM:@755VY5VNS;N3W3/J#@->?*TZ6GKH>N-YPYK:!=&G-IUBC;0:\*D
MH3%,U^P7L%6/'[I5Y]NIOFGE;]+ [M'.VD,VJ<ND"=B<L)2U;7KH;E-_ R0(
MN/&Y_X>X_'T#ES? W=^_"ZV+M;/6SQ*LMP,T3FYK#M6IF'DWV/3+[<#_\W 1
M#W?#3IVQAH[M;DY!_]AK/.9]YS2P9J[^7<6H(50I"A@=FZB'%#1W?G8<D+!E
M#[-^1>2NBTQG?OQG(.[;'I CC\M2<>"#)ANGPCRXVL)8?16@CQ*^T@,*1OV^
M&I>LOV2.3,ER&G069#V*J>&(S_2,-*E< ?J5'#X*>#0T_E6'C]Q;_Y1A'O P
M)SP+OU04_6-6O&1^MNI593#.XRS7TG\8)^+AMMQ12Z?0S")41_G468/G1+6:
MFGMAV9YEE!.] -$@ :CS4AZD7TKS%@ZR+B*J.0VL@:88QS5_I2AQXBRA!%IH
MU3.P$H)$79+T[645:N DH'%/,W<4KW^(3>\UO%K( &/3AQBICHWI$!Q3$35<
M<93@7L5>';9^R$YZ=5^*[FSMU(;YP_%S=QP[>_<=R'JTT5G[ %O1C=S@-G"\
MGJX+'W9R8^A_X_4O/^ LG&@R(<8)D&+\#)6?!NF*R@Q8>>BL8NEE#%827O37
MW>DV-2U$#H IB@A2STD)^O(.5"8UPI C^JV)Q# BTIC]^ ;BHV T/.G(CBF6
M,<ELUYLCA^C8#YYM[Y#98<-MP:%SX@I2!,.3W7ZY ,^U7= AG@@@AIUE!.T>
ME'VT'KRY7<)"80B7289F!$5D<;H[^\_L[#IK_O06.;M+V%J7>,@<1,65T^.F
MSK(I MLJUC'Z>*O" #).UKA]*.::9Z#($RYAO;NQ_GV#"!3IKW36TDK["*V)
MI)G+B[!<J62 NE'#5BG0^B7UZDL:3>Z(0E!ZL:,>>$<\'^I'A'U!"8SD>7O\
M+A@G%<P<_K%^ZTS)##Z8>^RTTLDMZWFWG;5C6,LKM?DQ2Y6=T.>Q/1+TM3.8
M0![W2Q-(^Y*B9^L'YS.JDC(>)[%"0O+$WLO$3M%TQDGPNJ-&%P]TD2:X,0%C
MBY^(XT9:@(S*^W&!*XY5Q;2D=F?:6:M-=4M7.'ATY1EV_PJU&7Z=^]F(G_=5
M$9-=?QC=-LB<VV 0@5),:"(XBT &\854G#F]*/U6Z$..=.7.&NY)1+9D>1I'
M@01>C1Z-@_AGEG\CZ6'BO@.\+^L!/1A<0[HDHM758(&R>582=YU4G;5: 'K@
MF!T8?IX6J)];03AH12E\ #4^OS_K3DR<3E.47ED2#VCQ/H_2N%<5P?MJ<*E*
MD*A@5/?I!$=2=/ELVGGU\AD9^Y[;W=,D]U^]W'X_ 1-"RR-XCI<OXA+.]6/\
MY]'9\7F77A>ADPZ9QK&C!ZIIU&P%H,?@3('64,DW>&S/_9?]<MMZP@O0+8JL
M7U."["85OPYN(F0DV*Q*<JO00ANHL:)QH'L#-$OTR(7:2Q?B0]I/5_?H9#D?
MGWCVP2EXKH&:H#8MDA'-B<^S:22)_O&UAZ5AJ34YQ:!AA@%&62,NT!1:- MZ
MB^[W%OQU!%)3T*]D&N,U5D?O]3(P3L+:ZZSO/.3'6(K"-J([U_LR[KF^!HIQ
M[7/Z:U&?7%AT+U6)PA]T1' )F.$(AE?>.F9+XYYO4A;#"37)UPC/ORP#LW^
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M!SCY!!F5%<BK<=DG2 +5=DW[MZ$Q.7-V\!&<NV?J"QJ<;HZ]C?%7L"!L7DJ
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M;;&=1#+)\X]-]6@/+7WWE$4SOO]L V>RG;7WBYGM(EEN7B2N!6_4P1P&Y2$
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M&*0J-C]_3]3M]#Z@$[?ANNYN;^\^8N_QSLI[_'-XZNA@C@*ACG,"CP737O;
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MGZ$UYA2;"LB]45MC=@@FZ#!#7T95TG_+*(^'P\),$;$;10%T$<0)#B0OR1<
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MMY^$P)G-266PA9V.I<=8K$S*,5*\I@O@9Y!VPN:0<L0B;-P.0YRWN0(V]BN
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M#"FF8+X0N-9ML3N@M>9%-E_K>V#!5@M(%3<[0&6II1FF,75Q?VUS:7WEMK-
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M^5ZP.5R.8O2XGW[X:7-&Q4)DJ/V$C7;7BZ,34@PP!H?VY>;0*QB8 65"T-Y
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MBKO?Z3?9R0=90I)1NJ%N=61W>Q7@57./5O5Z==UF.[^3S^/O=1G1G]QK%*\
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M#RQH%^T'FCZ[(79D6.&!'AA@E48-';BN\EU/H77A3["RCA&-7U,T'J3+;/>
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M)1QG.2X.$;8/'W^Y5' M_-Q=%RUGEK1V8BA'-4W+TA@0<'MI N 7M:3Y=)A
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M6R+>8^=AZV3BRPRK28E(WQ3"]^XLS[&0"..O*<*&,U<+8#=5NR&SZ*:.DC#
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M>V3V<QQ4Y_\3K<S4/1_8(CQI<O9"12Y4_AH0&^B!#D<2DT43)@GD"(&%05!
M,KM+1K]<%37+MGHH*#O1W"++/$3Z5TK>EN][OX?G-#(*49[)>EQT*,"?&=R
MY^_:Q>UT[&$0'P#%I5_JS-*F!B/,X!(^VQ%NL8#A8@ 1>"L5NVTRXO0#M8PI
M!UV$H87?"VA,=+XR@M@!1U);H1+YLKD%>FSP--KW( 6Y7I,69#-[[TZ!G,=?
MN[[D52$/LD*H$K[RK+FJ^?=-R- B[*?(BE1UZRTY<9CRE;G%J<1EH52I5)N-
MQ*2^X*SPRZ]9X4_<Z4>%I .V@T<PI1@[ =08:1PH-@'(W<'ZY"9;8O]ME0P*
M3O6)G7<1_D; 6_;;)DWC=B#XRGRD"AM7""&"9'1;,-$87+DM-P6$+?BW$F
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MH.\.OFOZ2K"!X22(',8C#1W^44!<UFP[A*#M"AI@V)=HD87&TIYD 4O74,@
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M6J^R7#]\['+-^JLUW[U<_0..1Q._:AN$%8#WX!;MG3Y.N0I6*9H+6<FIG7]
MF>7?QUPEV-YIYFCBUPH21R?>*5I$N^R8&<5PJ+.+8TZTNSNN],\UT<>:Y_3(
MCT</-\7!-Q7%BH<403[5P/?+-+VD#+$>NV-2##9(.Q267"3W0-+<7O>NQR0
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M>#B#'A0ROL22R-.O)9&')QK&PJXX.\8@&2>=06=H4FN <Y\:*XYKW+#.0%2
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M]4E9"XM*$7QQ<'546]'+4_^/BK7$JUV"+#NXNSPI_1M^:TT'4F!6[)52B!.
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MS+!L':0&A?O9LXT>)^]W"?[,_LZ3*D'3VT;+0]7P-G2$EN6+*JSW8 EE5=9
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MD7K*C83R!$N-AQ_S& [W17"VJ=LVX;>#P!1[PO'32E&8&75)O!^!+,@43"=
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M>D9@B5<>"(V7<W:9C^'+35F!<[/6@IYQ/D^+002.A(+>;$3:5'7G>(+VV>Z
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MQ\ (JIEDQ-C*,"/4:]G,5W9N9J).+?L(9ZVET2O2^[L()2%>//*(-B&3-M_
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MHF2TWD8HWW(RNBCEP719Q"G?6KA_H[>_ULMZCWVS@0EFUXOV #MZ<(I=,1[
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M=N&I^-A"!0T;M9YE@RL&8]*(B!Z;]X&Y]"'LSL%ZLA\*?7UZ4YT<4RBT*\E
MGSJ;M&6JVHVCH W@Z@I.XMAV+I--V;)UI?GNT$AP>8K?@1=CIUS> %PLNAR0
M#N(5LC',)_07DT<#>2VZ5%2>S#AZ7TUS*T1*^BJ6CF$^@Q[A3,NS!3?PXC+.
M:#27G)8E-$'(T! NV^>78!->4B2^7$LWHT$; 0I"ZOFYI?2"^UYD0&<N()E
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M:F^7,%GF-(7\[HLW3?AN[C@QY6?<U+)$H ,HB2+BB9)S'RVIFVP ,1UBCX2
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M/GD2'P>!PCJCC%9?RLTV$M69/+3G$2T.NKXS.V];EN3L./, O/&)+,>J(U6
MH(Y$&-:)6"(;2:].ZI(4J[+7F\>IW09L# VW"7)XYI7GPIZ0Y@!)M] #=C$J
M3GF?<V$@/VIU!9^U1IP.ZVZ.!F;[G^8NZVW9_VI=K(4G2_#T70$CO8OB51M=
MP9J-Y M85<,<01+10\MZP)Z&5MEOGTQDA,W2DHW-3>YK;]X-6,U%W%M^+*L?
M+"J.I!!&U=LZWA?@LY]A<VL$.%H.C[97L>R9;7=L&\:%T>:365858WT(AEPT
MR]FAV&%8I#N_8\J-'YZB]]^6<N,=')Q&FVNF.-WAN"/VX10>8]#E$*VZY'V?
M<6P[I)&'CB3.PF@\0B<=47!&^>QMFP/L-$#Z&RT_>J9F!%Z:E\:E R-AJ*[P
MO"\X$#5Z/@5C40 ;PERXNB+>V,BIQ,8,$&!XU*%0;$T=M2)RE,7E:,,78@'(
ME>.54)X(XGQ0Y2+,K2JSY8)SCE<RL%7&W&Q]+FZ6]CE<*R]D5G9%O#8NW[A/
MI$_M67D)KF"'%L3J/^B:SG@$V ZNHBR7"+EZA_C#$^?2$:L3Q:>E3KIY_9J/
MPX#)G-<U6[%FG1W[6FMA<.M\J9IG6=;U5!7#P<I/A0O=+/)TG"-/E8.:)Q&V
MB[!*LVWS^1W?\%!Q827U!L&V'&0DRK&#MV';FSI,650L>U\VP9"ZBKC+LOH*
M1P4WFKW KY.G7+CZM<JI$62U<.R*;4?%YQ&%]![6I(O)Q;EN):'X4FSP87R3
M:H@\<D-7;I+I\A=T&37GA!"!&3<=^BAQ(RU"L8,XAAP.)EV@;#1'@]^&P@/9
MVIU? @> /7X'EO1IZO0>FRR# $-0D:WE$#'I<:<YR4*+S?5YE8I70G")%FIA
M;^CHL*WF:(KA+NI_G46)]+,O[$?1L^!7TKNHR8-0CF\^1P4,F'1!M>\$J>,#
MJK#67?26YA)T->4$>\>D]P"ZXS5L]=45!>:7'ZSC2DB-M^9!61!PZZ*:>,&\
MCF7GA@$/136*G-F.<->I+\<[C9@+03L!]D1+AQT^V8XGP;QCSR57=K/+KA3*
MG6V/3:*DIZ88M ,^>OW,_>Q*K#K5([^FJJ=F@D&<)518)9>M.>HM;,MQM?AD
M2H2&#G9;:8I2N]UYXP9O4$AP0]%A2.#:TKO@],1\Q2XVPLZ2X[3EISQ]*ET-
M23SL@U)RMQ-KG-G"S0,^Q>82VV@^!Q4QR!6H(UKJKZ< L!43*E8'+4)'LZB$
M%&(Z15"9>7.IU8,D,4#S&ML' XK2]!T) T!U4L#$]F51!I$T^?#!"/" /^83
M\O\QV#Y:%VUO[^+52Q6B/C+OO%G8PP4+QK5,8IW4Z5)4O8JE:VH88R]",6[0
M U<5T'JXP+43OOG'*IM;1E+!,/*NASSJ1^%SB'2<-RM_)CPOU*K5!:!H;]!F
M\+[ >C!*.DF[#L=C$.^,TZK:*;)&</J@-TZ8=5,2NLFKO/$#5QYY0[V1!+R6
MQ L)@.&H?38&63X>9Y.\G-<04>*FQ0M)(>]&*)M1H5#>,[8BY:(H_GRHH/U8
M#OI;5D%]BY3!'%3Y,SEH6W)FWR?Z%@=E/6M>0^_9MY+=HBCB),^;O'(I1PJ]
M41&)AAN8#[Q(77C07*8R;U[1N-Y,8'-E3!0;3 #WQ L*=JBA3CNT;7W=[T@;
MY:0SCJ;?X$>1Q#FVP8Y<"XW):^.KY:!TO*D4OS/$<&TBHBDZ50=IWY4C[/O2
M<CH)Q;1ZV.J*/*U9!,7??,>AO;=/H;UO+*9>@)CJ"8^4N _>09"R0^X_YM#U
MG)NQ:DBY"2>EL*O9>J&&'-&R0]>'DFY#9*G'L_T1X,%!F3 (D!S%#BV@CXS-
MAN54\]:JX7IOZ <";16Z8[M@&BS_"423Q"86=,G@M$V3+"/YM312*Q+4,A]P
M7$ND<28VEXT)=H\[,'/",=L"+B.:'%N8%5C4^PU%L+D7V%,<":D=<Y)Z/+G&
M_B.,=T3/L-4@: TO^6L9(#'U3T5O1]XUV(76SEN\18I1BI4]*&7A#^Y<*K-1
M>-US,DK'N:;#&  +]N[J2J/LG5:=P$763LQF_H9L&=^W&-X2738>QA!Z";O\
M-V -J!27^STS=/? ('#;B_GB>$\1I8%( ?@+9IH"H<S>5W)S!^^P 4Z;PE&I
MM_D#TC1;[#Y#MBKKBK2Y#QS0)!BW#:HQ5COUPZ/L<\=Y7JEX 8E;LJOVQT&0
MEQXG$>R;/I#DBKBUA'; A??YN[KN_%YX.F P9.1@),N($ =M5QF3]AN"<X-C
MI5$9NQ,[[ZHE4?EL>V\VS-"ET<NW<. /L*]/UF$[\3YED0ZK[66(>7.[@(M?
M3==80_;";[H%%,0^6'JN9%Q\XZ(U,)4%K7G(F)^/KR#HSJ055*DI]KT7,'8G
MV&+1J7T8#=2K(U!A!DCB9PR R<GYYA":@'@EQ@&C0F\?;730J@7*;\0LWQI%
M=Q/A^PJ$;]_X4U7N5NF]T6-SL$GA9!GW4A @2#G4A_+0JIR8UT'2OO.BKADN
M^#$;($ ICYJ)HGGHO AC%U3;,&<7U(D[E\QRLCMZ7YM*J;W"]H:'%T:WO$ZN
MHV3;<3TP''3KU\/(0"-V6I/33"[>-1<]FT_=-U3U+@AKC$'1--NW(% Z@MSJ
M?)A3>@ZM%?6B< F>) DFFON:#>!ZVJ%_6 $"*CLO*?YVDL\ND9/)A8 D3AAK
M>!SP@BJN5!9VKIVNEV85AU?EJL"O#3UD/C#V/8?\WKI=+A"KSLV?%+C$L#$=
MI @^"(EFP=]M<T0T?S[7;F/.5S9T:FTB'5QPV)D,-C/W%E9LPOIBM;+EQ'44
M H8GM6LIT9(+?@H3GOB>5VZ,B@@"\WYNF%[4;%V8>60AS9\C.6Y8P.V.Y4P?
M2W/3C8/MCPEE#=V[^C5' )0/X\DN?+R(%/A!)-=K=$R]8._[Y!^J+UA4"#E>
M?FQ/I-C*<$FK.6V;8,^1E!AGERYP.B-ALKHB;4E2)N!']<97X2_PH)PCI,+%
M:^GQS9 UHU''S-]HCI;YAL+]<#-,^?J41N9H#O*<..#;SWV@U"5_<MVF#6%G
M#>W[\*-^=*Z7US,&Y9C=14BGP'8P%V_,3\X5A[1+&WF]WN!*HROGBA9[3O;J
MUADLEVMJ+BOD^L:454@J278'WL$V/D95[HO$U14]!JD@0&A]Y0;0]E#\XLL$
M6];@]S6P4<XJ<S?^L?#ZVH_5#5+E+,("20,*U]%<10W%AHGN#@6+!YB")A3,
MAU[9"L2$0ZEK'@8)7[NV(@3:&NZE0#M&'Z'Y5-.6T@U8QP27I^4L5*%,=/C2
M/H\H^LWMAYVWM^ *H?2OD$<8\,X3\\2"<?=S1/,,2[OT_EHG<$R=*V2>FD<6
M@RF!"$U> AD75?XH>W+AZ[F"(NO\%R,IR!$3,:8.(POPEI(N3=L=8P^CYNE<
M7>%)=.@O3-Z#5V44C9F1J^\X*/SN*2C\C77O&]2]".7G;$:WL@T)0(>Z?@YM
M/L9;DFE83"#\P9$5EMA,YFX+**UBBS%*:GY06W10MYNQ#NWDC7_B%&$01G49
MU7@N6(*1-<?A2NQ@Q55&0D!*DN%2./$Q^.(QXZDXD7.<6!!9*B9JD)T/-=^N
M>UP\5NK>B[@5HF\3'68X$)F0^,#M*D.:FSP5[%A+,NYAPHT_4-X5H8^T:WOD
MI%@L)+U>@(@,R0-/\C#JV@;!1\( 9 )U80>L7+1(*'=OIUZ-5_'!Z.,)*)/M
M3!)X5*A9L_(R^_;/F7^9<#"GQ!0TK7(H1$B3BR(S>]C\Q;4K6%M#/C $W\$8
M1;$/VK* ER25IJR/.55=,,6SM'_(*-QF/S^! G2BJ[#ZGP.+0Z25]!JYX98'
MHDSO'L".R=D+\ X1 .E\G35BS78]W3W?A^E_75D_WW3=I8K>_/C\>3+=.-_
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MP*Q&%E #6V&>'[/!-7326MXR2A^;3:#4F,J>13_)7S4Q@].[\A-C;\;FC)2
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M\21S[D7FC!ZAS#'.>C&Y,(X@285L\A4LDY.JQ/^."FD*3LH8O49L]FT.9=
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M<)+-\*ZJ9 =:JF(U2S;-Y[-B4.,;Z2>NKGA+'$X?&R[!K&TD6]FTF!D]__\
MQX]565@?!K58 /-W%33#?,1E","[$C:@4S2=YWDVP3J%K!Y4Q0G5!]@V<K44
M*X;KV41S+2,C;G5:>S4U@R Z.:9B&,X'M@PHC[!=P,=P+NA41 EDL+RXQ.('
M(XHSYCCLZEH.A44CVZ#[%)@OJ*IN/$=R:+B5489"4$$S/LB+J3 E,H7>X,JQ
M!!8Q9HXA_5C+*+[(X]]W].2I:J<NY*HYN3RJ6:J0\5RCKS<,'&H$J8?7--I=
MW6,["\>-C-S8;7TXKZ1O(#+M#[FG^T :BNF[<NL_I,+@;X:T1-2X<//%<_/!
M5:WHT^27VW!=XV0=YL3$;X9T@$\/SEA3"_W;%VJ]ZRK4ZN;86"L>8:46="LU
M&G"*1\R<F'P\3K%,"]B!B<$%/H'_)UZJJ11$Z8NF\VI@U*ZY@?RKY6)FFH=;
M8L])=5DJQ/254.[X=_;(\Y!L:B1-[&L@A<#F>=30GEIM0^$D_[6F6%-M>_E4
MN+;JRVP*A660ZJHS:))T!K-AGZ@L'CCI3OXQ,R"/I<9&UJ =<^[H"H+7"(KX
MH%)-Y2J-*GTV(.A,8K1L59\54[GRBY,C0MM'(7_0J/IP'_.P&O81OC*U7G(B
MC6*9%# #,E4NE%YP85'7T"<&!176[57<4]82,09L?^NJ/U;P%?,+0#4JW95%
MJA:<9C?4<]X94?VU9LS(L12>-BVQULEK3!*2C9R,BX%9-K/!L-TK\3?9]JYF
M#.?9U_S_;^]*>QHW\_A[)+Z#M=)*B>2APUSM3JN1 F1*=F< A; K5/6%8SO@
MUHE3.X')M]__]5P^DE#.@;QIA_AZKO]]_ R^!=,2" 8Z0XJDZ)S[-2>61/?/
M^/>F/O9>V>Y3Y+N6(G9S%D1(SFNS(08K:^*-=\V&2N!/UY<QCU\1B3WN*%9Z
M-A;A$NB.:;#&!1.9@)+JJ[IO6"&M%=!43[FS0A2GB%*Q( :TG'/IA2VXTV@2
M\[J%07'IB)HUJM?OW",P8+.$=#/=)\YN.5MM!@G+(;9W%3J:P-&G4\*;_=CL
M#7RAK.46I?>MI]@G2\G]8B6I?MQT@GIY"G\RJFA5V!T6&U]3]E>0HB5:<)\]
MWVMU%!0'"RJ^1JB@^-C$2\8(4TIU;C0 ;QQ3;S4^?-M;]H>HEW6EAUO%9^BK
M=CVE5SOM]]%7PYVK"+@/N")*)^"%PS3+(A^7+4\"5,"B#%9D!D(-Q: 68R"2
M(F5X((,<@UG03 _/-B[V/(AT]VTME393''92'6?L.YE(A6:8S8MDT@9CT;$9
M/O.Q_DK'NLY.0,H M69>D$MI+*!MY)TA'<O6MPR\=I4,#19YZ8KBVLY("C T
M6GN&.!N>B0D?TO>X 97R-45Q,+NL^9*/!(3>*9_L''@V7!A5*9N*&T] .($[
M["ME#?V1PVP2P%I&L7>1C%A1]<!X!^U*>0)!HQG.I3EM83RKR$H<7=!I5?_^
M]6XK;+?>MC5/P6XF.>*+]&/&4]S/(FH6L_NOGSYP0WF%H= ZD!$.%Y7Q.^9D
M( B9E#KA>W_-@5*H/;]F'W1%+/MRQY@ ]OHJRT.ECBI-O=4ML4_#@GS'CP_W
M-OO=R2NZQ)% *YNEU!T9R#&@-L9)H7Y/!3Z"KC#.*[Z@$-#5D/5BN=G<J3&;
MJPY,T$=_8-QWK=<[A[-5M+%[V4:Q>$DF[1+-PCKIODL#S8=>LYV8^BM4U!'L
MT<HWW,';M0\=E8K1".XEAWE0Z. 1TTH?VV3NOAF^>J.XIT*<\CKAK%W+4HTS
M+9E< 2LANAK-,0+JC@)C-&N0).(5!=$5V*8&5;V\\,:#YWM+ 40P_%&[;>Y"
M8I^L68$M9 D/2JXQBP?R1\A05.U<!0OGJ)VL/$^>MN%$!BI6G@.1JJ4:"96(
MT(*'TL,\1R9(,':,:/?7'#>/,_P*:ZE-/,=NTPB6?BZ,F21UKB=DL5\U&%\T
M68NKPK];%KIRP3#'"NN]Y%YNEY!-_#J9;WE:=;0G36!6D0[OXHQA=5.KBWNS
M4Q2V36+;SEL(#L9TGZS3$YR5;#^2:/>49-_>NH%HGQF+U_&M,M(U$%V67E'X
MS!-232:BAX6(WVOYMBR!362U(A"XQ'F[$75W)NJ^,UE'E@!+*U'Z* *0\?'4
MYXY DN34TR--[5YOF 1T(T<C(UYI8!H4@@;V2K5F#HI8\;B!&\0PC-D-S%C^
MVJ#M,S/0CR9,EBB5,$F FY13ND*436+R?"<813$K94EK1>IQ[ P!_F2O .Z%
M@+V3*QC'HX+V-0E,,L61I,C6NR/J\157>9<Y(E1R,;.:0:DGB.?A%9F>44Y*
M.C%[F5/T\\97>X>^VJ?8EUVI$<,T*2['(EO0F4#]4EF6VZ3%ZN?KX?M7NZ(I
MEE70LO>";][>PI2W<MZ94@Q-:++V-,,QK+()7_$)T>!PI%$6,VW+G?0!':M2
M+NDZ>K'28"HY*;["1L:X6-,+7!U(5@CGC'BF0%$D_MVV7/+O:@B9K6T:/' Q
M1*$K=9U5J7_+1XUY:)(KB(I0,J%@S;)GVNN(@ T/N 4/>(I][0<F;HLGO/ =
M%5:??O+KLA$)9QP/KXVWUEIA^>@8\_:6#BP3_&U@A9;;-?8!!7]S<;+CP<TL
MT1=R!B9L84-(U2)7E<C#?L[0P%)6/L@R.9N"?(2E_A,3P0DBD_,Q.,N"$,D7
M.M^4UBAP<CXS2_EGC%^:0^S.8$E2R\I<$QB44@K@3>:=5NK?IH7__=+S4^SA
M;^*OKE!"$_H5F="@9N:1@*+,8NG536EX8TE(1TL3R_6T;U@(2RC6(GT@:.VZ
MLJQ\(EE.)8U,*I6<=CJJ8NDK"MS+@IR(_8"\RIDMJWW&?L-98.*T/%A!CW6Y
M08W9S? R[-$R[U['!D%?@ #0B&<!5VU[:^FR-9 >%H--&^I(*D?!L\_"3R7Z
M>[#2KC>>T/LF$OG4N5F]JV-9(-)0=SD]2BQE=%FG\4PEP#=G7K&2FA, 0#GW
MW4DGJL(P5(U>-U8OP#AB6FAZQLH-(NAJ:-XQ+%HJ#6QX>X[7)JZ031S$6?%$
MQ\JKPK(^<I0D7QRDG,$ #USDV9P2VK3'/Y*KA>^*])*B8]);$?&<L^TKN^>F
M"A?B!EGKZ]YU-D\CXK2<ET!1ZO>O_ZG4"U#OJ(8*V>L50VS7*ETM93K-\ZN$
MF#&'.]J;\-Q]JB5/$I)%JR6H3(=AEG,L2(>/-+!5O56<H.E+<0H;XC:@6JM+
MMDN(E6QO?1$W6SD-,1CFB9W3RNA&H"<G?$ASAI1?$>%PXP<['_!UI=]V=QNG
M07H1<T)@!?TXC=&[235\/?C@>$+6OA7V:RCYPCSVLH>T*>?=7VO%]^-\1E#A
M[)HXB+D DRKBUEU[;]72K[W,?N,NV4D4H'PZ2_]A]63L<"@:I?NF:J!57?;F
M][3Q>A[3\-N;)/I[9VFC)\W2'$MKHC)U1E92#Z:ESU,N:(;5FH2-MOE-ZSAO
M%'#!T(1K\/C>"$9XB:EERNCAXL5RU$%5=+8"%9A%(.VAG2V/F8P>*A/L'5$)
M1PL[S$Q8ZMD$V1?'6\" E'7$WTR Q3?AE2PO15NDCMMEO+N:_!V'M-;EQ'\3
M3";9?!+:[&D8LX5IX[_7)%D9%:M:1[/4L5KV8+/-;!;<U!S XLCZK3]!&OJR
MS\LL0Q V.<V, ?U,]"F; 2-7Z.^DL"M#5P;#ZFRAE/DPR</Y&#5 +,]PPNOZ
M=& L>UC.06!<8U-$X20L6$[N::XL;E="D*"4,04>=9;9??O9UUB \->O))#-
MWP<Z X3<YF-Y+<Z3KM KI<**1!G()E1\J0X;)J2B=X7"<B;_1AI<6T2M(-IF
M!<.T86J@O'*.Y>53L"S")-8%W, ?D@G&%9$[<'1SB+F?<2'HR#<L[KA=*3<N
MS0S+.;3!0F'2B7>59*F+-E<7FV3Z@3N ]@6IEX"CYVDJ,-8@"OR&LAPJ/$8C
M+[<_'C-H'&U:.)MS?HP!Q+N*/5V5;4+8,F['T#1EUHV&)C<+4!71#,Z'JI+Q
M!),9AN,'_F,'J79 95/,4Z4U47JH5>%925PTY>%6,3<SQ3F6CT^G&1XA:R-0
M6LQTK(R'89(V[=@9#=:8888NI?$ 3D/5M<]GEUG.K0LRN#,DN&Z[HM!^L?72
M9%1B@V0JDAU>@&4'S!D(TSHX8'+GIA= W0;LJ(7 8%5(47O*0HH1+]S:P6&<
M9M=,S/KB?(A,:)80JB"2YU60.@3.)5K3- A5F2C.+31J7:MH&PD19<#6X'DP
MENEP<<I$0N>.?O=BROT*A=4ZU07*&>*4JM7X]RL54.M0N TC=?/6*H>@.!YV
M^MU3K]\]@?^AG^S VSOW!H>]4U#U^H/>Y]Y^9]#UX";O]&SOW]W]@3<X]CI'
M!][7SKEW?/3EW-OK;F\-^IVCT\_=?A^>[QUY^\=?3[[T.D?[75#C!H=>I]K]
MR8<?]X]/SK$UU/\.>_N''GSR^,C[W -UM@-?@<&=]'M'^[V3SA>X"0;2Q7OQ
M=WQ]Y^C\X7GBP"5;#%H1V>0Q2*:"3@)Q#:X3%WHNTSJRL!%P06^:75,%8J3(
M#OWNI5X8]9310=M)/R-D#*2F\S68H2B49W-%,16[:*_&XM+JSS"9.$F VULZ
MJQ(+NPN\O^#4&*()=A0%J5F1 /ERW4<>??>J/7^2!NL<O0=6K%RE#P #*U3O
MD-K5R]F.%_T$?[37725*U&_QRL%:8L**[!$S!WTRA-W'C=-&?6.O%(X7I@F)
M*MGGVJK-'>7M_^[B%&]?0ISBX0#E.JKE$GOU8VH3)DPH_H9T7Z0+B^G0H9+C
M*NJ*.JU*352 R2!G27&^$G<4:8R@?L7?P$XL\&>5U4R"F;YN?XKY,6D#P):_
ML#;..<2^)I7X6YR'Z#[2D?KRL-1')K'ZA%8$87IHLL;NFVI&525A6\G#WD!@
M [/Q$P5C[&P?DG<]"T&ILO,#N:;%'EXU^D@F-5J1Q0JU'-/J:1IQ+D5A-4Y
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M2?#'P?[9I]^>;&UN_D.KZ7N#H[/!R4_K7+ ,-9CF[Z?&<F[;63<U&NXDD;9
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M78/*8>&&);)\!CH^F@+C?%03,-RF=C<^=;W= <$HVT.QXT9=!%0^_(IQ(Q:
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MAEA9-L[.J1UCDC5)E*@QM&H"88$XAQBQ3 82HZ204D>2OX#]T.\I*(M1I+J
M2YC;6J0XP'"]955$#%8'BGZ&_MT,^XD8X]0&":/WR0*OK=0HFGCT*L)8T"Z5
M6.N%.ROD0RF!W[;N_?68YSDZ%R),]HXK8#8Y$KBGQ%SCEI%6/U-XWJU7FSI=
M1+<&\ LEJ]T->Q^'-@9TU1NG>R5:_F1:B2$%!6#DE2L7+S83( @*!Z9AG1C?
M(R.8HH'JW(MA4O%./DM!J+F,BJK[I.2<&"?E7(E @CD6^2B.QU)>SY1.H>SK
M*P57MC?==??BH=!1EUI44?BK$6EIK=5K6H28/W +?6=5S(_TF0[])<*MFN,V
MRA4=6U?OH7R''"V*RBD0:P76*^<4H-YX,&D 0+3;+XZ*-&&G@C<;"7T7R?<
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M+66X )VD: -5#UAU.8ETA"?B@MZMQ/D.3X/54U?!G;!$L*<<GDD0L[PZW!.
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M- <O?]2Q%!_Q>U706)+1+SHAC+Z)$+% U7KK#QI.&QX6OY8+J+2\)2\27$%
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M#MC8L.V*9;N8CV,+AUQ:.7"EO!4CQX9"=;C;=LOJ2>8S69HL5F,.#\C=!M_
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MTHI*= [NOC:'B67N_I9@>1MI:K&S]89N+HU \%<GG_"0_YC8_P%02P,$%
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M!O-?!.L]YL4\$X];O@)02P$"% ,4    " !=0 =76[&H#($C   RSP  #@
M            @ $     9#0V.3(P-&0X:RYH=&U02P$"% ,4    " !=0 =7
M%L6.J7%>  "7P $ $0              @ &M(P  9#0V.3(P-&1E>#$P,2YH
M=&U02P$"% ,4    " !=0 =7AY]IB59] 0 __ @ $               @ %-
M@@  9#0V.3(P-&1E>#(Q+FAT;5!+ 0(4 Q0    ( %U !U=+Q8&19S@  /@@
M 0 0              "  ='_ 0!D-#8Y,C T9&5X,S$N:'1M4$L! A0#%
M  @ 74 '5VLDM@?:$@  4TP  !$              ( !9C@" &0T-CDR,#1D
M97@Y.3$N:'1M4$L! A0#%     @ 74 '5Z?@AO)$ P  6PL  !$
M     ( !;TL" &EK;F$M,C R,S X,#0N>'-D4$L! A0#%     @ 74 '5TGW
M->7_!@  D$\  !4              ( !XDX" &EK;F$M,C R,S X,#1?;&%B
M+GAM;%!+ 0(4 Q0    ( %U !U>[8H$&#P4  (PQ   5              "
M 116 @!I:VYA+3(P,C,P.# T7W!R92YX;6Q02P4&      @ " #[ 0  5EL"
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
